


**OBSTRUCTIVE SLEEP APNEA IN CHILDREN WITH
SYNDROMIC CRANIOSYNOSTOSIS**

Publication of this thesis was financially supported by the Carolien Bijl Stichting, the J.E. Jurriaanse Stichting and the Esser Stichting.

 **CAROLIENBIJL**
stichting



J.E. Jurriaanse
Stichting

Lay-out: Optima Grafische Communicatie, Rotterdam, The Netherlands

Cover design: Marijke van den Elzen

Printed by: Optima Grafische Communicatie BV, Rotterdam, The Netherlands

This research project was funded by the Carolien Bijl Stichting and sponsored by Trustfonds Erasmus University Rotterdam.

ISBN: 978-90-8559-055-2

© Natalja Bannink, 2010

All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, without the prior permission of the author.

**OBSTRUCTIVE SLEEP APNEA IN CHILDREN WITH
SYNDROMIC CRANIOSYNOSTOSIS**

OBSTRUCTIEF SLAAP APNEU SYNDROOM BIJ KINDEREN MET EEN
SYNDROMALE CRANIOSYNOSTOSE

Proefschrift

ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus

Prof.dr. H.G. Schmidt

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
woensdag 1 september 2010 om 13.30 uur

door

Natalja Bannink
geboren te 's-Gravenhage



PROMOTIECOMMISSIE

Promotoren: Prof.dr. S.E.R. Hovius

Overige leden: Prof.dr. D. Tibboel
Prof.dr. F.C. Verhulst
Prof.dr. H.A.M. Marres

Co-promotoren: Dr. I.M.J. Mathijssen
Dr. K.F.M. Joosten


CONTENTS

Part I	Introduction	7
Chapter 1	General introduction	9
Part II	Screening tools, diagnostic methods and treatment of obstructive sleep apnea	29
Chapter 2	Can parents predict obstructive sleep apnea in children with syndromic or complex craniosynostosis?	31
Chapter 3	Use of ambulatory polysomnography in children with syndromic craniosynostosis	39
Chapter 4	Obstructive sleep apnea in children with syndromic craniosynostosis: long-term respiratory outcome of midface advancement	51
Part III	Functional problems in syndromic craniosynostosis	65
Chapter 5	Papilledema in patients with Apert, Crouzon and Pfeiffer syndrome; prevalence, efficacy of treatment and risk factors	67
Chapter 6	Long-term functional outcome in 167 patients with syndromic craniosynostosis; defining a syndrome-specific risk profile	79
Part IV	Quality of life and behavior	93
Chapter 7	Health-related quality of life in children and adolescents with syndromic craniosynostosis	95
Chapter 8	Reliability and validity of the obstructive sleep apnea (OSA)-18 survey in healthy children and children with syndromic or complex craniosynostosis	115
Chapter 9	Obstructive sleep apnea-specific quality of life (OSA-18) and behavioral problems in children with syndromic or complex craniosynostosis	129
Part V	Discussion and summary	145
Chapter 10	Discussion and future perspectives	147
Chapter 11	Summary	165
Chapter 12	Nederlandse samenvatting	173
	Abbreviations	176
	Dankwoord	177
	Curriculum vitae	180
	List of publications	181
	PhD portfolio	182

- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.

Part I


Introduction





Chapter 1

General introduction



1. INTRODUCTION

2.

3. In the Netherlands between 179.000 and 204.000 children were born annually during the
 4. last ten years. Congenital anomalies occur in 1 in 33 births. The most frequent anomaly
 5. involves the heart with a prevalence of 1 in 150 births (66.7 per 10.000 births). The ven-
 6. tricular septal defects occur the most frequent (30.0 per 10.000 births) (Central Bureau
 7. of Statistics Netherlands, European Registration of Congenital Anomalies, National
 8. Neonatology Registration). A rare congenital anomaly is craniosynostosis, affecting 1 in
 9. 2,500 births.

10. The newborns cranial vault is composed of seven individual bones separated by sutures.
 11. This arrangement accommodates transient skull distortion during birth and permits
 12. future growth of the brain, the volume of which quadruples during the first two years
 13. of life. There are six major cranial sutures: the metopic, two coronal, the sagittal, and
 14. two lambdoid sutures. Six additional sutures are considered minor: two frontonasal, two
 15. temporosquamosal, and two frontosphenoidal. At the anterior of the skull, the sagittal,
 16. coronal, and metopic sutures meet to form the anterior fontanelle. The posterior fontanelle
 17. is formed by the intersection of the sagittal and lambdoid sutures. The sutures function
 18. as growth centres. In the center of a suture lie undifferentiated, proliferating cells. A part
 19. of these cells undergo osteogenic differentiation and migrate to the borders of the bone
 20. sheets. After differentiation in osteoblasts growth of the sheets occurs by apposition¹.

21. At two months of age, the posterior fontanelle closes, followed by anterior fontanelle
 22. closure at approximately two years of age². While the metopic suture typically closes within
 23. the first year of age, all remaining cranial sutures close in adulthood, although they are no
 24. longer involved in skull growth after approximately the age of six. Then skull growth takes
 25. place by apposition of bone at the outer side of the skull and resorption at the inner side.

26.

27.

28. SYNDROMIC CRANIOSYNOSTOSIS

29.

30. **Craniosynostosis** is characterized by the premature fusion or agenesis of calvarial sutures,
 31. which usually happens at 15 weeks of gestation for the metopic suture, at 16 weeks for
 32. the coronal and lambdoid sutures and at 18 weeks for the sagittal suture³. Due to the
 33. craniosynostosis normal growth of the skull related to the affected suture is restricted. In
 34. order to accommodate the growing brain, compensatory skull growth occurs in the other
 35. directions resulting in cranial deformation: this is categorized as scaphocephaly in case of
 36. involvement of the sagittal suture, as frontal plagiocephaly in case of one coronal suture,
 37. as brachycephaly in case of both coronal sutures, as trigonocephaly in case of the metopic
 38. suture, and as pachycephaly in case of synostosis of one lambdoid suture. In about 40%

39.

1. of the cases (1:6.250) the craniosynostosis is part of a syndrome, such as Apert, Crouzon,
2. Pfeiffer, Muenke or Saethre-Chotzen syndrome⁴.

3.

4. **Apert syndrome** is an autosomal dominant syndrome caused in >98% of the cases by one of
5. the two FGFR (fibroblast growth factor receptor) 2 mutations on chromosome 10, S252W
6. and P253R with full penetrance^{5, 6}, very rare is S252F⁴. Recently, two rare mutations were
7. found, a partial large FGFR 2 gene deletion and an Alu element insertion into the FGFR
8. 2 gene⁵. The syndrome is characterized by symmetric complex syndactyly (involving both
9. soft tissues and bone) of hands and feet, bicoronal synostosis, exorbitism, hypertelorism
10. and midface hypoplasia. The intelligence varies from near normal to mentally retarded
11. with a mean IQ of 62 to 74⁷⁻⁹. Apert is the most severe type of syndromic craniosynostosis.

12.

13. **Crouzon syndrome** occurs in 1 in 25.000 births and is an autosomal dominant syndrome
14. predominantly caused by mutations in FGFR 2 on chromosome 10 with variable expres-
15. sion¹⁰, but the FGFR 3 mutation, A391E has also been reported in individuals with Crou-
16. zon syndrome and acanthosis nigricans¹¹. Crouzon syndrome is characterized by midface
17. hypoplasia, exorbitism and various forms of craniosynostosis, which may have a postnatal
18. onset. The intelligence of patients with Crouzon syndrome is overall significantly better
19. than the intelligence of patients with Apert syndrome, with an average IQ of 84 to 92^{9, 12}.

20.

21. **Pfeiffer syndrome** is an autosomal dominant syndrome but most cases are sporadic. The
22. syndrome is mainly caused by mutations in FGFR 2 on chromosome 10, but the P252R
23. mutation in the FGFR 1 gene on chromosome 8 have also been described incidentally^{4, 13, 14}.
24. The phenotype of this syndrome is characterized by craniosynostosis (bilateral coronal or
25. pansynostosis), midface hypoplasia and broad thumbs and great toes. With the discovery
26. of the genetic background in syndromic craniosynostosis the same genotype in Pfeiffer
27. syndrome was found as in Crouzon syndrome. The clinical presentation is also very similar
28. to Crouzon syndrome besides the characteristically hand and foot anomalies. So there is
29. an overlap between both syndromes and they can be considered as phenotypic variations
30. of the same genetic defect¹⁵.

31.

32. **Muenke syndrome** is an autosomal dominant disorder with incomplete penetrance, caused
33. by the P250R mutation of the FGFR 3 gene on chromosome 4, discovered in 1997¹⁶. It is
34. one of the most commonly found mutations in the human genome, but does not always
35. result in craniosynostosis¹⁷. The phenotype associated with this syndrome incorporates
36. macrocephaly, uni- or bilateral coronal synostosis, hearing loss and developmental and
37. language delay^{18, 19}. The cognitive function seems to be normal with a mean IQ of 93²⁰.

38.

39.

1. **Saethre-Chotzen syndrome** is an autosomal dominant syndrome with incomplete pen-
 2. entrance, predominantly caused by mutations or deletions in the TWIST gene on chromo-
 3. some 7. The syndrome is characterized by coronal synostosis, upper eyelid ptosis, external
 4. ear anomalies and limb abnormalities, such as brachydactyly, syndactyly, clinodactyly or
 5. broad halluces. Most patients with Saethre-Chotzen have a normal intelligence^{21, 22}, with
 6. the exception of patients with TWIST deletions who have a higher frequency of mental
 7. retardation²³.

8.

9. In a significant number of patients one of the above-mentioned genetic mutations is
 10. found. FGFR's and their ligands the fibroblast growth factors (FGF's), play a central
 11. role in the growth and differentiation of mesenchymal and neuroectodermal cells^{21, 24}.
 12. FGFR binds FGF and plays a substantial role in signal transduction. FGFR's regulate cell
 13. proliferation and differentiation and are thus involved in cranial suture fusion²⁴⁻²⁶. Also the
 14. TWIST gene encodes for a basic transcription factor that is responsible for mesenchymal
 15. cell development during cranial neuralization¹⁸.

16.

17. But not in all patients with a phenotypically syndromic craniosynostosis a mutation can
 18. be found. **Complex craniosynostosis** is defined as fusion of two or more cranial sutures
 19. without known FGFR or TWIST mutation^{4, 18}. In the future new mutations are likely to
 20. be found in this group of patients with complex craniosynostosis²⁷.

21.

22.

23. INTRACRANIAL PRESSURE

24.

25. Pathophysiology

26. The skull protects the intracranial compartment consisting of brain parenchyma (80%),
 27. cerebrospinal fluid (10%) and blood (10%). Because of the rigid structure of the skull with
 28. a fixed internal volume once growth is completed, intracranial pressure (ICP) is a function
 29. of the volume and the compliance of each component of the intracranial compartment.
 30. An increase in the volume of one component or the presence of pathologic components
 31. results in displacement of other structures, an increase in ICP, or both. In severe cases it
 32. can diminish the cerebral blood flow resulting in ischemia, cell injury and death²⁸. The
 33. relationship between intracranial volume and pressure is not linear. An initial increase in
 34. volume results in a small increase in ICP due to compensation, but once the compensation
 35. mechanism is overcome, a further increase in volume results in a steep rise in ICP²⁹.

36.

37.

38.

39.

1. **Factors involved in elevated intracranial pressure**

2. Traumatic brain injury is the most common risk factor to develop elevated ICP. A brain
3. tumour, hematoma or hydrocephalus can result in elevated ICP, just as cerebral edema due
4. to an infection, tumour, head injury or stroke.

5. Patients with syndromic craniosynostosis are at risk for elevated ICP. Factors suggested
6. to contribute to elevated intracranial pressure in craniosynostosis are craniocerebral dis-
7. proportion, ventriculomegaly or hydrocephalus, venous hypertension and obstructive
8. sleep apnea.

9.

10. *a. Craniocerebral disproportion*

11. Due to premature fusion of calvarial sutures, the intracranial pressure may be elevated if
12. the brain grows more rapidly than the skull³⁰. In healthy children the intracranial volume
13. does not increase linear with age. The growth is most rapid in the first 5 years of life; by the
14. age of 2 years 77% of the intracranial volume observed at the age of 15 is reached and by
15. 5 years 90% of the volume³¹. In children with syndromic craniosynostosis the intracranial
16. volumes seem to be significantly smaller at birth with an increase to the normal growth
17. curve before the age of one³². Except for Apert syndrome, in these children the intracranial
18. volume is in the normal range at birth, but at 6 months of age much higher than the
19. norm³²⁻³⁶. The explanation remains unclear. In Apert syndrome this increased intracranial
20. volume was not related to cranial decompression or ventriculomegaly³⁵. Posnick et al.³⁶ also
21. found greater intracranial volumes than the mean in patients with Crouzon syndrome in
22. contrast with Gault et al.³⁴.

23. Children with elevated ICP, due to their craniosynostosis, also had a significantly lower
24. intracranial volume, but a lower intracranial volume did not result in elevated ICP in each
25. case³⁷. However, in a study from London no relationship between elevated intracranial
26. pressure and decreased intracranial volume was found in children with craniosynostosis³⁸.

27.

28. *b. Ventriculomegaly or hydrocephalus*

29. Ventricular dilatation is a common finding in patients with syndromic craniosynostosis.
30. The increase in ventricular size can result in elevated ICP due to an increase in cerebrospi-
31. nal fluid volume. Enlarged ventricles are defined as hydrocephalus when the condition is
32. progressive and as ventriculomegaly when it is non-progressive³⁹. Ventricular dilatation of
33. either origin is reported in 30 to 70% of the patients with Crouzon or Pfeiffer syndrome
34. with frequently true hydrocephalus and in 40 to 90% of the patients with Apert syndrome,
35. which mainly concerns ventriculomegaly. In Muenke and Saethre-Chotzen syndrome
36. ventricular dilatation is rare, but specific literature for these syndromes is rare³⁹.

37. In craniosynostosis, hydrocephalus can hypothetically result from cerebrospinal fluid
38. outflow obstruction due to constriction of the posterior fossa, malabsorption due to ve-
39. nous sinus hypertension³⁹ or increased cerebrospinal fluid production⁴⁰. Ventriculomegaly

1. seemed to be associated with primary brain maldevelopment or sometimes with second-
 2. ary brain atrophy. Other less common causes of hydrocephalus are basilar invagination,
 3. aqueductal stenosis and compression by the midline occipital bone crest⁴¹.

4.

5. *c. Venous hypertension*

6. Venous hypertension is also common in syndromic craniosynostosis and another factor
 7. contributing to elevated ICP^{30, 42}. It can be caused by anomalous venous drainage and
 8. anatomical vascular variations resulting in development of collateral veins^{30, 43}. Abnormal
 9. intracranial venous drainage seems to be present in patients with severe stenosis of the
 10. sigmoid sinus- jugular bulb and jugular segment (intraosseous part of the jugular sinus)
 11. complex. These patients are more likely to show earlier signs of elevated ICP, mostly before
 12. the age of 3. Presence of elevated ICP due to the effects of venous hypertension is unusual
 13. after six. After this age the collateral venous drainage will likely become sufficient to allow
 14. the ICP to normalize⁴³.

15. Early fusion of the lambdoid sutures in combination with the petro-occipital synchon-
 16. droses can be associated with stenosis of the jugular foramen⁴¹. And in presence of a small
 17. posterior fossa this stenosis is possibly related to venous hypertension^{39, 44, 44}. Jugular fora-
 18. men stenosis is suggested to result in a rise of the sagittal sinus pressure, which increases
 19. the cerebrospinal fluid pressure⁴⁴.

20.

21. *d. Obstructive sleep apnea*

22. Forty percent of the patients with syndromic craniosynostosis will develop obstructive
 23. sleep apnea⁴⁵. During invasive ICP monitoring, plateau waves of elevated ICP are recog-
 24. nized to be associated with obstructive apneas and desaturations. Obstructive sleep apnea
 25. results in hypoxia and hypercapnia with subsequent vasodilatation and an increase of
 26. the cerebral blood flow resulting in elevated ICP⁴². In the next part of this introduction
 27. obstructive sleep apnea will be discussed extensively.

28.

29. **Prevalence of elevated intracranial pressure**

30. In isolated, single-suture craniosynostosis the frequency of elevated ICP before vault
 31. expansion differs for the various types of craniosynostosis⁴⁶⁻⁴⁸. In patients with syndromic
 32. craniosynostosis, either Apert or Crouzon syndrome, elevated ICP before vault expansion
 33. is seen in 45% and 63% respectively^{7,49}. Regular screening with visual evoked potentials
 34. (VEP) for signs of elevated ICP prior to vault expansion, demonstrated an incidence of
 35. elevated ICP of 83% in children with Apert syndrome with a mean age of 18 months (range
 36. 1 month- 4 years 5 months)⁵⁰. In the different types of craniosynostosis the frequencies of
 37. elevated ICP (≥ 15 mm Hg), invasively measured before surgery, are shown in table 1^{7, 18,}

38. ^{37, 46-49, 51, 52}.

39.

I. **Table 1:** Frequencies of elevated intracranial pressure per type of craniosynostosis

2.	Type of craniosynostosis	Frequency of elevated ICP (range, %)
3.	Trigonocephaly	0-33
4.	Scaphocephaly	13-24
5.	Frontal plagiocephaly	6-22
6.	Brachycephaly	31-50
7.	Complex craniosynostosis	47-64
8.	Apert syndrome	39-50
9.	Crouzon/ Pfeiffer syndrome	63-65
10.	Muenke syndrome	0
11.	Saethre-Chotzen syndrome	29-43

10.

11. **Recurrent elevated intracranial pressure**

12. Despite early treatment elevated ICP may still reoccur or persist after early cranial expansion^{43, 53}. Late-presenting children with a smaller intracranial volume than normal have
 13. a higher chance to develop recurrent elevated ICP due to craniocerebral disproportion
 14. with a need for reoperation³². Information on the frequency of this problem, however,
 15. is limited⁵⁴. In Saethre-Chotzen syndrome the postsurgical rate of elevated ICP raised to
 16. 42% after 5 years of follow-up⁵³. In Apert syndrome 35% will develop a second episode of
 17. elevated ICP on average 3 years and 4 months after vault expansion⁵⁰.

19.

20. **Diagnostic methods**

21. Elevated ICP can be diagnosed in different ways, either through direct measurement or
 22. through indirect methods. The classic clinical symptoms of acute elevated intracranial
 23. pressure are headache, vomiting and disturbed consciousness. Gradually development of
 24. elevated ICP seen in craniosynostosis is difficult to recognize with more subtle features as
 25. deterioration in schoolwork and sight, and change in behavior²⁹.

26. The 'gold standard' for measuring ICP is an invasive overnight measurement during at
 27. least 12 hours with direct monitoring of the intracranial pressure. An intraparenchymal
 28. device is most commonly used in daily practice. A drawback of the ICP monitoring is the
 29. need for a surgical procedure, hospital admittance and the risk of complications such as
 30. haemorrhage, cerebrospinal fluid leak and infection^{29, 54}.

31. The analysis of ICP measurements includes the identification of the baseline ICP and
 32. the presence of wave patterns. There are three waveforms. C-waves are a normal variation
 33. in ICP related to the cardiac cycle. B-waves are rises in pressure to a level between 20
 34. and 50 mm Hg during 5 to 10 minutes with decline to the baseline afterwards. They can
 35. be normal, especially during sleep. A-waves are abnormal plateau waves present in the
 36. acute phase of elevated ICP due to traumatic brain injury for example. Loss of cerebral
 37. autoregulation results in these waves with a sudden rise in pressure above 50 mm Hg
 38. during at least 20 minutes without recurrence to the baseline²⁹.

39.

1. In children, a baseline pressure below 10 mm Hg is considered as a normal ICP. An
 2. upper limit of the baseline pressure between 10 and 15 mm Hg is borderline elevated.
 3. A baseline pressure of 15 mm Hg or more and/ or at least four B-waves during at least 5
 4. minutes during sleep is considered to be elevated^{29, 49}.

5. Indirect methods to screen for elevated ICP are palpation of the fontanelle in infants and
 6. measurement of the head circumference. The head circumference growth curve can form
 7. a notion of the growth of the skull, although it does not take growth in upward direction
 8. (turricephaly) into account. A decline of the curve can be associated with elevated ICP.

9. Radiological evaluation for screening on elevated ICP consists of a skull radiograph,
 10. a computed tomography (CT) angiography scan or magnetic resonance imaging (MRI)
 11. scan. A skull radiograph might demonstrate a beaten-copper pattern, also known as digital
 12. impressions, which correspond to the gyral pattern of the underlying brain. These radio-
 13. graphic changes are visible as markings in the skull of the gyri in presence of elevated ICP.
 14. To screen for elevated ICP this method is insensitive⁵⁵. A CT angiography scan of the brain
 15. can show ventricular dilatation or signs of venous hypertension^{39, 55}.

16. A reliable symptom of elevated ICP, although rather late in onset, is papilledema⁵⁶.
 17. If fundoscopy reveals papilledema, it is a sure sign for elevated ICP after exclusion of
 18. hyperopia, which can resemble papilledema without being a sign of elevated ICP, so-
 19. called pseudopapilledema⁵⁷. The specificity of papilledema is 98%, but the sensitivity is
 20. age-dependent. Above eight years the sensitivity is 100%, but in younger children absence
 21. of papilledema does not exclude the presence of elevated ICP and thus fundoscopy is
 22. likely to result in an underestimation of the incidence of elevated ICP⁵⁶. Ocular cohe-
 23. rence tomography can measure the retinal nerve fibre layer thickness. The thickness is
 24. increased if severe papilledema is present. But it is not effective to differentiate between
 25. mild papilledema and pseudopapilledema⁵⁸. Visual evoked potentials (VEP) can be used
 26. if neurophysiologic expertise is available. Prolongation of the N2 wave latency period is
 27. correlated with elevated ICP⁵⁹.

28.

29. **Treatment of elevated intracranial pressure**

30. Treatment of elevated ICP is dependent on the causal factor. In craniosynostosis the first
 31. treatment or prevention of elevated ICP is surgical decompression to expand the skull
 32. within the first year of life⁴⁸. Other options can be the insertion of a ventriculoperitoneal
 33. shunt or treatment of obstructive sleep apnea.

34.

35. **Consequences of untreated elevated intracranial pressure**

36. If left untreated, elevated ICP may lead to irreversible visual loss caused by optic nerve
 37. dysfunction, mental impairment or tonsillar herniation^{41, 48, 60, 61}. Visual loss is a very rare,
 38. but severe complication. In our hospital visual loss is described in three cases with Crou-
 39. zon and in one case with Apert syndrome in presence of papilledema but without other

1. symptoms of elevated ICP⁶⁰. Renier et al.⁴⁸ mentioned an observed frequency of optic
2. atrophy in 10% of the Crouzon cases and no optic atrophy was observed in the other
3. syndromes. Regularly screening of sight and the presence of papilledema can possibly
4. prevent these severe complications.

5. Vault expansion done after the age of 1 results in a higher risk to develop elevated ICP.
6. The mental development seems to be better after early surgical treatment done before the
7. age of 1⁴⁸. Possibly there is an association between elevated ICP and the mental develop-
8. ment. Another study found no correlation between the mental development and the age
9. at surgery⁸. So, the association between craniosynostosis, age at surgery, untreated elevated
10. ICP and mental impairment is not clear yet.

11. Elevated ICP appears to cause herniation of the cerebellar tonsils through the fora-
12. men magnum. More than one third of the patients with tonsillar herniation will develop
13. symptoms or syringomyelic cavities, but in most craniosynostosis patients it remains
14. asymptomatic. Chronic tonsillar herniation can cause suboccipital pain, compression of
15. the lower brainstem and upper cervical spinal cord (respiratory problems) and deforma-
16. tion of the fourth ventricle⁴¹.

17. Tonsillar herniation of the cerebellum is also known as Chiari malformation and is com-
18. monly observed in Crouzon and Pfeiffer syndrome (73%) and rarely in Apert syndrome
19. (2%). In Crouzon syndrome 20% will develop symptoms of chronic tonsillar herniation
20. before the age of 20. In these syndromes the herniation is not present at birth, but acquired
21. after. It seems to be related to an abnormally small posterior fossa, in particular after
22. fusion of the lambdoid sutures within the first two years of life^{39, 41}. In Crouzon syndrome
23. the sagittal and lambdoid sutures fuse significantly earlier than in Apert syndrome, which
24. can explain the different occurrence. Another factor that may explain the difference is
25. hydrocephalus. All patients with Crouzon syndrome and hydrocephalus show a Chiari
26. malformation. Of the Crouzon patients with a Chiari malformation 53% do not have a
27. hydrocephalus⁴¹.

28.

29.

30. **OBSTRUCTIVE SLEEP APNEA**

31.

32. **Definition and pathophysiology**

33. Obstructive sleep apnea (OSA) is a clinical syndrome due to partial or complete upper
34. airway obstruction characterized by difficulties in breathing, snoring and apneas during
35. sleep resulting in sleep fragmentation, hypoxia and hypercapnia. Other features of OSA
36. are restless sleep, mouth breathing, sweating, and daytime sleepiness^{62, 63}. Between inspira-
37. tion and expiration a substantial change in the size of the airway is shown, which is
38. most apparent in the rhinopharynx⁶⁴. Collapse occurs when the pressure surrounding the
39. airway becomes greater than the pressure within the airway.

1. OSA can result in development of elevated ICP. The causal relationship and the exact
 2. underlying mechanism between airway obstruction and elevated ICP are not fully clear.
 3. A possible hypothesis is that the muscular tone of the pharyngeal dilators, who maintain
 4. the patency of the airway, reduces during active sleep. This causes accumulation of carbon
 5. dioxide and reactive vasodilatation, followed by a rise in ICP. With the elevated ICP
 6. the cerebral perfusion pressure decreases resulting in more vasodilatation. A vicious cycle
 7. exists, which can be broken by an arousal resulting in correction of the blood gases and
 8. the airway obstruction^{30, 42, 65}.

9.

10. **Causes of obstructive sleep apnea**

11. The upper airway obstruction is due to an anatomically small upper airway and/ or to a
 12. decreased neuromuscular tone of the pharyngeal dilators during sleep. Anatomic factors
 13. along the upper airway, such as nasal obstruction, enlarged tonsils and adenoids, pha-
 14. ryngeal collapse or fat deposition by obesity can decrease the airway size or stability, and
 15. may therefore contribute to the development of OSA. Also endocrine disorders, such as
 16. hypothyroidy or acromegaly, and neuromuscular factors, such as hypotonia or hypertonia
 17. can result in OSA. Medicaments, such as analgesics or muscle relaxants can affect the
 18. neural control or collapsibility of the airway or reduce the size of the upper airway⁶⁶.

19. Also craniofacial anomalies, such as midface hypoplasia, retro- or micrognathia, skull
 20. base anomalies or a narrow maxillary arch can lead to a decrease in the size of the rhino-
 21. pharynx, oropharynx, or hypopharynx, and can predispose to obstructive sleep apnea^{67, 68}.

22.

23. **Prevalence of obstructive sleep apnea**

24. Obstructive sleep apnea exists in 2 to 5 percent of the healthy children, which can occur at
 25. any age with a peak incidence between three and six years of age⁶². At that age adenotonsil-
 26. lar hypertrophy is the major risk factor for development of OSA, because the tonsils and
 27. adenoid are the largest in relation to the oropharynx^{62, 69}.

28. The risk to develop OSA is 40% in children with Apert, Crouzon and Pfeiffer syndrome
 29. mainly during the first six years of life^{45, 68, 70}. Beside the anatomical anomalies in these
 30. syndromes they also develop adenotonsillar hypertrophy. In Muenke and Saethre-Chotzen
 31. syndrome and complex craniosynostosis the incidence of OSA is unknown.

32. In 1982, Schafer described upper airway obstruction and sleep disorders in children with
 33. craniofacial anomalies⁷¹. Up till then, little attention was paid to respiratory difficulties in
 34. syndromic craniosynostosis. Only the severe OSA patients are recognized and the initial
 35. treatment was a tracheostomy⁷². However, in the last years due to the familiarity with the
 36. risk to develop OSA in presence of syndromic craniosynostosis also the moderate and mild
 37. cases are diagnosed.

38.

39.

1. **Diagnostic methods**

2. A questionnaire on presence of symptoms can be helpful to screen for obstructive sleep ap-
3. nea. This questionnaire is developed and validated for normal, otherwise healthy children
4. and consists of three questions about the presence of difficulty in breathing during sleep,
5. observed apneas and snoring. From this questionnaire the Brouillette score is calculated
6. which is related to the likelihood of having OSA⁷³.

7. Another tool to estimate the presence of OSA is observation of the child during sleep.
8. The parents' observation includes different items: effort of respiration (difficulty in brea-
9. thing), apneas during breathing, snoring, retractions, sleep position, hyperextension of the
10. neck, restless sleep and mouth breathing.

11. The gold standard to diagnose presence and severity of OSA is polysomnography (PSG).
12. Polysomnography can be done at the hospital or ambulatory at home. A lot of studies to
13. diagnose OSA and to analyze PSG's are done in adults. Much fewer studies are performed
14. in children and different definitions for duration and severity of OSA are used. The degree
15. of OSA is expressed in an obstructive apnea hypopnea index (OAHI), the number of ob-
16. structive and mixed apneas and hypopneas followed by desaturation per hour. An OAHI
17. ≥ 1 is defined as OSA. Also an oxygenation desaturation index (ODI) is measured by the
18. number of desaturations ($\geq 4\%$ decrease with respect to the baseline) per hour. A score
19. < 1 is considered to be normal, between 1-5 is defined as mild OSA, between 6 and 25 as
20. moderate OSA, and > 25 as severe OSA^{62, 63, 74, 75}.

21.

22. **Treatment of obstructive sleep apnea**

23. According to its severity and cause or level of obstruction, OSA can be treated phar-
24. macologically (e.g. with nasal corticosteroid spray or antibiotics), surgically (e.g. with
25. adenotonsillectomy (ATE) or midface advancement), or non-surgically (e.g. with noc-
26. turnal oxygen or continuous or bi-level positive airway pressure (CPAP or BiPAP))^{67, 69, 76}.

27. Because of the associated midface hypoplasia in children with Apert, Crouzon or
28. Pfeiffer syndrome, midface advancement appears to be the treatment of choice for OSA
29. in syndromic craniosynostosis⁷⁷. But on long-term mixed respiratory results of midface
30. advancement in patients with syndromic craniosynostosis are reported⁷⁸. It is unclear how
31. long and to which level the improvement in breathing lasts, and which factors are predic-
32. tors of respiratory outcome. It is known that growth of the maxilla in anterior direction is
33. very limited in Apert, Crouzon and Pfeiffer syndrome, so if surgical advancement of the
34. maxilla is performed at an early age further advancement at adult age will be needed^{79, 80}.

35.

36. **Consequences of untreated obstructive sleep apnea**

37. If OSA is not treated sufficiently, disturbed sleep patterns may result in major physical
38. and functional impairment, for instance failure to thrive, recurrent infections, feeding
39. difficulties, disturbed cognitive functions, delayed development, cor pulmonale or sudden

1. death⁸¹. Because of the major consequences of untreated OSA early recognition is mandatory⁷⁰. Specific attention for upper airway obstruction during follow-up is needed.

3.

4.

5. **QUALITY OF LIFE AND BEHAVIOR**

6.

7. **Quality of life**

8. Quality of life is a method to describe the impact on daily functioning of a disorder.
9. International standardised quality of life questionnaires are available and there are two
10. different types of quality of life, the general health-related quality of life (Infant Toddler
11. Quality of Life questionnaire (ITQoL) or Child Health Questionnaire (CHQ)) and the
12. disease-specific (OSA-18)⁸²⁻⁸⁵. With the health-related quality of life questionnaires several
13. domains are examined and a general reproduction of the impact of the sickness of the
14. child is given on the physical and psychosocial aspects of the health of the child, parent
15. and family. With the disease-specific questionnaire special domains associated with a
16. disease are evaluated to show the impact of this specific disease.

17. In different fields the health-related quality of life is assessed, such as in children with
 18. cancer, meningococcal septic shock and cleft lip and palate⁸⁶⁻⁸⁸. For obstructive sleep apnea
 19. the OSA-18 survey is developed to use in healthy children with a history of snoring and
 20. disrupted sleep for three months or longer due to adenotonsillar hypertrophy. A significant
 21. correlation between the mean OSA-18 score and the severity of OSA is found⁸².

22. Warschausky et al.⁸⁹ reported health-related quality of life in children with craniofacial
 23. anomalies. They compared 27 children with primary cleft lip and/ or palate with 28 chil-
 24. dren with other craniofacial diagnoses, including only 5 children with Apert, Crouzon or
 25. complex craniosynostosis. They found significant perceived general health concerns in the
 26. second group, but no specific physical or mental health concerns.

27. Health-related and disease-specific quality of life in a selected group of children with
 28. syndromic or complex craniosynostosis is not studied before.

29.

30. **Behavior**

31. Behavior, attention and concentration are important aspects in the development of chil-
 32. dren. These aspects are possibly impaired in children with craniosynostosis that is associ-
 33. ated with developmental delay and lower intelligence in some syndromes. Problems can
 34. be assessed with the Child Behavior Checklist (CBCL), a widely used norm-referenced
 35. measure^{90, 91}.

36. Boltshausen et al.⁹² evaluated behavior and quality of life in 30 patients with isolated
 37. sagittal craniosynostosis. Parents reported the behavior of their children in the normal
 38. range and the health-related quality of life was comparable with the norms, except lower
 39. scores on positive emotional functioning.

1. The amount of behavioral and emotional problems in children with syndromic or
2. complex craniosynostosis is unknown.

3.

4.

5. **HYPOTHESIS AND OBJECTIVES**

6.

7. The aim of this thesis is to assess the importance and impact of obstructive sleep apnea in
8. children with syndromic or complex craniosynostosis. The topics of interest are the preva-
9. lence, diagnostics and treatment outcome of obstructive sleep apnea and the influence on
10. prevalence of papilledema, health-related quality of life and general behavior.

11.

12. **Hypothesis**

13. Obstructive sleep apnea is an important feature in children with syndromic and complex
14. craniosynostosis, which requires regular screening and affects daily functioning.

15.

16. **Objectives**

17. The risk for developing obstructive sleep apnea in children with syndromic craniosy-
18. nostosis is known for a few years, but the prevalence and consequences in these children
19. are unknown. Diagnostic methods and treatment modalities need to be evaluated. The
20. objectives of this thesis are:

21. 1. To determine the prevalence, evaluate screening tools, diagnostic methods and determi-

22. nants of obstructive sleep apnea in children with syndromic and complex craniosynostosis

23. 2. To assess the respiratory outcome of midface advancement for treatment of obstructive

24. sleep apnea and to determine the factors contributing to its efficacy

25. 3. To describe the prevalence of functional problems in children with syndromic cranio-
26. synostosis

27. 4. To assess the health-related and disease-specific quality of life and behavioral problems
28. in these children.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

I. REFERENCES

1. Merrill AE, Bochukova EG, Brugger SM, et al. Cell mixing at a neural crest-mesoderm boundary and deficient ephrin-Eph signaling in the pathogenesis of craniosynostosis. *Human molecular genetics* 2006;15:1319-1328.
2. Tunnessen WW, Jr. Persistent open anterior fontanelle. *Jama* 1990;264:2450.
3. Mathijssen IM, van Splunder J, Vermeij-Keers C, et al. Tracing craniosynostosis to its developmental stage through bone center displacement. *Journal of craniofacial genetics and developmental biology* 1999;19:57-63.
4. Lajeunie E, Heuertz S, El Ghouzzi V, et al. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet* 2006;14:289-298.
5. Bochukova EG, Roscioli T, Hedges DJ, et al. Rare mutations of FGFR2 causing apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new subfamily. *Human mutation* 2009;30:204-211.
6. Wilkie AO, Slaney SF, Oldridge M, et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. *Nat Genet* 1995;9:165-172.
7. Renier D, Arnaud E, Cinalli G, et al. Prognosis for mental function in Apert's syndrome. *J Neurosurg* 1996;85:66-72.
8. Yacubian-Fernandes A, Palhares A, Giglio A, et al. Apert syndrome: factors involved in the cognitive development. *Arquivos de neuro-psiquiatria* 2005;63:963-968.
9. Da Costa AC, Walters I, Savarirayan R, et al. Intellectual outcomes in children and adolescents with syndromic and nonsyndromic craniosynostosis. *Plastic and reconstructive surgery* 2006;118:175-181; discussion 182-173.
10. Reardon W, Winter RM, Rutland P, et al. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. *Nat Genet* 1994;8:98-103.
11. Meyers GA, Orlow SJ, Munro IR, et al. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. *Nat Genet* 1995;11:462-464.
12. Yacubian-Fernandes A, Ducati LG, Silva MV, et al. [Crouzon syndrome: factors related to the neuropsychological development and to the quality of life]. *Arquivos de neuro-psiquiatria* 2007;65:467-471.
13. Cornejo-Roldan LR, Roessler E, Muenke M. Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome. *Human genetics* 1999;104:425-431.
14. Muenke M, Schell U, Hehr A, et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. *Nat Genet* 1994;8:269-274.
15. Rutland P, Pulleyn LJ, Reardon W, et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. *Nat Genet* 1995;9:173-176.
16. Muenke M, Gripp KW, McDonald-McGinn DM, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. *American journal of human genetics* 1997;60:555-564.
17. Moloney DM, Wall SA, Ashworth GJ, et al. Prevalence of Pro250Arg mutation of fibroblast growth factor receptor 3 in coronal craniosynostosis. *Lancet* 1997;349:1059-1062.
18. Kress W, Schropp C, Lieb G, et al. Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. *Eur J Hum Genet* 2006;14:39-48.
19. Doherty ES, Lacbawan F, Hadley DW, et al. Muenke syndrome (FGFR3-related craniosynostosis): expansion of the phenotype and review of the literature. *American journal of medical genetics* 2007;143A:3204-3215.

1. 20. Arnaud E, Meneses P, Lajeunie E, et al. Postoperative mental and morphological outcome for nonsyndromic brachycephaly. *Plastic and reconstructive surgery* 2002;110:6-12; discussion 13.
2. 21. Kimonis V, Gold JA, Hoffman TL, et al. Genetics of craniosynostosis. *Seminars in pediatric neurology* 2007;14:150-161.
3. 22. Pantke OA, Cohen MM, Jr., Witkop CJ, Jr., et al. The Saethre-Chotzen syndrome. *Birth defects original article series* 1975;11:190-225.
4. 23. de Heer IM, de Klein A, van den Ouweland AM, et al. Clinical and genetic analysis of patients with Saethre-Chotzen syndrome. *Plastic and reconstructive surgery* 2005;115:1894-1902; discussion 1903-1895.
5. 24. Morriss-Kay GM, Wilkie AO. Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies. *J Anat* 2005;207:637-653.
6. 25. Lajeunie E, Catala M, Renier D. Craniosynostosis: from a clinical description to an understanding of bone formation of the skull. *Childs Nerv Syst* 1999;15:676-680.
7. 26. Britto JA. Advances in the molecular pathogenesis of craniofacial conditions. *Oral and maxillofacial surgery clinics of North America* 2004;16:567-586.
8. 27. Passos-Bueno MR, Serti Eacute AE, Jehee FS, et al. Genetics of craniosynostosis: genes, syndromes, mutations and genotype-phenotype correlations. *Frontiers of oral biology* 2008;12:107-143.
9. 28. Allen CH, Ward JD. An evidence-based approach to management of increased intracranial pressure. *Critical care clinics* 1998;14:485-495.
10. 29. Wiegand C, Richards P. Measurement of intracranial pressure in children: a critical review of current methods. *Developmental medicine and child neurology* 2007;49:935-941.
11. 30. Hayward R. Venous hypertension and craniosynostosis. *Childs Nerv Syst* 2005;21:880-888.
12. 31. Sgouros S, Goldin JH, Hockley AD, et al. Intracranial volume change in childhood. *J Neurosurg* 1999;91:610-616.
13. 32. Sgouros S, Hockley AD, Goldin JH, et al. Intracranial volume change in craniosynostosis. *J Neurosurg* 1999;91:617-625.
14. 33. Anderson PJ, Netherway DJ, Abbott AH, et al. Analysis of intracranial volume in apert syndrome genotypes. *Pediatric neurosurgery* 2004;40:161-164.
15. 34. Gault DT, Renier D, Marchac D, et al. Intracranial volume in children with craniosynostosis. *J Craniofac Surg* 1990;1:1-3.
16. 35. Gosain AK, McCarthy JG, Glatt P, et al. A study of intracranial volume in Apert syndrome. *Plastic and reconstructive surgery* 1995;95:284-295.
17. 36. Posnick JC, Armstrong D, Bite U. Crouzon and Apert syndromes: intracranial volume measurements before and after cranio-orbital reshaping in childhood. *Plastic and reconstructive surgery* 1995;96:539-548.
18. 37. Gault DT, Renier D, Marchac D, et al. Intracranial pressure and intracranial volume in children with craniosynostosis. *Plastic and reconstructive surgery* 1992;90:377-381.
19. 38. Fok H, Jones BM, Gault DG, et al. Relationship between intracranial pressure and intracranial volume in craniosynostosis. *British journal of plastic surgery* 1992;45:394-397.
20. 39. Collmann H, Sorensen N, Krauss J. Hydrocephalus in craniosynostosis: a review. *Childs Nerv Syst* 2005;21:902-912.
21. 40. Reid S, Ferretti P. Differential expression of fibroblast growth factor receptors in the developing murine choroid plexus. *Brain research* 2003;141:15-24.
22. 41. Cinalli G, Spennato P, Sainte-Rose C, et al. Chiari malformation in craniosynostosis. *Childs Nerv Syst* 2005;21:889-901.
23. 42. Hayward R, Gonzalez S. How low can you go? Intracranial pressure, cerebral perfusion pressure, and respiratory obstruction in children with complex craniosynostosis. *J Neurosurg* 2005;102:16-22.
24. 39.


1. 43. Taylor WJ, Hayward RD, Lasjaunias P, et al. Enigma of raised intracranial pressure in patients with complex craniosynostosis: the role of abnormal intracranial venous drainage. *J Neurosurg* 2001;94:377-385.
- 2.
3. 44. Rich PM, Cox TC, Hayward RD. The jugular foramen in complex and syndromic craniosynostosis and its relationship to raised intracranial pressure. *AJNR Am J Neuroradiol* 2003;24:45-51.
- 4.
5. 45. Pijpers M, Poels PJ, Vaandrager JM, et al. Undiagnosed obstructive sleep apnea syndrome in children with syndromal craniofacial synostosis. *J Craniofac Surg* 2004;15:670-674.
- 6.
7. 46. Arnaud E, Renier D, Marchac D. Prognosis for mental function in scaphocephaly. *J Neurosurg* 1995;83:476-479.
- 8.
9. 47. Mathijssen I, Arnaud E, Lajeunie E, et al. Postoperative cognitive outcome for synostotic frontal plagiocephaly. *J Neurosurg* 2006;105:16-20.
10. 48. Renier D, Lajeunie E, Arnaud E, et al. Management of craniosynostoses. *Childs Nerv Syst* 2000;16:645-658.
11. 49. Renier D, Sainte-Rose C, Marchac D, et al. Intracranial pressure in craniostenosis. *J Neurosurg* 1982;57:370-377.
- 12.
13. 50. Marucci DD, Dunaway DJ, Jones BM, et al. Raised intracranial pressure in Apert syndrome. Plastic and reconstructive surgery 2008;122:1162-1168; discussion 1169-1170.
- 14.
15. 51. Thompson DN, Harkness W, Jones B, et al. Subdural intracranial pressure monitoring in craniosynostosis: its role in surgical management. *Childs Nerv Syst* 1995;11:269-275.
- 16.
17. 52. Thompson DN, Malcolm GP, Jones BM, et al. Intracranial pressure in single-suture craniosynostosis. *Pediatric neurosurgery* 1995;22:235-240.
- 18.
19. 53. Woods RH, Ul-Haq E, Wilkie AO, et al. Reoperation for intracranial hypertension in TWIST1-confirmed Saethre-Chotzen syndrome: a 15-year review. *Plastic and reconstructive surgery* 2009;123:1801-1810.
- 20.
21. 54. Tamburrini G, Caldarelli M, Massimi L, et al. Intracranial pressure monitoring in children with single suture and complex craniosynostosis: a review. *Childs Nerv Syst* 2005;21:913-921.
- 22.
23. 55. Tuite GF, Evanson J, Chong WK, et al. The beaten copper cranium: a correlation between intracranial pressure, cranial radiographs, and computed tomographic scans in children with craniosynostosis. *Neurosurgery* 1996;39:691-699.
- 24.
25. 56. Tuite GF, Chong WK, Evanson J, et al. The effectiveness of papilledema as an indicator of raised intracranial pressure in children with craniosynostosis. *Neurosurgery* 1996;38:272-278.
- 26.
27. 57. Fried M, Meyer-Schwickerath G, Koch A. Excessive hypermetropia: review and case report documented by echography. *Annals of ophthalmology* 1982;14:15-19.
- 28.
29. 58. Karam EZ, Hedges TR. Optical coherence tomography of the retinal nerve fibre layer in mild papilloedema and pseudopapilloedema. *The British journal of ophthalmology* 2005;89:294-298.
- 30.
31. 59. Desch LW. Longitudinal stability of visual evoked potentials in children and adolescents with hydrocephalus. *Developmental medicine and child neurology* 2001;43:113-117.
- 32.
33. 60. Bartels MC, Vaandrager JM, de Jong TH, et al. Visual loss in syndromic craniosynostosis with papilloedema but without other symptoms of intracranial hypertension. *J Craniofac Surg* 2004;15:1019-1022; discussion 1023-1014.
- 34.
35. 61. Stavrou P, Sgouros S, Willshaw HE, et al. Visual failure caused by raised intracranial pressure in craniosynostosis. *Childs Nerv Syst* 1997;13:64-67.
- 36.
37. 62. Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol* 1996;13:198-207.
- 38.
39. 63. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Arch Pediatr Adolesc Med* 2005;159:775-785.

64. Arens R, Sin S, McDonough JM, et al. Changes in upper airway size during tidal breathing in children with obstructive sleep apnea syndrome. *American journal of respiratory and critical care medicine* 2005;171:1298-1304.
65. Gonsalez S, Hayward R, Jones B, et al. Upper airway obstruction and raised intracranial pressure in children with craniosynostosis. *Eur Respir J* 1997;10:367-375.
66. Al Lawati NM, Patel SR, Ayas NT. Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration. *Progress in cardiovascular diseases* 2009;51:285-293.
67. Hoeve HL, Joosten KF, van den Berg S. Management of obstructive sleep apnea syndrome in children with craniofacial malformation. *Int J Pediatr Otorhinolaryngol* 1999;49 Suppl 1:S59-61.
68. Lo LJ, Chen YR. Airway obstruction in severe syndromic craniosynostosis. *Ann Plast Surg* 1999;43:258-264.
69. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2002;109:704-712.
70. Hoeve LJ, Pijpers M, Joosten KF. OSAS in craniofacial syndromes: an unsolved problem. *Int J Pediatr Otorhinolaryngol* 2003;67 Suppl 1:S111-113.
71. Schafer ME. Upper airway obstruction and sleep disorders in children with craniofacial anomalies. *Clinics in plastic surgery* 1982;9:555-567.
72. Lauritzen C, Lilja J, Jarlstedt J. Airway obstruction and sleep apnea in children with craniofacial anomalies. *Plastic and reconstructive surgery* 1986;77:1-6.
73. Brouillette R, Hanson D, David R, et al. A diagnostic approach to suspected obstructive sleep apnea in children. *J Pediatr* 1984;105:10-14.
74. Guillemainault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995;127:905-912.
75. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg* 2003;129:1281-1284.
76. Goldstein NA, Fatima M, Campbell TF, et al. Child behavior and quality of life before and after tonsillectomy and adenoidectomy. *Arch Otolaryngol Head Neck Surg* 2002;128:770-775.
77. Nout E, Cesteley LL, van der Wal KG, et al. Advancement of the midface, from conventional Le Fort III osteotomy to Le Fort III distraction: review of the literature. *Int J Oral Maxillofac Surg* 2008
78. Nelson TE, Mulliken JB, Padwa BL. Effect of midfacial distraction on the obstructed airway in patients with syndromic bilateral coronal synostosis. *J Oral Maxillofac Surg* 2008;66:2318-2321.
79. Bachmayer DI, Ross RB, Munro IR. Maxillary growth following LeFort III advancement surgery in Crouzon, Apert, and Pfeiffer syndromes. *Am J Orthod Dentofacial Orthop* 1986;90:420-430.
80. Meazzini MC, Mazzoleni F, Caronni E, et al. Le Fort III advancement osteotomy in the growing child affected by Crouzon's and Apert's syndromes: presurgical and postsurgical growth. *J Craniofac Surg* 2005;16:369-377.
81. Nixon GM, Brouillette RT. Sleep. 8: paediatric obstructive sleep apnoea. *Thorax* 2005;60:511-516.
82. Franco RA, Jr., Rosenfeld RM, Rao M. First place--resident clinical science award 1999. Quality of life for children with obstructive sleep apnea. *Otolaryngol Head Neck Surg* 2000;123:9-16.
83. Raat H, Bonsel GJ, Essink-Bot ML, et al. Reliability and validity of comprehensive health status measures in children: The Child Health Questionnaire in relation to the Health Utilities Index. *Journal of clinical epidemiology* 2002;55:67-76.
84. Raat H, Landgraf JM, Bonsel GJ, et al. Reliability and validity of the child health questionnaire-child form (CHQ-CF87) in a Dutch adolescent population. *Qual Life Res* 2002;11:575-581.

1. 85. Raat H, Landgraf JM, Oostenbrink R, et al. Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQOL) in a general population and respiratory disease sample. *Qual Life Res* 2007;16:445-460.
- 2.
3. 86. Waters EB, Wake MA, Hesketh KD, et al. Health-related quality of life of children with acute lymphoblastic leukaemia: comparisons and correlations between parent and clinician reports. *International journal of cancer* 2003;103:514-518.
- 4.
5. 87. Buysse CM, Raat H, Hazelzet JA, et al. Long-term health-related quality of life in survivors of meningococcal septic shock in childhood and their parents. *Qual Life Res* 2007;16:1567-1576.
- 6.
7. 88. Damiano PC, Tyler MC, Romitti PA, et al. Health-related quality of life among preadolescent children with oral clefts: the mother's perspective. *Pediatrics* 2007;120:e283-290.
- 8.
9. 89. Warschausky S, Kay JB, Buchman S, et al. Health-related quality of life in children with craniofacial anomalies. *Plastic and reconstructive surgery* 2002;110:409-414; discussion 415-406.
- 10.
11. 90. Rescorla LA. Assessment of young children using the Achenbach System of Empirically Based Assessment (ASEBA). *Mental retardation and developmental disabilities research reviews* 2005;11:226-237.
- 12.
13. 91. Ivanova MY, Dobrean A, Dopfner M, et al. Testing the 8-syndrome structure of the child behavior checklist in 30 societies. *J Clin Child Adolesc Psychol* 2007;36:405-417.
- 14.
15. 92. Boltshauser E, Ludwig S, Dietrich F, et al. Sagittal craniosynostosis: cognitive development, behavior, and quality of life in unoperated children. *Neuropediatrics* 2003;34:293-300.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.

Part II

Screening tools, diagnostic methods and treatment of obstructive sleep apnea





Chapter 2

Can parents predict obstructive sleep apnea in children with syndromic or complex craniosynostosis?

Bannink N

Mathijssen IMJ

Joosten KFM

1. **ABSTRACT**

2.

3. **Objective**

4. Obstructive sleep apnea (OSA) is a clinical syndrome characterized by snoring, apneas and
5. difficulty in breathing. These symptoms can be rated and a risk score (Brouillette score) can
6. be calculated to estimate the likelihood of OSA. This study aimed at establishing the pre-
7. dictive value of the Brouillette score and observation by parents at home in children with
8. syndromic or complex craniosynostosis, compared with ambulatory polysomnography.

9.

10. **Methods**

11. This prospective study included 78 patients (37 boys, mean age 7.3 years). Sensitivity and
12. negative predictive values were calculated.

13.

14. **Results**

15. Polysomnography showed clinically significant OSA in 11 children. The Brouillette score
16. had a negative predictive value of 90% and a sensitivity of 55% in comparison with poly-
17. somnography. More than three quarters of all patients snored. The single question ‘Is there
18. difficulty with breathing during sleep?’ showed a sensitivity of 64% and a high negative
19. predictive value of 91%.

20.

21. **Conclusion**

22. Thus, asking parents whether the child has difficulty in breathing during sleep can exclude
23. the presence of clinical significant OSA and avoid polysomnography in children with
24. syndromic and complex craniosynostosis.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Obstructive sleep apnea (OSA) is a clinical syndrome characterized by difficulty in
 4. breathing, snoring and apneas during sleep resulting in sleep fragmentation, hypoxia and
 5. hypercapnia. Other features of OSA are restless sleep, mouth breathing and sweating.
 6. The 'gold standard' for diagnosing the presence and severity of OSA is polysomnography
 7. (PSG), but a feasible alternative is a questionnaire about the presence of symptoms. After
 8. discriminant analysis Brouillette et al. developed an OSA score, known as Brouillette
 9. score, to predict the presence of OSA with a high sensitivity¹. This score is calculated from
 10. a respondent's rating on three items (figure 1). Some studies showed that the Brouillette
 11. score could not reliably distinguish between the presence of OSA and simple snoring^{2,5}
 12. and that its sensitivity and specificity were not sufficient for affirming OSA⁶.

13. Children with syndromic or complex craniosynostosis have a 40% risk of developing
 14. OSA due to midface hypoplasia and collapse of the pharynx. They must be screened for
 15. OSA from birth on. This is usually done by PSG, as the value of the Brouillette score
 16.

17.

18. Questionnaire/ observation

19.

20. D. Difficulty in breathing during sleep?

21.

0 = never; 1 = occasionally; 2 = frequently; and 3 = always

22.

23. A. Stops breathing during sleep?

24.

25.

0 = no; 1 = yes

26.

27. S. Snoring?

28.

0 = never; 1 = occasionally; 2 = frequently; and 3 = always

29.

30.

31.

32. Brouillette score = $1.42 D + 1.41 A + 0.71 S - 3.83$

33.

34. > 3.5: diagnostic for OSA

35.

36. between -1 and 3.5: suggestive for OSA

37.

38. < -1: absence of OSA

38.

39. **Figure 1:** Items of the questionnaire and observation for calculating the Brouillette score

1. as a screening tool in these children has not been established. An earlier study by the
2. authors found a discrepancy between the high prevalence of OSA as established by the
3. questionnaire and analysis of the medical records⁷. The present study aimed to determine
4. the reliability of the Brouillette score and parents' observation at home compared with
5. ambulatory PSG to predict clinically significant OSA in children with syndromic or
6. complex craniosynostosis.

7.

8.

9. **METHODS**

10.

11. **Study design**

12. A prospective cohort study was carried out at the authors' hospital. All patients between
13. 0 and 18 years with syndromic or complex craniosynostosis registered at the Dutch
14. Craniofacial Center were invited to participate in the study between January 2007 and
15. March 2008. Syndromic craniosynostosis included Apert, Crouzon, Muenke, Pfeiffer and
16. Saethre-Chotzen syndromes. Complex craniosynostosis was defined as fusion of two cra-
17. nial sutures or more without known fibroblast growth factor receptor (FGFR) or TWIST
18. gene mutation. 98 of the eligible 111 patients (88%) were included after informed consent.

19. This study at home had three components. The parents rated the three items of the
20. Brouillette score (breathing difficulty, apnea and snoring) with regard to the sleep brea-
21. thing pattern of their child over the previous 3 months. The parents observed their child
22. at home during sleep for one period of 30 minutes and rated the items of the Brouillette
23. score every 5 minutes and recorded any mouth breathing. The children underwent a
24. cardiorespiratory polysomnography at home for one night.

25. The data were incomplete for 20 patients. Questionnaires on two patients and observa-
26. tion forms on 15 were not completed for various logistic reasons. During PSG the total
27. sleep time was below 360 minutes for three patients, which was too short for analysis. The
28. data from 78 patients were analyzed: 37 boys and 41 girls with a mean age of 7.3 ± 5.4 years
29. (SD) at the time of PSG.

30. From the questionnaire and the observation form a Brouillette score (Br score 1) and
31. observation score (Br score 2) were calculated using the equation $1.42 D + 1.41 A + 0.71$
32. $S - 3.83$ (figure 1)¹. OSA is likely if the score is above -1 and is thought to be absent if
33. the score is below -1 . Mouth breathing was considered as continuous if parents observed
34. mouth breathing during the whole observation.

35. Ambulatory PSG was carried out with Embletta Portable Diagnostic System and analyzed
36. with Somnologica for Embletta software 3.3 ENU (Medcare Flaga, Reykjavik, Iceland).
37. Thoracic and abdominal movements, nasal flow, saturation, and pulse were monitored. A
38. minimum of 360 minutes total sleep time was required. Obstructive apnea was defined as
39. absence of airflow (measured by a nasal cannula) or as out-of-phase movement of thorax

1. and abdomen (scored as X flow). Hypopnea was defined as $\geq 50\%$ reduction in nasal flow
 2. signal amplitude or X flow signal amplitude, both for more than two breaths^{6, 8, 9}. The X
 3. flow signal was the sum of the amplitudes of the thoracic and abdominal movements^{8, 9}
 4. and was used when nasal airflow was insufficient. Mixed apnea was defined as a type of
 5. obstructive apnea with a central component that mostly preceded the obstructive pattern,
 6. for more than two breaths. Central apneas were not included in this study. Desaturation
 7. was defined as $\geq 4\%$ decrease with respect to the baseline value. The severity of OSA was
 8. expressed in an obstructive apnea hypopnea index (OAHI), which consisted of: the hourly
 9. number of obstructive and mixed apneas; and the hourly number of hypopneas followed
 10. by desaturation.

11. A score of ≤ 5 is considered to be of no clinical significance with no necessity to treat,
 12. between 6 and 25 as moderate OSA, and > 25 as severe OSA^{10, 11}.

13. For statistical analysis, contingency tables were made and the sensitivity (sens) and nega-
 14. tive predictive value (NPV) with accessory 95% confidence intervals (CI) were calculated.
 15. The sensitivity of the questionnaire and observation (the number of Br scores ≥ -1 that
 16. correctly identified OSA) was tested in comparison with the results of the PSG. The nega-
 17. tive predictive value (the number of Br scores < -1 that correctly diagnosed the absence of
 18. OSA) of the two scores was calculated.

19.

20.

21. RESULTS

22.

23. For 52 of the 78 patients (67%) the Brouillette score (Br score 1) was < -1 . For 57 of the 78
 24. patients (73%) the observation score (Br score 2) was < -1 . Continuous mouth breathing
 25. was observed in 23 patients. The X flow was used in 15 of them, for whom the nasal flow
 26. registration was insufficient. Eleven PSG's were clinically significant and scored as OSA,
 27. based on OAHI.

28. The predictive results for the presence of clinical significant OSA are shown in table 1.
 29. The questionnaire had a high negative predictive value of 90% and a sensitivity of 55%
 30. when related to PSG. Combining the questionnaire with the parents' observation gives
 31. a slight improvement of predicting OSA (sensitivity 64% and negative predictive value

32.

33.

Table 1: Questionnaire and observation as tools for predicting clinically significant OSA (OAHI >5)

	Questionnaire				Observation
	Br score 1 < -1	Difficulty in breathing +	Apnea +	Snoring +	Br score 2 < -1
Sens (%)	6/ 11 (55%)	7/ 11 (64%)	3/ 11 (27%)	10/ 11 (91%)	4/ 11 (36%)
95% CI	[0.23-0.83]	[0.31-0.89]	[0.06-0.61]	[0.59-1.00]	[0.11-0.69]
NPV (%)	47/ 52 (90%)	40/ 44 (91%)	54/ 62 (87%)	17/ 18 (94%)	50/ 57 (88%)
95% CI	[0.79-0.97]	[0.78-0.97]	[0.76-0.94]	[0.73-1.00]	[0.76-0.95]

39.

1. 91%). In 89% of the observations the findings of the parents for the observed 30 minutes
2. corresponded with those for the matching PSG period.

3. For the questionnaire the sensitivity and negative predictive value for prediction of OSA
4. were calculated per item of the Brouillette score (table 1). Only asking about difficulty in
5. breathing during sleep (with the answer 'yes' or 'no') resulted in a sensitivity of 64% and a
6. high negative predictive value of 91%. Snoring is very sensitive (91%), but not specific due
7. to its high prevalence (77% 60/ 78).

8.

9.

10. **DISCUSSION**

11.

12. Children with syndromic or complex craniosynostosis can be screened for the presence or
13. absence of clinically significant OSA using a questionnaire administered at the outpatient
14. clinic. The sensitivity of this questionnaire is relatively low, whereas its negative predictive
15. value is high. This means that in the absence of positive answers on questions related to
16. the child's breathing pattern, clinically significant OSA is highly unlikely. If the single
17. question 'Has the child difficulty in breathing during sleep?' was answered negatively, the
18. presence of OSA could also be excluded. Similar observation by parents at home for 30
19. minutes did not give a higher predictive value for OSA compared with the questionnaire.

20. The sensitivity of the questionnaire according to the Brouillette score for OSA was
21. relatively low at 55%. In two earlier studies on normal healthy children sensitivities of
22. 89% and 80% were reported^{1, 12}. The Brouillette score was developed as a screening tool
23. for normal, healthy children with OSA, related to adenotonsillar hypertrophy and not to
24. craniofacial abnormalities⁴. A specific finding in children with syndromic and complex
25. craniosynostosis is that nearly all snore (in this study 77%) due to a narrow nose and mid-
26. face hypoplasia. In this specific population the question about snoring did not have any
27. additional value. On the contrary, if there was no difficulty in breathing during sleep as
28. reported by the parents, OSA can almost be excluded and additional PSG is not necessary.

29. In this study, the parents' observation during 30 minutes at home proved not to be a
30. more sensitive test for OSA than the questionnaire. In a similar study, in children up to the
31. age of 14 years and referred to a pediatric chest clinic, parents' observations at home did
32. not reliably predict the severity of OSA⁸. PSG was needed for this assessment, although
33. higher incidences of cyanosis, obstructive apnea and extremely loud snoring were reported
34. for these children with severe OSA⁸.

35. The present study is the first study to compare the results of ambulatory PSG with
36. parental observation at home and a questionnaire. Ambulatory PSG was successful in
37. this group of children in contrast to a previous study in healthy children scheduled for
38. adenotonsillectomy¹¹. As a possible explanation, children with syndromic or complex
39.

1. craniosynostosis may be more familiar with examinations due to frequent check-ups and
2. their parents may be more motivated.
3. A limitation of ambulatory PSG is the lack of various signals, such as nasal flow, which
4. are gathered during a clinical registration. In 15 patients the nasal flow signal was insuf-
5. ficient and obstructive apneas needed to be analyzed using the X flow. A possible reason is
6. the continuous mouth breathing commonly observed in these children.
- 7.
8. In conclusion, the answer 'no' to the question 'Has the child difficulty in breathing during
9. sleep?' is helpful to exclude OSA in children with syndromic and complex craniosynostosis.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.

I. REFERENCES

2. 1. Brouillette R, Hanson D, David R, et al. A diagnostic approach to suspected obstructive sleep apnea in children. *J Pediatr* 1984;105:10-14.

3. 2. Carroll JL, McColley SA, Marcus CL, et al. Inability of clinical history to distinguish primary snoring from obstructive sleep apnea syndrome in children. *Chest* 1995;108:610-618.

4. 3. Goldstein NA, Sculerati N, Walsleben JA, et al. Clinical diagnosis of pediatric obstructive sleep apnea validated by polysomnography. *Otolaryngol Head Neck Surg* 1994;111:611-617.

5. 4. Suen JS, Arnold JE, Brooks LJ. Adenotonsillectomy for treatment of obstructive sleep apnea in children. *Arch Otolaryngol Head Neck Surg* 1995;121:525-530.

6. 5. Wang RC, Elkins TP, Keech D, et al. Accuracy of clinical evaluation in pediatric obstructive sleep apnea. *Otolaryngol Head Neck Surg* 1998;118:69-73.

7. 6. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Arch Pediatr Adolesc Med* 2005;159:775-785.

8. 7. Pijpers M, Poels PJ, Vaandrager JM, et al. Undiagnosed obstructive sleep apnea syndrome in children with syndromal craniofacial synostosis. *J Craniofac Surg* 2004;15:670-674.

9. 8. Preutthipan A, Chantarojanasiri T, Suwanjutha S, et al. Can parents predict the severity of childhood obstructive sleep apnoea? *Acta Paediatr* 2000;89:708-712.

10. 9. Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol* 1996;13:198-207.

11. 10. Guilleminault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995;127:905-912.

12. 11. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg* 2003;129:1281-1284.



13. 12. Brouillette RT, Morielli A, Leimanis A, et al. Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea. *Pediatrics* 2000;105:405-412.

14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39.



Chapter 3


Use of ambulatory polysomnography in children with syndromic craniosynostosis



Bannink N

Mathijssen IMJ

Joosten KFM



I. **ABSTRACT**

2.

3. **Objective**

4. Children with syndromic or complex craniosynostosis are at risk to develop obstructive
5. sleep apnea due to midface hypoplasia and collapse of the pharynx. The golden standard
6. to diagnose OSA is polysomnography. The aim of this study is to analyze the feasibility of
7. a home cardiorespiratory monitor in children with syndromic or complex craniosynostosis
8. and to analyze whether oximetry alone or the sum of the amplitudes of the thoracic and
9. abdominal movements (X flow) are valuable alternative assessments to diagnose obstructive
10. sleep apnea at home, when complete recording was not achieved.

11.

12. **Methods**

13. We performed a prospective study in 129 children and analyzed 200 different ambulatory
14. polysomnographies.

15.

16. **Results**

17. In 41% of the measurements a complete analysis of the obstructive apnea hypopnea index
18. was possible based on adequate recording of all sensors. Oximetry in comparison with
19. polysomnography had a positive predictive value of 82% and negative predictive value of
20. 79% for diagnosing obstructive sleep apnea. Moderate obstructive sleep apnea could be
21. excluded with a negative oximetry. Comparing the X flow and the nasal flow signals the
22. hypopneas were adequately recorded in 86% and the obstructive apneas in 55%, resulting
23. in an underestimation of the severity of OSA in 10%.

24.

25. **Conclusion**

26. In children with syndromic or complex craniosynostosis the home cardiorespiratory
27. monitoring is feasible to diagnose obstructive sleep apnea. Oximetry alone can be used as
28. a rough estimate screening and with a negative test moderate OSA can be excluded. X flow
29. can be helpful to diagnose OSA in absence of nasal flow.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Children with syndromic or complex craniosynostosis are at risk to develop obstructive
4. sleep apnea (OSA) due to midface hypoplasia and collapse of the pharynx¹. Regular
5. screening of these patients for the presence of OSA is indicated. The golden standard
6. to diagnose OSA is polysomnography (PSG) in a hospital setting. In 2003, Poels et al.²
7. evaluated the feasibility of the home cardiorespiratory recording device during a single-
8. night to assess OSA in children who snore, between the ages of two to seven. Only 29%
9. of the recordings that were performed in 24 children were classified as successful. Possible
10. explanations for this low percentage of successful studies were the limited tolerance of the
11. patients for the sensors and the fact that caregivers had to apply the device themselves with
12. the help of a written instruction.

13. In contrast to the healthy children studied by Poels et al.² children with syndromic or
14. complex craniosynostosis undergo medical examinations regularly and might therefore
15. tolerate application of the device better. With a successful use of home cardiorespiratory
16. monitoring the number of the visits and admissions to the hospital for routine polysomnog-
17. raphy can be reduced, which is of particular interest for these children and their families.

18. Home cardiorespiratory monitoring can be analyzed in the same way as polysomnogra-
19. phy in a hospital setting, but the use of definitions for apnea and hypopnea in children is
20. not uniform^{2,5}. The aim of our study is to analyze the feasibility of a home cardiorespira-
21. tory monitor in children with craniosynostosis and to analyze whether oximetry alone or
22. the sum of the amplitudes of the thoracic and abdominal movements (X flow) are valuable
23. alternative assessments to diagnose OSA at home, when complete recording of all the
24. sensor signals was not achieved.

25.

26.

27. METHODS

28.

29. Patients and study design

30. In a prospective longitudinal study children with a craniosynostosis syndrome or complex
31. craniosynostosis were included. Syndromic craniosynostosis included children with Apert,
32. Crouzon, Muenke, Pfeiffer and Saethre-Chotzen syndrome. Complex craniosynostosis is
33. defined as fusion of two cranial sutures or more without a known mutation in fibroblast
34. growth factor receptor (FGFR) 1, 2, 3 or TWIST gene.

35. After informed consent the child underwent a polysomnography at home. This proce-
36. dure was repeated annually. When treatment for OSA was needed the PSG was repeated
37. three months after starting the treatment.

38. The institutional medical ethics committee of the Erasmus Medical Center Rotterdam
39. approved the study protocol (MEC-2005-273).

1. **Equipment**

2. Polysomnography was done ambulatory with Embletta Portable Diagnostic System
3. (Medcare Flaga, Reykjavik, Iceland). Thoracic and abdominal movements were registered
4. by elastic trace belts. Nasal flow was measured by a nasal cannula (pressure transducer),
5. oxygen saturation and heart rate (pulse) were recorded by a pulse oximeter. The signals
6. from the sensors were displayed and analyzed with Somnologica for Embletta software 3.3
7. ENU (Medcare Flaga, Reykjavik, Iceland).

8.

9. *Procedure of ambulatory polysomnography*

10. The recording devices were transported to the children by a courier. Caregivers were
11. instructed to apply the sensors and start the recording by connecting the adapter to the
12. device at the usual bedtime. A manual was supplied. The next morning the recording was
13. ended and the courier brought the device back to the hospital.

14.

15. *Criteria for analysis*

16. 1. Feasibility was assessed in terms of the number of adequate performed recordings (i.e.
17. recordings during a minimal total sleep time) and the number of successful recordings
18. (i.e., recordings with sufficient artefact-free signals of the various determinants to allow
19. scoring of the PSG).

20. 2. Definitions of the various determinants.

21. a. Nasal flow as tool for the registration of respiration was used to differentiate between an
22. obstructive or central character of the apnea or hypopnea.

23. b. The minimum duration of total sleep time for overnight recordings on sleep apnea
24. evaluation in adults and children is 360 minutes⁶⁻⁸. In this study in children with cranio-
25. synostosis a measurement was also considered adequately performed and successful if a
26. minimal total sleep time of 360 minutes with artefact-free signals of the various determi-
27. nants was available.

28. c. Obstructive apnea was defined as absence of airflow (measured by a nasal cannula) and
29. hypopnea as reduction by $\geq 50\%$ in nasal flow signal amplitude, both for more than two
30. breaths⁸⁻¹⁰. Mixed apnea was defined as a type of obstructive apnea with a central compo-
31. nent that mostly preceded the obstructive pattern, for more than two breaths. A central
32. apnea was defined as the absence of airflow without effort of thorax and abdomen for more
33. than two breaths and was considered pathologic if it was followed by a desaturation. A
34. desaturation was defined as $\geq 4\%$ decrease in saturation with respect to the baseline.

35.

36. *Criteria for diagnosis*

37. The degree of OSA was expressed in an obstructive apnea hypopnea index (OAHI), the
38. number of obstructive and mixed apneas with or without desaturation in combination
39. with hypopneas followed by desaturation per hour. An OAHI score < 1 is considered to

1. be normal, between 1 and 5 is defined as mild OSA, between 6 and 25 as moderate OSA,
 2. and > 25 as severe OSA^{8, 9, 11}. A central apnea index (CAI) was calculated as the number
 3. of central apneas followed by desaturation per hour. An abnormal central apnea index was
 4. defined as ≥ 1 . A combined obstructive apnea hypopnea index and central apnea index
 5. (OAHCAI) was calculated. The similar scores for gradation of the index were used.

7. *Alternative assessments*

8. 1. Oximetry.

9. An oxygenation desaturation index (ODI) was determined, based on the number of
 10. desaturations per hour. A negative oximetry was defined as an $ODI < 1$.

11. 2. X flow.

12. The X flow is the sum of the amplitudes of the thoracic and abdominal movements and
 13. in case of obstruction out-of-phase movement of the thoracic and abdominal movements
 14. is present. Within the group of successful recordings a comparison was made between the
 15. obstructive apneas and hypopneas determined with the nasal flow and the X flow. The
 16. correlations between nasal flow and X flow were determined with intraclass correlation
 17. with the accessory 95% confidence interval (CI)¹². In the recordings in which nasal flow
 18. was absent the X flow was used to determine obstructive apneas and hypopneas.

20. **Statistical analysis**

21. For statistical analysis contingency tables were made to calculate the positive (PPV) and
 22. negative predictive value (NPV) for oximetry in comparison with polysomnography. A
 23. p-value of < 0.05 was considered to be statistically significant. All numbers are expressed
 24. as median and range.

27. **RESULTS**

29. Of 150 eligible children 129 (86%) participated in the study, of whom 50% were boys.
 30. Their median age at the moment of PSG was 6.2 years (range 2.5 mnths-20.3 yrs). In this
 31. group 200 different polysomnographies were performed. Overall, 81 (40.5%) recordings in
 32. 65 children were suitable for calculating an OAHI (figure 1) with all signals being present.
 33. Of the remaining 119 recordings an oxygen saturation profile was available in 83 (41.5%),
 34. the oxygen saturation recording was too short in 3 (1.5%), and the recording was not
 35. adequately performed in 33 (16.5%) because the total sleep time was too short ($n = 28$, 14%)
 36. or the child did not co-operate ($n = 5$, 2.5%).

37. The analysis of the 81 successful recordings demonstrated 26 recordings (32%) in 21
 38. children with mild OSA and 8 (10%) recordings in 7 children with moderate OSA, based
 39. on OAHI (table 1).




Figure 1: Analysis of 200 polysomnography recordings in 129 children

Central apneas

An abnormal central apnea index was seen in 14 recordings in 12 children. The number of pathologic central apneas varied from one to six per hour (median of two per hour). There was a significant difference ($p=0.000$) in age between children diagnosed with or without an abnormal central apnea index (1.5 versus 9.0 years). A combined obstructive apnea hypopnea and central apnea index (OAHCAI) resulted in 42 (52%) recordings in 33 children in a mild index (between 1 and 5) and in 11 (14%) recordings in 9 children in a moderate index (between 6 and 25).

Oximetry

Analysis of the oxygenation desaturation index in the 81 successful recordings in 65 children showed a negative ODI in 53 recordings in 49 children (table 1). In these 53 recordings a positive OAH despite of the negative oximetry was found in 11 measurements (negative predictive value of 79%). A negative oximetry never resulted in missing of moderate OSA;

Table 1: Overview of the results of 81 successful polysomnographies

| | Polysomnographies
n = 81 (65 children) |
|-----------------------|---|
| TST (min) | 557 (360-900) |
| Mean saturation | 97.5 (sd 1.1) |
| Nadir saturation | 89.8 (sd 5.1) |
| Mean respiratory rate | 17.2 (sd 4.3) |
| Mean heart rate | 80.2 (sd 20.1) |
| OAHI < 1 | 47 (37 children) |
| OAHI 1-5 | 26 (21 children) |
| OAHI 6-25 | 8 (7 children) |
| CAI \geq 1 | 14 (12 children) |
| OAHCAI < 1 | 28 (23 children) |
| OAHCAI 1-5 | 42 (33 children) |
| OAHCAI 6-25 | 11 (9 children) |
| ODI < 1 | 53 (49 children) |
| ODI 1-5 | 20 (16 children) |
| ODI 6-25 | 8 (6 children) |

sd standard deviation

1. so the negative predictive value for moderate OSA was 100%. Of the 28 recordings with a
2. positive ODI also a positive OAHl was found in 23 (positive predictive value 82%).

3. Of the 83 recordings in 65 children with only an available oximetry signal 40 recordings
4. (48%) in 34 children showed OSA based on ODI; 30 mild OSA in 26 children, 9 moderate
5. OSA in 7 children and 1 severe OSA.

6.

7. X flow

8. Comparison of nasal flow with the X flow in successful recordings showed overall that 86%
9. of the hypopneas recorded with nasal flow were also scored with the X flow, whereas 55% of
10. the obstructive apneas recorded with nasal flow were also scored with the X flow. However,
11. after comparison the degree of OSA in no, mild or moderate measured by nasal and X flow
12. in these patients, in 10% the severity of OSA was underestimated.

13. In the 81 recordings with all signals the intraclass correlation of 0.77 between nasal flow
14. and X flow was good (95% confidence interval [0.65-0.86]). Of the 83 recordings with only
15. an available oximetry signal in absence of nasal flow the X flow was analyzed in 69 (34.5%)
16. recordings in 56 children. These showed OSA in 33 recordings in 29 children; 23 mild in
17. 20 children and 10 moderate in 9 children.

18. Analysis of the oxygenation desaturation index in these 69 recordings showed a negative
19. ODI in 36 recordings in 35 children. In these 36 recordings a positive OAHl despite of
20. the negative oximetry was found in 10 measurements (negative predictive value of 72%).
21. A negative oximetry resulted in missing of one moderate OSA; so the negative predictive
22. value for moderate OSA was 97%. Of the 33 recordings with a positive ODI also a positive
23. OAHl was found in 23 (positive predictive value 70%). Using X flow as screening method
24. raised the overall success rate from 40.5 to 75% (table 2).

25.

26. **Table 2:** Diagnosis of obstructive sleep apnea based on OAHl measured by nasal flow or X flow and based on
27. ODI

| OSA | OAHl nasal flow
n = 81 (65 children) | OAHl X flow
n = 69 (56 children) | ODI
n = 83 (65 children) |
|------------------|---|-------------------------------------|-----------------------------|
| Mild | 32% (21 children) | 33% (20 children) | 36% (26 children) |
| Moderate/ severe | 10% (7 children) | 14% (9 children) | 12% (8 children) |

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. DISCUSSION

2.

3. In children with syndromic or complex craniosynostosis the use of home cardiorespira-
4. tory monitoring resulted in 40.5% successful recordings. This result is better than the
5. previously mentioned study in 'healthy' children scheduled for adenotonsillectomy by
6. Poels et al.² with a successful recording rate of only 29%. The higher number of successful
7. recordings might be explained by the fact that parents of children with a serious medical
8. condition were more motivated and maybe these children were more cooperative due to
9. their frequent medical investigations. The first explanation seems to be confirmed by the
10. high participation rate of 86% in this study, compared to 45% in the study of Poels et al.²
11. Of the recordings 59.5% were not successful due to absence of nasal flow, technical failure
12. or too short registration of the signals. Only 2.5% of the children did not accept the device.

13. The most logical reason for the absence or decreased presence of nasal flow was the shift
14. of the nasal cannula during sleep, or the fact that children did not tolerate the nasal can-
15. nula. We expected that children below the age of one and older children who understand
16. the aim of the recording would accept the nasal cannula better, but this was not seen in
17. this study. In these children with syndromic or complex craniosynostosis we speculate that
18. the main reason for the failing signal of the nasal cannula is the absence of nasal passage
19. due to the severe anatomical malformations of the nasal cavity, leading to almost complete
20. obstruction of the upper airway and as a consequence preferred mouth breathing¹³. This
21. problem might be solved using a mouth thermistor to record oral flow but this application
22. is not (yet) used at home.

23. In our definition of the OAH I we did not account for pathologic central apneas whereas
24. in some previous studies this was done². A combined OAHCAI showed a 20% increase
25. of the children with an index between 1 and 5 and a 4% increase of the children with an
26. index between 6 and 25. The high number of pathologic central apneas found in the very
27. young children was especially related to central irregularity of breathing^{14, 15}. It is however
28. important to notice that in patients with severe OSA, which was not the case in this
29. study, an increase of central apneas can be found due to ventilatory control instability¹⁶.
30. ¹⁷. Therefore when central apneas are taking into account in the analysis of OSA the AHI
31. can be considerably higher. Based on this study in children with syndromic or complex
32. craniosynostosis we recommend excluding the pathologic central apneas in the AHI for
33. defining OSA.

34. Concerning the definitions for the apnea hypopnea index we used the criteria stated in
35. 2005 by the American Academy of Sleep Medicine¹⁷. Brouillette et al.³ advocated using
36. oximetry alone to show OSA in healthy children. A high positive predictive value of 97%
37. was found if desaturations were recorded, but a negative oximetry could not rule out OSA.
38. Children with a negative oximetry had a 47% probability of having OSA on full poly-
39. somnography in the hospital. In our study we compared within the successful recordings

1. oximetry with the other signals and found compared with the study of Brouillette et al.³ a
2. lower positive predictive value for oximetry (82%) and a higher negative predictive value
3. (79%). However, if only moderate OSA is considered to be clinical significant a negative
4. oximetry never resulted in missing a case of moderate OSA. Overall, we concluded that
5. oximetry can be used as a rough estimate screening tool but with limited accuracy. In
6. the 83 recordings in 65 children in which only an oximetry signal was present we found a
7. negative test in 43 recordings in 31 children.

8. The use of X flow might be an alternative method in absence of the nasal flow. Previ-
9. ously Ciftci et al.¹⁸ showed in a clinical setting in 90 symptomatic adult patients with an
10. apnea hypopnea index > 5 that hypopneas monitored by only the effort amplitude of tho-
11. racoabdominal movements without regard for airflow amplitude had a sensitivity of 97%
12. and a specificity of 84% to distinguish between OSA and non-OSA. They concluded that
13. thoracoabdominal movements can be useful in situations when the nasal flow is difficult
14. to interpret¹⁸. We are the first to report the use of X flow in ambulatory polysomnography
15. in children in absence of a nasal flow measurement. Comparing the X flow and the nasal
16. flow signals we found using the X flow that in 86% the hypopneas were recorded and in
17. 55% the obstructive apneas. It was remarkable that hypopneas were detected better with
18. X flow than obstructive apneas because obstructive apneas will result in a more extensive
19. out-of-phase movement of thorax and abdomen. A possible explanation for the fact that
20. this out-of phase movement was less well recorded could be the positioning of the trace
21. belts during the recordings. Due to shifting of the trace belts, the same registration of
22. movements of either the abdominal or thoracic movements could occur. On the contrary,
23. the measurement of hypopnea is less dependent on the correct position of the trace belts
24. and the definition itself is more flexible than the definition of an obstructive apnea. How-
25. ever, the underestimation of the degree of OSA is limited with 10%. In 69 recordings in 56
26. children using the X flow in absence of nasal flow OSA was showed in 33 recordings (48%)
27. in 29 children. The negative (72%) and positive (70%) predictive value for oximetry were
28. lower in comparison with nasal flow, but a negative oximetry resulted in missing of only
29. one case of moderate OSA. If X flow was used as additional screening method the overall
30. success rate for ambulatory polysomnography recordings would rise from 40.5 to 75%.

31. Overall, comparing the presence of OSA using the complete recording of all the sensor
32. signals, oximetry or X flow, an almost similar percentage of 34% was found for mild OSA
33. and 12% for moderate OSA in this patient group.

34. Several limitations are to be noticed in this study due to the use of ambulatory polysom-
35. nography in an uncontrolled environment. Parents were instructed by a written form to
36. apply the sensors by themselves and due to inexperience not all sensors might be applied
37. sufficiently. We tested the X flow measurements using these home recordings whereas
38. we were not informed if the abdominal and thoracic belts were at the appropriate place.
39. Furthermore only one of the researchers (Bannink N.) scored the signals whereas it should

1. be better to have two different scorers looking each at the same recording, one analyzing
2. all signals with nasal flow and the other analyzing all signals minus nasal flow based on
3. X flow. Even more ideal would be to apply the ambulatory polysomnography sensors in
4. the hospital together with the sensors of regular full polysomnography to test the X flow
5. for validity. However, despite these limitations we think that X flow can be helpful in the
6. diagnosis of OSA in absence of nasal flow.
7.
8. In conclusion, in children with syndromic or complex craniosynostosis the home cardio-
9. respiratory monitoring is feasible to diagnose obstructive sleep apnea. Oximetry alone
10. can be used as a rough estimate screening and with a negative test moderate OSA can be
11. excluded. X flow can be helpful to diagnose OSA in absence of nasal flow.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.



I. REFERENCES

2. 1. Bannink N, Nout E, Wolvius EB, et al. Obstructive sleep apnea in children with syndromic craniosynostosis: long-term respiratory outcome of midface advancement. *Int J Oral Maxillofac Surg* 2010;39:115-121.
3. 2. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg* 2003;129:1281-1284.
4. 3. Brouillette RT, Morielli A, Leimanis A, et al. Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea. *Pediatrics* 2000;105:405-412.
5. 4. Guillemainault C, Li K, Khramtsov A, et al. Breathing patterns in prepubertal children with sleep-related breathing disorders. *Archives of pediatrics & adolescent medicine* 2004;158:153-161.
6. 5. Marcus CL, Omlin KJ, Basinki DJ, et al. Normal polysomnographic values for children and adolescents. *Am Rev Respir Dis* 1992;146:1235-1239.
7. 6. Ferber R, Millman R, Coppola M, et al. Portable recording in the assessment of obstructive sleep apnea. *ASDA standards of practice. Sleep* 1994;17:378-392.
8. 7. Friedman M, Ibrahim H, Bass L. Clinical staging for sleep-disordered breathing. *Otolaryngol Head Neck Surg* 2002;127:13-21.
9. 8. Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol* 1996;13:198-207.
10. 9. Guillemainault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Archives of pediatrics & adolescent medicine* 2005;159:775-785.
11. 10. Preutthipan A, Chantarojanasiri T, Suwanjutha S, et al. Can parents predict the severity of childhood obstructive sleep apnoea? *Acta Paediatr* 2000;89:708-712.
12. 11. Guillemainault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995;127:905-912.
13. 12. Tsai WH, Flemons WW, Whitelaw WA, et al. A comparison of apnea-hypopnea indices derived from different definitions of hypopnea. *Am J Respir Crit Care Med* 1999;159:43-48.
14. 13. Lowe LH, Booth TN, Joglar JM, et al. Midface anomalies in children. *Radiographics* 2000;20:907-922; quiz 1106-1107, 1112.
15. 14. Oliveira AJ, Nunes ML, Fojo-Olmos A, et al. Clinical correlates of periodic breathing in neonatal polysomnography. *Clin Neurophysiol* 2004;115:2247-2251.
16. 15. Weintraub Z, Cates D, Kwiatkowski K, et al. The morphology of periodic breathing in infants and adults. *Respiration physiology* 2001;127:173-184.
17. 16. White DP. Central sleep apnea. *The Medical clinics of North America* 1985;69:1205-1219.
18. 17. White DP. Pathogenesis of obstructive and central sleep apnea. *Am J Respir Crit Care Med* 2005;172:1363-1370.
19. 18. Ciftci TU, Kokturk O, Ozkan S. Apnea-hypopnea indexes calculated using different hypopnea definitions and their relation to major symptoms. *Sleep Breath* 2004;8:141-146.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.



Chapter 4

Obstructive sleep apnea in children with syndromic
craniosynostosis: long-term respiratory outcome of
midface advancement



Bannink N



Nout E

Wolvius EB

Hoeve LJ

Joosten KFM

Mathijssen IMJ



1. **ABSTRACT**

2.

3. **Objective**

4. Almost 50% of patients with Apert, Crouzon or Pfeiffer syndrome develop obstructive
5. sleep apnea (OSA), mainly due to midface hypoplasia. Midface advancement is often the
6. treatment of choice, but the few papers on long-term outcome reported mixed results.
7. This paper aimed to assess the long-term respiratory outcome of midface advancement in
8. syndromic craniosynostosis with OSA and to determine factors contributing to its efficacy.

9.

10. **Methods**

11. A retrospective study was performed on 11 patients with moderate or severe OSA, re-
12. quiring oxygen, continuous positive airway pressure (CPAP), or tracheostomy. Clinical
13. symptoms, results of polysomnography, endoscopy and digital volume measurement of
14. the upper airways on CT scan before and after midface advancement were reviewed.

15.

16. **Results**

17. Midface advancement had a good respiratory outcome in the short term in 6 patients and
18. was ineffective in 5. In all patients without respiratory effect or with relapse, endoscopy
19. showed obstruction of the rhino- or hypopharynx. The volume measurements supported
20. the clinical and endoscopic outcome.

21.

22. **Conclusion**

23. Despite midface advancement, long-term dependence on, or indication for, CPAP or
24. tracheostomy was maintained in 5 of 11 patients. Pharyngeal collapse appeared to play a
25. role in OSA. Endoscopy before midface advancement is recommended to identify airway
26. obstruction that may interfere with respiratory improvement after midface advancement.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Craniosynostosis is a congenital disorder affecting in 1 in 2,500 births; it is characterized
4. by the premature fusion of calvarial sutures. This fusion restricts normal growth of the
5. skull, brain, and face, and necessitates surgical correction. In about 40% of the cases it
6. is part of a syndrome such as the Apert, Crouzon, Pfeiffer, Muenke or Saethre-Chotzen
7. syndrome¹.

8. Almost 50% of children with Apert, Crouzon or Pfeiffer syndrome develop obstructive
9. sleep apnea (OSA), mainly during the first 6 years of life.²⁻⁴ These patients are at risk for
10. OSA due to midface hypoplasia, but other factors such as adenotonsillar hypertrophy,
11. and mandibular hypoplasia may be involved as well.^{4,5} According to its severity and cause,
12. OSA can be treated pharmacologically, surgically (e.g. with adenotonsillectomy, midface
13. advancement or tracheostomy), or non-surgically (e.g. with nocturnal oxygen or continu-
14. ous positive airway pressure (CPAP)).^{5,6} If OSA is not treated sufficiently, disturbed sleep
15. patterns may result in major physical and functional impairment, for instance failure to
16. thrive, recurrent infections, disturbed cognitive functions, delayed development, cor pul-
17. monale or sudden death.⁷ As midface hypoplasia is the main cause of OSA in syndromic
18. craniosynostosis, midface advancement appears to be the treatment of choice.⁸

19. In the long-term, mixed respiratory results were reported following midface advance-
20. ment in patients with syndromic craniosynostosis.⁹ It is unclear how long and to which
21. level the improvement in breathing lasts, and which factors are predictors of respiratory
22. outcome. To assess the respiratory outcome of midface advancement for moderate to
23. severe OSA and to determine predictive factors, the authors carried out a retrospective
24. study in patients suffering from Apert, Crouzon or Pfeiffer syndrome.

25.

26.

27. METHODS

28.

29. Study group

30. Over 100 patients with Apert, Crouzon and Pfeiffer syndrome have been treated at the
31. Dutch Craniofacial Center since 1983. For this study, the authors were only interested in
32. the 14 patients with moderate or severe OSA, requiring treatment with nocturnal oxygen,
33. CPAP, nasopharyngeal tube (NPT), or tracheostomy, who presented between 1987 and
34. 2006. Their records were analyzed for clinical symptoms of OSA, results of polysomnogra-
35. phy (PSG) and endoscopy of the upper airways, and the different treatment modalities for
36. OSA. CT-scans were used to measure the airway volume before and after midface advance-
37. ment. For this case series, sufficient data and follow-up were available in 11 patients.

38.

39.

1. **Obstructive sleep apnea**

2. The clinical symptoms of OSA were snoring, difficulty in breathing, apnea during sleep,
3. perspiration, and daytime sleepiness. PSG was carried out ambulatory or during admis-
4. sion to hospital and the following criteria for analysis were used. Apnea was defined as
5. absence of airflow for more than two breaths and hypopnea as reduction by $\geq 50\%$ in nasal
6. flow signal amplitude for more than two breaths. The analysis was expressed in an apnea
7. hypopnea index (AHI), the number of obstructive apneas in combination with hypopneas
8. followed by desaturation per hour, and an oxygenation desaturation index (ODI), the
9. number of desaturations ($\geq 4\%$ decrease with respect to the baseline) per hour. A score $<$
10. 1 is considered to be normal, 1 - 5 is defined as mild OSA, 6 - 25 as moderate OSA, and > 25
11. as severe OSA.¹⁰⁻¹³

12.

13. **Respiratory outcome of midface advancement**

14. The timing, type and outcome of the following interventions were evaluated: oxygen,
15. NPT, CPAP, adenotomy and tonsillectomy, tracheostomy and midface advancement.
16. The different interventions in each patient were added to evaluate the total number of
17. procedures carried out to improve the breathing.

18. The efficacy of treating OSA was determined on the basis of clinical symptoms and
19. PSG before and after midface advancement. Midface advancement was considered to be
20. effective on respiration, in the short term, if oxygen, CPAP, NPT or tracheostomy were
21. discontinued within 1 year after midface advancement. Relapse of OSA was defined as the
22. need for respiratory support again. Long-term effectiveness was defined as independence
23. of respiratory support at least 2 years after midface advancement.

24.

25. **Endoscopy of the upper airway**

26. Endoscopies were carried out under general anesthesia in a supine position. In 2 patients
27. an additional endoscopy was done at the outpatient clinic in a sitting position. The endos-
28. copies were carried out to identify the possible level of obstruction including anatomical
29. malformations in the rhino- and hypopharynx.

30.

31. **Volume measurements of the upper airway**

32. A software program (MevisLab) was used to import and analyze the CT scans by means
33. of a custom-designed tool. Preoperative and postoperative scans were analyzed on trans-
34. versal slices. The maxillary, ethmoidal, frontal and sphenoidal sinuses, concha bullosa and
35. the oral cavity were manually excluded. The respiratory active air-holding cavities were
36. segmented using semi-automatic region growing. The volumes of 2 separate anatomically
37. defined areas were measured in mm^3 , taking the scale into consideration: nasal cavity and
38. rhinopharynx (defined to range from the most caudal point of the frontal sinus to the
39. cranial point where the soft palate transformed into the uvula); and the oro- and hypo-

1. pharynx (ranged from the most cranial point where the soft palate transformed into the
 2. uvula, to the most caudal point of the hyoid bone). The total volume is being calculated
 3. by adding the volumes of the 2 areas. All patients were scanned according to a protocol,
 4. using the same CT scan, and the thickness of the transversal slices was similar.

5.

6. **Statistical analysis**

7. The results were analyzed using SPSS 14.0 for Windows 2000. All numbers are expressed
 8. as median and range.

9.

10.

11. **RESULTS**

12.

13. Eleven patients with Apert (n = 3), Crouzon (n = 6) or Pfeiffer (n = 2) syndrome who had
 14. moderate or severe OSA, requiring treatment with nocturnal oxygen, CPAP, NPT, or tra-
 15. cheostomy, were included. Four of the 11 patients were boys (36%), aged 14.9 years (range
 16. 4.1-23.1 years). All patients had midface hypoplasia. Six of the 11 patients underwent PSG
 17. before the start of treatment for OSA; this showed moderate OSA in 3 patients and severe
 18. OSA in 3 (median ODI 25, range 10-66). In the other patients, no PSG was performed due
 19. to the severity of the respiratory distress at presentation, which necessitated instant airway
 20. management, namely intubation or insertion of a tracheostomy. Airway treatment after
 21. diagnosis of OSA involved tracheostomy in 4 patients, oxygen in 3, CPAP or NPT in 3, and
 22. monobloc with NPT in 1. All patients underwent a midface advancement with distraction
 23. followed by a control PSG; in 3 a monobloc was performed; and in 8 a le Fort III.


24. In 10 of the 11 patients an endoscopy of the upper airway was performed to identify
 25. the level of obstruction; this was done preoperatively in 5, postoperatively in 1, and both
 26. in 4. In 4 patients, a CT scan, carried out before and after midface advancement, was
 27. available. After advancing the midface for at least 20 mm the occlusion was corrected
 28. from class III in class II with overcorrection in all patients (figure 1). Clinically, a sufficient
 29. advancement of the midface was achieved in all patients. Final adjustment of the level of
 30. occlusion is performed in patients aged 18 or older. So far, an additional le Fort I has been
 31. performed in 2, no patient underwent mandibular correction. The follow-up time after
 32. midface advancement was 3.5 years (range 2.4-11.4 years, mean 5.7 years).

33.

34. **Respiratory outcome of midface advancement**

35. The follow-up of the 11 OSA patients at different ages is shown in figure 2. The respiratory
 36. outcome of each treatment option was considered. Adenotomy and tonsillectomy had a
 37. temporary beneficial effect on respiration in 1 of 5 patients, and no effect in 4.

38. In 6 of the 7 patients, oxygen and CPAP or NPT were effective in bridging time to the
 39. midface advancement. In the other patient, tracheostomy was required despite monobloc



11. **Figure 1:** Sufficient correction was achieved in all patients; after advancing the midface for 20 mm the occlusion
12. changed from class III to class II including the overcorrection

13.
14. and NPT. Midface advancements were carried out in three different modes: monobloc
15. with and without distraction, and le Fort III with distraction.

16. The patients with moderate or severe OSA underwent a median number of 5 (2-8)
17. invasive or non-invasive treatment procedures to improve their breathing. Midface ad-
18. vancement in the short term had a good or improved respiratory outcome in 6 patients
19. (patients 1, 2, 8, 10, 11 and patient 9, respectively), and was unsatisfactory in 5 (patients 3,
20. 4, 5, 6, and 7) (table 1). In 2 patients (patients 1 and 11) OSA relapsed. In the long term,
21. 4 of the 11 patients (patients 3, 4, 6 and 7) were still dependent on CPAP (2.5, 8.1 and 8.2
22. years after advancement) or tracheostomy (10.6 years) in spite of a surgically successful
23. midface advancement and 1 (patient 11) had severe OSA without treatment following a
24. parental decision.

25.
26. **Endoscopy and volume measurements of the upper airway**

27. Anatomical malformations of the rhino- and hypopharynx were a common feature in
28. nearly all patients, causing a functional obstruction at this level. Only 1 patient did not
29. have this feature and had a good respiratory outcome after midface advancement. All
30. patients had a narrow nasal cavity.

31. The volumes of the upper airway on CT scan before and after midface advancement
32. were calculated in patients 1, 4, 6 and 8 (table 2). In figure 3 the changes in these volumes
33. are shown. In patient 1 the CT scan 4 months post-surgery showed an increase in airway
34. volume (1.4 times), mostly in the region nasal cavity and rhinopharynx (1.6 times). One
35. year after midface advancement the CT scan illustrated the narrow hypopharynx seen
36. with endoscopy, with a volume decrease in the region oro- and hypopharynx (0.7 times).
37. The CT scans of patient 4, made 7 months before and 1 year after midface advancement,
38. showed no increase in the total volume of the upper airway. The volume of the oro- and
39. hypopharynx increased 1.2 times. Patient 6 showed no change in total volume of the




Figure 2: Follow-up of OSA in 11 patients at different ages

1. **Table 1:** Respiratory outcome of midface advancement in the short term

| 2. | Treatment | Number of treatments | Effect | Insufficient effect |
|----|------------------------------|----------------------|--------|---------------------|
| 3. | Monobloc without distraction | 3 | 1 | 2 |
| 4. | Monobloc with distraction | 3 | 2 | 1 |
| 5. | Le Fort III with distraction | 8 | 4 | 4 |
| 6. | Total view (N patients) | 14 (11) | 7 (6) | 7 (5) |

7. **Table 2:** Measurements of airway volume on CT scan before and 4 months and/or 1 year after midface advancement in mm³

| 10. | Patient | Nasal cavity and rhinopharynx | | | Oro- and hypopharynx | | | Total airway volume | | |
|-----|---------|-------------------------------|---------|---------|----------------------|---------|---------|---------------------|---------|---------|
| | | Before | After 1 | After 2 | Before | After 1 | After 2 | Before | After 1 | After 2 |
| 11. | 1 | 20.109 | 32.850 | 33.544 | 13.287 | 14.772 | 9.620 | 33.396 | 47.622 | 43.164 |
| 12. | 4 | 35.909 | 33.166 | | 6.408 | 7.913 | | 42.317 | 41.078 | |
| 13. | 6 | 19.639 | 20.327 | | 9.166 | 6.252 | | 28.804 | 26.578 | |
| 14. | 8 | 20.147 | 32.671 | | 3.683 | 6.081 | | 23.830 | 38.751 | |

15.
16.
17.
18.
19. upper airway 4 months after midface advancement in comparison with 1 year before,
20. which matches the clinical presentation. After midface advancement the nasal cavity and
21. rhinopharynx volume increased, but the oro- and hypopharynx region was 0.7 of the
22. volume before. In patient 8, with a clinical good result, the volume of the upper airway
23. increased by a factor of 1.6, 13 months after midface advancement in comparison with 3
24. months before. The volume of the nasal cavity and rhinopharynx increased 1.6 times and
25. the volume of the oro- and hypopharynx was 1.7 times larger.

28. DISCUSSION

29.
30. In the general population, adenotonsillectomy is the treatment of choice, as adenotonsillar
31. hypertrophy is an important cause of OSA.^{13, 14} In this study, in patients suffering from
32. Apert, Crouzon or Pfeiffer syndrome with moderate or severe OSA, neither tonsillectomy
33. nor adenotomy had a significant effect on respiration.

34. In patients with syndromic craniosynostosis, midface hypoplasia is generally considered
35. to be the major cause of upper airway obstruction.⁴ All children in this study also had mid-
36. face hypoplasia. Although, midface advancement seemed to be a good treatment modality
37. for compromised airways at the level of the midface^{4, 15}, in this study 6 of 11 patients (55%)
38. had a favourable effect in the short term after monobloc or le Fort III with distraction.
39. Witherow et al.¹⁶ found an improvement in all patients suffering from Apert, Crouzon or



1. Pfeiffer syndrome with abnormal PSG after monobloc with external distraction. Of the
2. 14 patients with severe OSA, treated with tracheostomy or CPAP, OSA was resolved after
3. surgery in 6 (43%). The other 8 patients remained dependent on tracheostomy or CPAP.
4. The mean follow-up was 24 months.¹⁶ Arnaud et al.¹⁷ showed a respiratory improvement
5. measured by oxygen level in 14 of 16 patients with Apert, Crouzon or Pfeiffer syndromes
6. after monobloc with internal distraction. In the severe cases, removal of tracheostomy
7. was possible in 4 of 6 (67%). In 1 patient a tracheostomy was needed 6 months after
8. removal of distractors because of relapse of OSA. The mean follow-up after surgery was 2.5
9. years.¹⁷ Nelson et al.⁹ studied 18 patients with syndromic bilateral coronal synostosis and
10. OSA, in 15 of them a tracheostomy or CPAP was required before midface advancement.
11. After midface advancement, 5 patients were decanulated and in 6 CPAP was discontinued
12. (73%). The mean time of follow-up was 3.2 years. In these 3 studies, midface advancement
13. did not result in good respiratory outcome in all (similar to the present study). These
14. studies and the present one showed that respiratory outcome after midface advancement
15. in syndromic craniosynostosis patients who need it the most is not as successful as is
16. generally thought. Inclusion of patients with mild OSA in other studies has given the
17. impression that midface advancement with distraction gives a guaranteed improvement
18. of OSA.

19. Endoscopy of the upper airway can show the level of obstruction and the dynamic
20. influence of breathing. In the 4 patients with persistent OSA after advancement and in
21. the patient with a relapse of OSA an obstruction of the rhino- or hypopharynx was seen.
22. In Apert, Crouzon and Pfeiffer syndrome, the anatomy of the upper airway is different
23. and there seems to be a dynamic function problem regarding the airway, possibly related
24. to the mutation of the fibroblast growth factor receptor.¹ The nasal cavity is narrow in
25. all patients; this is common in these syndromes. Collapse of the pharynx is a dynamic
26. problem that may or may not improve with midface advancement. In the non-responders,
27. the pharyngeal walls collapsed with each breath, and resulted in an airway obstruction.
28. So the advancement did not result in a larger airway volume and could not overcome
29. the tendency of the pharyngeal walls to collapse. The changes in airway volume on CT
30. scan after midface advancement were similar to the results of endoscopy, and thus seem
31. to illustrate the dynamic situation of the airway, including the level of obstruction. An
32. improvement of airway volume on CT correlated with a good respiratory outcome. The
33. authors consider that the degree of functional obstruction of the rhino- or hypopharynx
34. correlates with respiratory outcome after midface advancement: a mild tendency for
35. collapse can be overcome with the midface advancement. This hypothesis could not be
36. substantiated in this retrospective analysis.

37. Measurement of airway volume on CT scan has some limitations, in particular the diffi-
38. culty of manually defining the borders of the nasal cavity because of anatomical anomalies.
39. A cold can affect the thickness of the mucosa and the size of the tonsils, and the position

1. and respiration state of the patient in the CT scan can influence the volume of the airway
2. at the moment of scanning. The influence of growth in volume changes is not likely
3. in patients with syndromic craniosynostosis since they have growth retardation of the
4. maxilla¹⁸ and restriction of normal transverse growth of the mandible, possibly secondary
5. to cranial base abnormalities.¹⁹

6. Previous studies on airway changes after advancement were based on tracing of cepha-
7. lograms.^{20, 21} Ishii et al.²⁰ studying 16 patients with Apert or Crouzon syndrome found an
8. improvement on cephalogram in the nasopharyngeal airway after le Fort III osteotomy,
9. but no change in hypopharyngeal airway was found. In 12 'normal' adults who underwent
10. maxillary and mandibular advancement for OSA Li et al.²¹ found an increase in the airway
11. dimension after surgery measured by cephalometric imaging. Fiberoptic nasopharyngo-
12. scopy with Müller maneuver (take a breath while the mouth is closed and the nostrils
13. are plugged) showed a decrease in collapsibility of the upper airway, mostly the lateral
14. pharyngeal wall. They suggested a reduction of the thickness of the muscular wall. Man-
15. dibular advancement seemed to be needed to enlarge the pharyngeal airway. In the present
16. study group no mandibular advancement was carried out. Mandibular advancement is
17. generally not considered in children with syndromic craniosynostosis to treat their OSA,
18. although this may be an option in patients with disappointing results following midface
19. advancement and remaining obstruction at the hypopharynx.

20. This study showed that moderate or severe OSA in children with syndromic cranio-
21. synostosis is a major problem and difficult to treat. It is not only directly correlated with
22. midface hypoplasia. Endoscopy showed anomalies at different levels throughout the up-
23. per airway. Dynamic pharyngeal collapse can affect the respiratory outcome of midface
24. advancement; endoscopy of the upper airway before midface advancement may predict
25. respiratory improvement. It may be possible to treat obstructions at another level with
26. other procedures, such as widening of the palate to enlarge the nose and mandibular
27. advancement to create more space at the level of the hypopharynx. Long-term follow-up
28. is important because OSA may relapse.

29. To implement these findings and to improve the prognostic information on respiratory
30. outcome after midface advancement, the authors recommend performing an endoscopy
31. of the upper airway before midface advancement to identify all levels of obstruction (also
32. stated by Nelson et al.⁹). Treatment of OSA will then be better focussed on its cause. The
33. volume measurements of the upper airway will be continued in further research as a tool
34. to investigate the effect of midface advancement on airway volume and to specify the level
35. of largest gain on respiration.

36.

37. In conclusion, despite midface advancement, long-term dependence on, or indication
38. for, CPAP or tracheostomy was maintained in 5 of 11 patients in whom Apert, Crouzon
39. or Pfeiffer syndrome was combined with moderate or severe OSA. In the patients with


1. persistence of OSA despite optimal surgical treatment, pharyngeal collapse appeared to
2. play a role in obstruction of the airway. Endoscopy makes it possible to identify a static or
3. dynamic airway obstruction that may interfere with respiratory improvement, enabling a
4. prediction of respiratory improvement and treatment to be adapted to the specific level of
5. obstruction. Long-term follow-up is needed, because of the chance of relapse.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.

I. REFERENCES

2. 1. Lajeunie E, Heuertz S, El Ghouzzi V, et al. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet* 2006;14:289-298.
3. 2. Pijpers M, Poels PJ, Vaandrager JM, et al. Undiagnosed obstructive sleep apnea syndrome in children with syndromal craniofacial synostosis. *J Craniofac Surg* 2004;15:670-674.
4. 3. Hoeve LJ, Pijpers M, Joosten KF. OSAS in craniofacial syndromes: an unsolved problem. *Int J Pediatr Otorhinolaryngol* 2003;67 Suppl 1:S111-113.
5. 4. Lo LJ, Chen YR. Airway obstruction in severe syndromic craniosynostosis. *Ann Plast Surg* 1999;43:258-264.
6. 5. Hoeve HL, Joosten KF, van den Berg S. Management of obstructive sleep apnea syndrome in children with craniofacial malformation. *Int J Pediatr Otorhinolaryngol* 1999;49 Suppl 1:S59-61.
7. 6. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2002;109:704-712.
8. 7. Nixon GM, Brouillette RT. Sleep 8: paediatric obstructive sleep apnoea. *Thorax* 2005;60:511-516.
9. 8. Nout E, Cesteley LL, van der Wal KG, et al. Advancement of the midface, from conventional Le Fort III osteotomy to Le Fort III distraction: review of the literature. *Int J Oral Maxillofac Surg* 2008
10. 9. Nelson TE, Mulliken JB, Padwa BL. Effect of midfacial distraction on the obstructed airway in patients with syndromic bilateral coronal synostosis. *J Oral Maxillofac Surg* 2008;66:2318-2321.
11. 10. Guilleminault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995;127:905-912.
12. 11. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Archives of pediatrics & adolescent medicine* 2005;159:775-785.
13. 12. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg* 2003;129:1281-1284.
14. 13. Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol* 1996;13:198-207.
15. 14. Goldberg S, Shatz A, Picard E, et al. Endoscopic findings in children with obstructive sleep apnea: effects of age and hypotonia. *Pediatr Pulmonol* 2005;40:205-210.
16. 15. Mathijssen I, Arnaud E, Marchac D, et al. Respiratory outcome of mid-face advancement with distraction: a comparison between Le Fort III and frontofacial monobloc. *J Craniofac Surg* 2006;17:880-882.
17. 16. Witherow H, Dunaway D, Evans R, et al. Functional outcomes in monobloc advancement by distraction using the rigid external distractor device. *Plast Reconstr Surg* 2008;121:1311-1322.
18. 17. Arnaud E, Marchac D, Renier D. Reduction of morbidity of the frontofacial monobloc advancement in children by the use of internal distraction. *Plast Reconstr Surg* 2007;120:1009-1026.
19. 18. Firmin E, Coccato PJ, Converse JM. Cephalometric analysis in diagnosis and treatment planning of craniofacial dysostoses. *Plast Reconstr Surg* 1974;54:300-311.
20. 19. Boutros S, Shetye PR, Ghali S, et al. Morphology and growth of the mandible in Crouzon, Apert, and Pfeiffer syndromes. *J Craniofac Surg* 2007;18:146-150.
21. 20. Ishii K, Kaloust S, Ousterhout DK, et al. Airway changes after Le Fort III osteotomy in craniosynostosis syndromes. *J Craniofac Surg* 1996;7:363-370; discussion P-371.
22. 21. Li KK, Guilleminault C, Riley RW, et al. Obstructive sleep apnea and maxillomandibular advancement: an assessment of airway changes using radiographic and nasopharyngoscopic examinations. *J Oral Maxillofac Surg* 2002;60:526-530; discussion 531.

Part III

Functional problems in syndromic craniosynostosis





Chapter 5

Papilledema in patients with Apert, Crouzon and Pfeiffer syndrome; prevalence, efficacy of treatment and risk factors

Bannink N

Joosten KFM

van Veelen MLC

Bartels MC

Tasker RC

van Adrichem LNA

van der Meulen JNM

Vaandrager JM

de Jong THR

Mathijssen IMJ

1. **ABSTRACT**

2.

3. **Objective**

4. Patients with syndromic craniosynostosis are at risk for elevated intracranial pressure
5. because of various physiologic and anatomic abnormalities. The aims of this study were
6. to determine the prevalence of papilledema in syndromic craniosynostosis, to evaluate the
7. results of the treatment, and to examine the risk factors.

8.

9. **Methods**

10. This is a retrospective study on 84 patients with Apert, Crouzon, or Pfeiffer syndrome.
11. Papilledema was defined as blurring of the margins of the optic disk. The association
12. between clinical symptoms, beaten-copper pattern on skull radiograph, ventricular dilata-
13. tion on computed tomography scan, and papilledema was assessed.

14.

15. **Results**

16. Papilledema was present in 51% of the patients. No relation between specific clinical
17. symptoms and papilledema was found. The significant associations were complex cranio-
18. synostosis, exorbitism, and ventricular dilatation.

19.

20. **Conclusion**

21. The prevalence of papilledema in patients with Apert, Crouzon, or Pfeiffer syndrome is
22. high, not only before cranial decompression but also after vault expansion. Annual fun-
23. doscopy is recommended to screen for papilledema. We consider that early decompressive
24. surgery (within the first year of age) prevents the development of papilledema and, most
25. likely, elevated intracranial pressure.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Craniosynostosis is a congenital disorder, arising in 1 in 2500 births, characterized by the
4. premature fusion of calvarial sutures. This fusion restricts the normal growth of the skull,
5. brain, and face and needs surgical correction. In about 40% of cases (1:6250), craniosynostosis
6. is part of a syndrome, such as Apert, Crouzon, Pfeiffer, Muenke or Saethre-Chotzen
7. syndrome¹.

8. Due to fusion of calvarial sutures the intracranial pressure (ICP) may be elevated. In
9. isolated, single-suture craniosynostosis, the frequency of elevated ICP before vault ex-
10. pansion differs according to the site of the affected suture (e.g., 8% in trigonocephaly,
11. 13% in scaphocephaly and 16% in frontal plagiocephaly)²⁻⁴. The reported frequency of
12. elevated ICP is 31% in brachycephaly (bilateral coronal synostosis) and 47% in complex
13. craniosynostosis (combination of 2 sutures, e.g., coronal and sagittal suture synostosis)⁴.
14. In patients with either Apert or Crouzon syndrome, elevated ICP before vault expansion
15. is seen in approximately 45% and 63%, respectively^{5,6}. Untreated, elevated ICP may lead to
16. irreversible visual loss caused by optic nerve dysfunction and mental impairment^{4,7}. There-
17. fore, surgical decompression is recommended within the first year of life⁴. Unfortunately,
18. elevated ICP may still persist after early cranial expansion⁸. Information on the frequency
19. of this problem, however, is limited⁹.

20. Clinically, it is difficult to recognize significantly elevated ICP in these children because
21. symptoms can be vague. The classic symptoms of elevated ICP -vomiting and disturbed
22. consciousness- are typically absent. A skull radiograph and a computed tomography
23. (CT) scan of the brain might be helpful in diagnosing signs of elevated ICP^{10,11}. A reliable
24. symptom, although rather late, is papilledema¹². The criterion standard for measuring ICP
25. is an invasive measurement. A drawback is the risk of complications such as haemorrhage,
26. cerebrospinal fluid leak, and infection⁹.

27. We have undertaken a retrospective study in patients with Apert, Crouzon, or Pfeiffer
28. syndrome to determine the prevalence of papilledema before and after vault expansion.
29. We have also assessed the risk factors for papilledema, and the results of surgery on pap-
30. illedema.

31.

32.

33. METHODS

34.

35. Study group

36. The records of all patients with Apert, Crouzon, and Pfeiffer syndrome (n = 90) who were
37. treated at the Dutch Craniofacial Center between 1983 and 2006 were reviewed. Patients
38. with Saethre-Chotzen syndrome or Muenke syndrome (P250R mutation in FGFR3 gene)
39. were not included. On the basis of genetic analysis, Crouzon and Pfeiffer syndrome

1. often cannot be distinguished from each other¹. Therefore, in this study, these clinical
2. syndromes are considered to be a homogeneous group. The records were analyzed for
3. clinical symptoms of elevated ICP, beaten-copper pattern on skull radiograph, results of
4. fundoscopy, and CT scan.

5.

6. **Papilledema**

7. All fundoscopies were performed by an ophthalmologist by indirect ophthalmoscopy after
8. mydriasis of the pupil with phenylephrine 2.5% and tropicamide 0.5%. Papilledema was
9. defined as blurring of the margins of the optic disk (figure 1). If this was seen, objective re-
10. fraction (skiascopy) was performed to exclude hyperopia, which can resemble papilledema
11. without being a sign of elevated ICP, so-called pseudopapilledema³. Papilledema was
12. defined as persistent when it was still present 1 year after surgical intervention. Relapse of
13. papilledema was defined as a recurrence of papilledema after at least 1 normal fundoscopy
14. examination. The presence of papilledema on at least 1 occasion is included for analysis.
15. Invasive ICP measurements were not reported because of the small amount.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.


32.

33.

34.

35.

36.



37. **Figure 1:** Fundus photograph showing papilledema in the right eye of a girl with Crouzon syndrome

38.

39.

1. Signs of elevated ICP

2. 1. Clinical symptoms of elevated ICP.

3. Clinical symptoms suggestive of elevated ICP were taken as headache, vomiting, and
4. changes in vision, and/or behavior.

5. 2. Beaten-copper pattern on skull radiographs.

6. Beaten-copper pattern on skull radiographs were assessed until the age of 7 years. Only
7. digital radiographs were evaluated, and these were available for 28 patients. The area of
8. beaten-copper pattern was graded as mild (<33%), moderate (33-66%), and severe (66-
9. 100%)¹¹ using Image J software (Wayne Rasband, National Institute of Mental Health,
10. Bethesda, MD). The ratio of the area with beaten-copper pattern to the total area of the
11. skull, defined the gradation (J.J.N.M. van der Meulen, et al., unpublished data, 2007).

12. 3. Ventricular dilatation on CT scan.

13. Ventricular dilatation was defined by an enlargement of the ventricles on CT scan, accor-
14. ding to the radiology report¹⁰.

15.

16. Efficacy of treatment to resolve papilledema

17. The efficacy of cranial surgery for resolving papilledema was determined by fundoscopy
18. during follow-up. The surgical intervention was considered to be effective if papilledema
19. disappeared or if no papilledema developed within the first year after surgery.

20.

21. Risk factors for elevated ICP

22. Potential risk factors for elevated ICP were the age at vault expansion, the number of fused
23. sutures (with complex craniosynostosis defined as fusion of ≥ 2 sutures), midface hypo-
24. plasia, exorbitism, severe obstructive sleep apnea (OSA) -requiring supplemental oxygen,
25. continuous positive airway pressure, nasopharyngeal tube or tracheal cannula¹⁴⁻¹⁶ - and
26. ventricular dilatation on CT scan.

27.

28. Statistical analysis

29. The results were analyzed using SPSS 14.0 for Windows 2000. All numbers are expressed
30. as median and range. Comparisons of categorical variables between patients with and
31. without elevated ICP were performed using Fisher exact test. Logistic regression analysis
32. with backward elimination was used to determine variables independently predictive of
33. elevated ICP. Variables with a p-value < 0.20 after univariate analysis were used in a logistic
34. regression model. Significance was defined as a p-value < 0.05.

35.

36.

37.

38.

39.

1. RESULTS

2.

3. Six of the 90 patients were excluded because there was no information on the level of
4. papilledema (i.e., no funduscopy was performed). Therefore, 84 patients with Apert (n =
5. 33), Crouzon (n = 43), or Pfeiffer (n = 8) syndrome underwent full analysis. There were
6. 44 boys (52%) and the patients were aged 11.4 years (range 5 months to 23.5 years) at the
7. time of review.

8.

9. Papilledema

10. Preoperatively, 66 patients were examined and 25 had papilledema (38%; 95% confidence
11. interval 26-51%). The age at presentation with papilledema was 12 months (range 2-64
12. months) in the Crouzon/ Pfeiffer group (n = 23), and in 2 children with Apert syndrome,
13. it was 8 and 12 months (figure 2).

14. Postoperatively, 70 patients underwent funduscopy, and 30 patients had papilledema
15. (43%; 95% confidence interval 31-55%), 7 with persistent papilledema after skull surgery,
16. 5 with a relapse, and 10 with a first presentation after surgical decompression. In the
17. remaining 8 patients, there was no preoperative funduscopy. Two patients with Apert
18. syndrome had pseudopapilledema due to hyperopia and were thus considered to have no
19. papilledema. Another 7 patients with Apert syndrome and 2 with Crouzon syndrome had
20. hyperopia and also true papilledema.

21. In total, 43 (51%) of the 84 patients had papilledema on at least 1 occasion.

22.

23. Signs of elevated ICP (table 1)

24. 1. Clinical symptoms of elevated ICP.

25. Headache, vomiting, changes in vision and/or changes in behavior were recorded in 10
26. (24%) of 42 patients with papilledema, which was not significantly different with the 9
27. (27%) of 33 patients with normal funduscopy (table 1).

28.

29. **Table 1:** Predictive variables of papilledema after univariate analysis

| | Papilledema (n = 43) | Normal funduscopy (n = 41) | p-value |
|--|----------------------|----------------------------|---------|
| 30. Diagnosis Crouzon/Pfeiffer | 31/ 43 | 20/ 41 | 0.044* |
| 31. Complex craniosynostosis | 31/ 42 | 20/ 40 | 0.040* |
| 32. Midface hypoplasia | 39/ 42 | 33/ 41 | 0.116 |
| 33. Exorbitism | 42/ 43 | 34/ 39 | 0.097 |
| 34. Hyperopia | 11/ 41 | 12/ 29 | 0.302 |
| 35. Headache, vomiting,
changed vision and/or
changed behavior | 10/ 42 | 9/ 33 | 0.793 |
| 36. Impressiones | 15/ 17 | 6/ 11 | 0.076 |
| 37. Severe OSA | 8/ 41 | 3/ 31 | 0.331 |
| 38. Ventricular dilatation | 26/ 40 | 8/ 36 | 0.000* |

39. * p < 0.05




Figure 2: Papilledema before and after vault expansion

VP ventriculoperitoneal

ATE adenotonsillectomy

1. 2. Beaten-copper pattern on the skull radiograph.
2. There were 28 children younger than 7 years with available digital skull radiographs.
3. Fifteen (88%) of 17 with papilledema and 6 (55%) of 11 with normal funduscopy had
4. beaten-copper pattern. There was no significant difference between these 2 groups. The
5. gradation in the first group was 27% mild, 20% moderate, and 53% severe, and in the
6. second group, 67% mild and 33% severe.
7. 3. Ventricular dilatation on CT scan.
8. Ventricular dilatation on CT scan was seen in 26 (65%) of 40 patients with papilledema,
9. whereas it was present in only 8 (22%) of 36 patients with normal funduscopy ($p \leq 0.001$).
- 10.
11. **Efficacy of treatment to resolve papilledema (figure 2)**
- 12.
13. *Vault expansion*
14. All 25 children with papilledema before surgery were treated with decompressive surgery
15. within 2 months of the problem being diagnosed. In 8 patients, skull expansion was
16. combined with midface surgery because of severe airway obstruction in 4 patients (one
17. received supplemental oxygen and one had a tracheostomy), severe exorbitism in 1 patient,
18. and severe midface hypoplasia in 3 patients. After decompressive surgery, papilledema dis-
19. appeared in 10 (59%) of 17 patients for at least 1 year after surgery, it persisted in the other 7
20. patients (41%). The results were unknown 1 year after surgery in 8 patients. Thirty of the 41
21. patients without papilledema before decompressive surgery were screened postoperatively,
22. and 2 (7%) of 30 developed papilledema within 1 year after surgery. Of the 18 patients with
23. unknown preoperative state, papilledema was seen within 1 year of surgery in 2 (11%) of
24. 18 patients (figure 2).
25. Fifty-four (83%) of the 65 patients did not have papilledema 1 year after surgery. No
26. papilledema was seen preoperatively and postoperatively in 28 (93%) of 30 patients. After
27. surgical treatment papilledema was eliminated in 10 (59%) of 17 patients.
28. More than 1 year after vault expansion 70 patients were screened, and papilledema was
29. seen in 30 patients (43%); papilledema persisted in 7 patients; it relapsed after 2.5 years
30. (range, 14 months to 4.5 years) in 5 patients, and it developed postoperatively in 18 patients
31. (including 8 patients within 1 year). In 20 (67%) of the 30 patients with postoperative
32. papilledema, secondary surgery (vault expansion, monobloc, or le Fort III, ventriculoperi-
33. toneal shunting, revision of shunting and adenotonsillectomy) was performed, and it was
34. effective in treating papilledema in 14 patients (70%). In 6 patients, papilledema persisted,
35. and the known risk factors for elevated ICP were evaluated. In 4 of them, complementary
36. treatment (vault surgery and non-invasive OSA treatment) was necessary; in the other
37. 2, the known risk factors were excluded. All patients were followed up on regular basis.
38. The remaining 10 untreated children had papilledema, which occurred incidentally at
39. 1 or 2 follow-up examinations. In them, no symptoms of elevated ICP were present;

1. hydrocephalus and OSA could be ruled out. In these patients no surgical treatment was
 2. performed, and they were followed up intensively, and in at least 9 cases papilledema
 3. disappeared.

4.

5. *Ventriculoperitoneal shunt*

6. In the study group of 84 patients, 10 (12%) had a ventriculoperitoneal shunt; 6 because of
 7. hydrocephalus and 4 because of hydrocephalus and papilledema. Papilledema persisted in
 8. 1 patient and relapsed in 2 patients.

9.

10. **Risk factors for elevated ICP**

11. Premature fusion of calvarial sutures was seen in all patients; in 7% of the patients 1
 12. suture was fused; in 54%, 2 sutures; and in 39%, more than 2 sutures. The age at vault
 13. expansion in the children with preoperative papilledema was 20 months (range, 2 months
 14. to 5.5 years). In the group without papilledema, the age of vault expansion was 7 months
 15. (range, 2 months to 9 years). This difference is statistically significant ($p = 0.007$). In 11
 16. patients, severe OSA was present. Papilledema was present before OSA treatment in 4
 17. patients, absent in 4, and unknown in 3. After OSA treatment, papilledema disappeared
 18. in 1 patient, persisted in 1, relapsed in 2, and developed in 3; no control examination was
 19. done in 4 patients.

20. Univariate analysis revealed that the diagnosis of Crouzon/ Pfeiffer, complex craniosy-
 21. nostosis, and ventricular dilatation are statistically significant predictive variables for the
 22. presence of papilledema (table 1). Multivariate analysis showed that complex craniosyn-
 23. tosis, exorbitism, and ventricular dilatation were predictive of papilledema (table 2).

24.

25.

26. **DISCUSSION**

27.

28. There are 2 principal findings in this study of papilledema in syndromic craniosynostosis.
 29. First, based on fundoscopy, papilledema occurred in more than half of the patients with Ap-
 30. ert, Crouzon, or Pfeiffer syndrome, not only before but also after vault expansion. Second,
 31. we did not find any clinical symptoms that specifically indicated the presence of papilledema.

32.

33. **Table 2:** Predictive model of papilledema after multivariate analysis

| | Odds ratio | 95% CI lower | 95% CI upper | p-value |
|------------------------------|------------|--------------|--------------|---------|
| 35. Complex craniosynostosis | 6.119 | 1.549 | 24.179 | 0.010* |
| 36. Exorbitism | 18.800 | 1.376 | 256.916 | 0.028* |
| 37. Ventricular dilatation | 12.659 | 3.179 | 50.408 | 0.000* |

38. * $p < 0.05$

39. CI confidence interval

1. In this study, we have used the presence of papilledema as a surrogate marker of elevated
2. ICP. A major limitation of this approach, however, is that we may have underestimated
3. the extent of elevated ICP in our population because the absence of papilledema does
4. not definitely exclude elevated ICP¹². Despite this limitation, the high prevalence of
5. papilledema in our study is similar to that observed in previous studies^{4,5}, and we found
6. that before vault expansion, it was particularly common in patients with Crouzon and
7. Pfeiffer syndrome (~ 50%). Cases of Apert syndrome had a lower incidence of this finding
8. (~ 10%). This observation differs from the study reported by Renier et al. in which 45% of
9. patients with Apert syndrome had preoperative elevation in ICP^{4,5}. A possible explanation
10. for the lower percentage in our Apert group was the younger age at which fundoscopy was
11. performed (3 versus 6 months)⁵.

12. Because the absence of papilledema does not exclude elevated ICP¹², we also examined
13. whether clinical symptoms commonly associated with elevated ICP might reliably indi-
14. cate the presence of papilledema. In this study, they did not. It is possible that elevated
15. ICP might still have been present in those with symptoms had we measured it invasively.
16. However, our finding is consistent with the study reported by Tuite et al.¹², where only 8
17. of 41 patients with elevated ICP had clinical symptoms. Beaten-copper pattern on skull
18. radiograph was seen more often in children with papilledema.

19.

20. **Treatment to resolve papilledema**

21. Overall, within 1 year of primary surgery no papilledema was present in 83% of the patients.
22. On follow-up of children with no preoperative papilledema, 93% remained papilledema-
23. free after surgery. In respect to the timing of primary vault expansion, the children with
24. no preoperative papilledema were 6 months younger at surgery compared with those who
25. had preoperative papilledema. This significant difference suggests that decompressive
26. surgery at a younger age prevents the development of papilledema in craniosynostosis.
27. After surgical treatment, papilledema disappeared in 59% of the patients, but in a few
28. specific instances, it persisted, or developed within 1 year, after decompression. Possible
29. reasons for this finding were insufficient decompression, presence of ventricular dilatation,
30. or residual papilledema after correction of ICP. More than 1 year after vault expansion,
31. papilledema was seen in 43% of the patients. In 67% of these patients, secondary surgery
32. was performed, and it was effective in treating papilledema in 14 of the 20 patients. The re-
33. maining patients were treated conservatively despite the incidental finding of papilledema
34. on intensive follow-up with repeated fundoscopy.

35. Ventricular dilatation is a common finding in patients with craniosynostosis. Its con-
36. tribution to elevated ICP may be difficult to establish. In our study, ventricular size was
37. significantly increased in patients with papilledema, compared with those without (65%
38. versus 22%). In one third of the patients with ventricular dilatation, a shunt was needed
39. in addition to vault expansion.

1. These figures are comparable with a previous study reported by Collmann et al.¹⁰, where
2. it was found that papilledema could persist, relapse, or develop more than 1 year after
3. vault expansion and placement of a ventriculoperitoneal shunt. Thus, annual funduscopy
4. is highly recommended until adulthood.

5.

6. **Risk factors for papilledema**

7. We found that complex craniosynostosis, exorbitism, and ventricular dilatation were fac-
8. tors associated with papilledema. The first 2 of these variables were also reported in the
9. study by Gupta et al¹⁷. Significant correlations were found between optic nerve damage
10. from papilledema and multiple suture craniosynostosis and exorbitism¹⁷. Tuite et al.¹¹
11. showed that hydrocephalus had low sensitivity (40%), but high specificity (80%), for
12. elevated ICP.

13. Other factors, which result in elevated ICP, are OSA and venous hypertension^{18,19}. In a
14. study of 13 patients with syndromic craniosynostosis, a significant correlation was found
15. between the severity of upper airway obstruction and elevated ICP in active sleep¹⁵. In our
16. study 11 patients had severe OSA. However, they all had this problem treated, and thus,
17. association (or causation) with elevated ICP could not be shown. In addition, the retro-
18. spective design of our study meant that we could not obtain information about venous
19. hypertension and stenosis of the jugular foramen as causes of elevated ICP²⁰.

20.

21. In conclusion, in syndromic craniosynostosis, the prevalence of papilledema is high,
22. not only before cranial decompression but also after vault expansion. Given the high
23. prevalence of papilledema, annual review is highly recommended until adulthood. In our
24. hospital, funduscopy is the first choice, given its feasibility and low risk. We consider that
25. early decompressive surgery (within the first year of age) prevents the development of
26. papilledema and, most likely, elevated ICP. The origin of papilledema may be complex and
27. difficult to establish. It is therefore important to check all known risk factors to identify
28. the specific cause(s) and plan optimal treatment. Hence, management of these patients
29. should be multidisciplinary and focussed in specialized centers.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

I. REFERENCES

2. 1. Lajeunie E, Heuertz S, El Ghouzzi V, et al. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet* 2006;14:289-298.

3. 2. Arnaud E, Renier D, Marchac D. Prognosis for mental function in scaphocephaly. *J Neurosurg* 1995;83:476-479.

4. 3. Mathijssen I, Arnaud E, Lajeunie E, et al. Postoperative cognitive outcome for synostotic frontal plagiocephaly. *J Neurosurg* 2006;105:16-20.

5. 4. Renier D, Lajeunie E, Arnaud E, et al. Management of craniosynostoses. *Childs Nerv Syst* 2000;16:645-658.

6. 5. Renier D, Arnaud E, Cinalli G, et al. Prognosis for mental function in Apert's syndrome. *J Neurosurg* 1996;85:66-72.

7. 6. Renier D, Sainte-Rose C, Marchac D, et al. Intracranial pressure in craniostenosis. *J Neurosurg* 1982;57:370-377.

8. 7. Bartels MC, Vaandrager JM, de Jong THR, et al. Visual loss in syndromic craniosynostosis with papilledema but without other symptoms of intracranial pressure. *J Craniofac Surg* 2004;15:1019-1022.

9. 8. Taylor WJ, Hayward RD, Lasjaunias P, et al. Enigma of raised intracranial pressure in patients with complex craniosynostosis: the role of abnormal intracranial venous drainage. *J Neurosurg* 2001;94:377-385.

10. 9. Tamburrini G, Caldarelli M, Massimi L, et al. Intracranial pressure monitoring in children with single suture and complex craniosynostosis: a review. *Childs Nerv Syst* 2005;21:913-921.

11. 10. Collmann H, Sörensen N, Krauß J. Hydrocephalus in craniosynostosis: a review. *Childs Nerv Syst* 2005;21:902-912.

12. 11. Tuite GF, Evanson J, Chong WK, et al. The beaten copper cranium: a correlation between intracranial pressure, cranial radiographs, and computed tomographic scans in children with craniosynostosis. *Neurosurgery* 1996;39:691-699.

13. 12. Tuite GF, Chong WK, Evanson J, et al. The effectiveness of papilledema as an indicator of raised intracranial pressure in children with craniosynostosis. *Neurosurgery* 1996;38:272-278.

14. 13. Fried M, Meyer-Schwickerath G, Koch A. Excessive hypermetropia: review and case report documented by echography. *Ann Ophthalmol* 1982;14:15-19.

15. 14. Davidson Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol* 1996;13:198-207.

16. 15. Gonzalez S, Hayward R, Jones B, et al. Upper airway obstruction and raised intracranial pressure in children with craniosynostosis. *Eur Respir J* 1997;10: 367-375.

17. 16. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Arch Pediatr Adolesc Med* 2005;159:775-785.

18. 17. Gupta S, Ghose S, Rohatgi M, et al. The optic nerve in children with craniosynostosis. A pre and post surgical evaluation. *Doc Ophthalmol* 1993;83:271-278.

19. 18. Hayward R, Gonzalez S. How low can you go? Intracranial pressure, cerebral perfusion pressure, and respiratory obstruction in children with complex craniosynostosis. *J Neurosurg* 2005;102:16-22.

20. 19. Hayward R: Venous hypertension and craniosynostosis. *Childs Nerv Syst* 2005;21:880-888.

21. 20. Rich PM, Cox TCS, Hayward RD: The jugular foramen in complex and syndromic craniosynostosis and its relationship to raised intracranial pressure. *Am J Neuroradiol* 2003;24:45-51.

22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39.



Chapter 6

Long-term functional outcome in 167 patients with syndromic craniosynostosis; defining a syndrome-specific risk profile

de Jong T
Bannink N
Bredero-Boelhouwer HH
van Veelen MLC
Bartels MC
Hoeve LJ
Hoogeboom AJM
Wolvius EB
Lequin MH
van der Meulen JJM
van Adrichem LNA
Vaandrager JM
Ongkosuwito EM
Joosten KFM
Mathijssen IMJ

1. **ABSTRACT**

2.

3. **Objective**

4. Little is known about the long-term prevalence of elevated intracranial pressure (ICP),
5. obstructive sleep apnea (OSA), level of education, language and motor skills, impaired
6. sight and hearing in craniosynostosis syndromes. The objective of this study was to define
7. the prevalence per syndrome of elevated ICP, OSA, impaired sight and impaired hearing.

8.

9. **Methods**

10. A retrospective study was undertaken on 167 consecutive patients diagnosed with Apert,
11. Crouzon, Pfeiffer, Muenke or Saethre-Chotzen syndrome, aged 1-25 years and treated
12. between 1983 and 2008. The mean age at time of referral and review was 1 years and 2
13. months and 10 years and 3 months, respectively.

14.

15. **Results**

16. Patients with Apert and Crouzon/ Pfeiffer syndrome had the highest prevalence of elevated
17. ICP (33% and 53%, respectively) and OSA (31% and 27%, respectively), while Saethre-
18. Chotzen syndrome was also associated with a fair risk for elevated ICP. The prevalence of
19. impaired sight (61%) and hearing (56%) was high in all syndromes.

20.

21. **Conclusion**

22. Based on these data a syndrome specific risk profile with suggestions for screening and
23. treatment is presented.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Syndromic craniosynostosis is a complex disease with a broad spectrum of problems.
 4. Elevated intracranial pressure (ICP) has a high prevalence in patients with Apert and
 5. Crouzon/ Pfeiffer syndrome^{1, 2}, but its prevalence in Muenke or Saethre-Chotzen syn-
 6. drome is unclear. One of the factors that is related to elevated ICP is obstructive sleep
 7. apnea (OSA)^{3, 4}. OSA is a known problem in children with craniosynostosis but little is
 8. known about the prevalence among the different syndromes⁵. Other problems that are
 9. often seen are ocular and hearing deficits, with the most frequent ocular problems being
 10. strabismus and refractive errors⁶⁻⁸. Hearing deficits are conductive in most cases caused
 11. by recurrent otitis media that occurs during their entire life^{9, 10}. A retrospective study was
 12. undertaken to determine the prevalence of these problems per syndrome. Based on these
 13. data, guidelines for follow-up of patients per syndrome are suggested.

14.

15.

16. METHODS

17.

18. Study group

19. A retrospective study on all consecutive patients with Apert, Crouzon, Pfeiffer, Muenke
 20. or Saethre-Chotzen syndrome treated at the Dutch Craniofacial Center between 1983 and
 21. 2008 was performed. Crouzon and Pfeiffer syndrome often cannot be distinguished from
 22. each other genetically, and were therefore considered to be a homogeneous group in this
 23. study. The only exclusion criterium was an age of less than 12 months at the time of review,
 24. leaving a total of 167 patients were included.

25.

26. Protocol for intake, treatment and follow-up

27. Patients who were referred to our center were assessed by a multidisciplinary team, which
 28. consisted of a plastic surgeon, neurosurgeon, maxillofacial surgeon, clinical geneticist,
 29. orthodontist, ophthalmologist, otolaryngologist, paediatrician, radiologist, psychologist,
 30. and a nurse practitioner. All patients were offered a genetic analysis. Depending on their
 31. phenotype, exons of FGFR 1, 2 and 3 and TWIST were tested. Routine diagnostic tests,
 32. besides a complete physical examination, were skull X-rays, cephalograms, photographs,
 33. fundoscopy, and a three-dimensional computed tomography (3D-CT) scan of the skull.
 34. In case of anamnestic respiratory problems, a polysomnography was done either at home
 35. or at the clinic. The day before surgery fundoscopy was repeated.

36. Vault remodelling is scheduled at the age of 6-9 months or as soon as possible if patients
 37. were already older at time of referral. During the period under review, a fronto-orbital
 38. advancement was performed routinely as primary vault remodelling. A monobloc was
 39. only done in the very young in case of severe OSA or severe exorbitism. Le Fort III or

1. monobloc was preferably postponed until adult age, unless functional problems neces-
2. sitated an earlier intervention. Psychosocial functioning and the wish for correction of
3. patient and parents were also taking into account in timing the midface advancement. If
4. for these reasons the midface advancement was performed between the ages of 9 and 12,
5. the necessity for le Fort I osteotomy at 18 is the resulting consequence.

6. Follow-up visits of these patients are scheduled once every 3-6 months during their first
7. 2.5 years. Thereafter, check-ups are scheduled once a year, up to the age of 9, after which
8. the frequency drops to once every 3 years until the age of 18 for those patients who have
9. no functional problems requiring extra attention. During follow-up visits, patients and
10. their parents were specifically asked about complaints suggestive for elevated ICP, respira-
11. tory problems, ocular problems, and hearing difficulty. Skull circumference was measured
12. and facial features were assessed. Skull X-rays were checked for impressions, progressive
13. sutural synostosis, sutural widening, vascular impressions, and deepening of the sella.

14. Ophthalmologic and audiologic tests were regularly repeated. CT scans were taken
15. on indication only, such as anamnestic complaints suggestive of elevated ICP, decline in
16. growth curve of skull circumference, presence of papilledema or indication for surgery
17. (e.g. vault remodelling, le Fort III or monobloc).

18.

19. **Functional assessment**

20.

21. *Intracranial pressure*

22. Papilledema was used as an indicator of elevated ICP. A paediatric ophthalmologist per-
23. formed all fundoscopies after pharmacological pupillary dilation with a combination of
24. phenylephrine 2.5% and tropicamide 0.5%. Papilledema was diagnosed when blurring of
25. the optic disc margins was present. Pseudopapilledema, which can resemble papilledema
26. without being a sign of elevated ICP, was excluded. To differentiate papilledema from
27. pseudopapilledema, objective refraction was performed to rule out high hyperopia. If
28. papilledema was still present 1 year after surgery it was defined as persistent, and a relapse
29. was defined as reappearing papilledema following at least one normal fundoscopy. All
30. patients with papilledema were considered to have elevated ICP¹¹.

31. ICP measurements were performed with an intraventricular catheter or with an intrapa-
32. renchymal device (Camino or Codman). Invasive ICP measurements were recorded for at
33. least 24 hours. Elevated ICP was defined as an average of 15 mmHg or higher and/or more
34. than three plateau waves of 35 mmHg lasting more than 5 minutes¹². For the analysis the
35. term elevated ICP refers to the presence of papilledema and/or elevated ICP on invasive
36. measurement. Invasive ICP measurement was not done routinely, but only in specific
37. cases such as severe OSA, headache or persisting papilledema after surgery.

38.

39.

1. *Obstructive sleep apnea*

2. OSA was diagnosed based on a nocturnal pulse oximetry, which measures the oxygen saturation¹³. This was usually done ambulatory, with an Embletta Portable Diagnostic System
3. using a Nonin Oximeter and analyzed with Somnologica for Embletta software 3.3 ENU
4. (Medcare Flaga, Reykjavik, Iceland). From this oxygen saturation profile the oxygenation
5. desaturation index (ODI) was calculated. The ODI was defined as the average number
6. of oxygen desaturations of 4% or more, below the baseline level, per hour. Patients were
7. classified as having mild OSA with an ODI of 1-5, moderate OSA with an ODI of 6-25
8. and severe OSA with an ODI higher than 25^{14, 15}.

10.

11. *Sight and hearing*

12. Sight was assessed based on the test results done by an orthoptist or ophthalmologist. It
13. was scored as normal, myopic, hyperopic, astigmatic, anisometropic or blind.

14. Hearing was assessed based on the results of hearing tests performed by an otolaryngologist
15. or audiologist. Hearing was scored as normal or loss due to conductive, sensorineural
16. or mixed cause.

17.

18. **Statistical methods**

19. Statistical analyses were performed using SPSS 14.0 for Windows 2000 (SPSS, Inc., Chicago, IL, USA). All numbers are expressed as mean and range. The Pearson's chi-square
20. was used or when a table contained numbers smaller than 5 the Fisher's exact test was used
21. to compare proportions. A two-sided p-value of 0.05 or less was considered significant.

23.

24.

25. **RESULTS**

26.

27. **Baseline**

28. Of the 167 patients who were included, 36 had Apert, 55 had Crouzon/ Pfeiffer, 38 had
29. Muenke and 38 had Saethre-Chotzen syndrome. The mean age at time of referral and
30. review was 1 year and 2 months and 10 years and 3 months, respectively. Of the 167
31. patients, 81 (48%) were boys and 123 (74%) diagnoses were confirmed genetically (table 1).
32. Of the 43 in whom no mutation was found, 12 were not tested, because parents did not
33. give consent or they were tested in another hospital but no information was available. In
34. the Apert patients 24 were tested, 16 had the S252W mutation and eight the P253R mutation.
35. In nine of the tested patients with Crouzon/ Pfeiffer syndrome, no mutation was
36. found. No TWIST mutation or deletion was found in 11 patients with Saethre-Chotzen
37. syndrome, in whom a FGFR 2 or 3 mutation was excluded. In these patients, we adhered
38. to the clinical diagnoses made by the geneticist. All patients with the Muenke syndrome
39. had the FGFR 3 P250R mutation.

I. **Table 1:** Overview of genetic diagnosis

| | Apert
n = 36 | Crouzon/ Pfeiffer
n = 55 | Muenke
n = 38 | Saethre-Chotzen
n = 38 |
|--------------------------|----------------------|-----------------------------|------------------|---------------------------|
| FGFR 2 | | | | |
| 4. | S 252 W | 16 | | |
| 5. | P 253 R | 8 | | |
| 6. | C 342 Y | | 4 | |
| | C 342 W | | 1 | |
| 7. | C 342 T | | 1 | |
| 8. | C 278 F | | 4 | |
| 9. | Y 105 C | | 1 | |
| | Y 340 H | | 3 | |
| 10. | F 276 V | | 2 | |
| 11. | G 271 V | | 1 | |
| 12. | G 338 R | | 1 | |
| 13. | Q 289 P | | 3 | |
| | S 351 C | | 2 | |
| 14. | S 354 C | | 1 | |
| 15. | S 267 P | | 3 | |
| 16. | W 290 R | | 3 | |
| | A 362 T | | 3 | |
| 17. | C 342 R | | 2 | |
| 18. | C 342 W | | 1 | |
| 19. | K 641 R | | 1 | |
| 20. | 1084+3a>g | | 1 | |
| FGFR 3 | | | | |
| 21. | A 391 E | 1 | | |
| 22. | P 250 R | | 38 | |
| TWIST | | | | |
| 23. | Y103X | | | 2 |
| 24. | D157A | | | 1 |
| 25. | N114S | | | 1 |
| 26. | R116G | | | 1 |
| 27. | P136S | | | 1 |
| 28. | P136H | | | 1 |
| | R749C | | | 1 |
| 29. | T137M | | | 1 |
| 30. | 7p21 | | | 1 |
| 31. | 165ins10 | | | 2 |
| | 417dup21 | | | 1 |
| 32. | CA-repeat | | | 1 |
| 33. | Unilateral deletion | | | |
| 34. | TWIST region chr. 7 | | | 3 |
| 35. | Deletion region 7p21 | | | 3 |
| No mutation found | | | | |
| 36. | Not tested | 12 | 8 | 7 |
| 37. | | | | |
| 38. | | | | |
| 39. | | | | |

I. **Table 2:** Overview of surgery per syndrome

| Syndrome | Primary vault expansion | Secondary vault expansion | Midface advancement |
|-------------------|-------------------------|---------------------------|---------------------|
| Apert | 35 (97%) | 5 (14%) | 16 (44%) |
| Crouzon/ Pfeiffer | 46 (84%) | 10 (18%) | 21 (38%) |
| Muenke | 38 (100%) | 2 (5%) | 0 |
| Saethre-Chotzen | 34 (89%) | 5 (15%) | 0 |
| Total | 153 (92%) | 22 (13%) | 37 (22%) |

7. **Table 3:** Type and timing of first midface advancement

| | Mean age first midface advancement (years) | Apert (n = 12) | Crouzon/ Pfeiffer (n = 17) |
|-------------|--|----------------|----------------------------|
| Monobloc | 2.3 | 5 | 6 |
| Le fort III | 10.3 | 6 | 9 |
| Le fort II | 10.3 | 1 | 2 |

13. The type of primary surgery is described in table 2. No surgery was performed in 14 patients because they were relatively old at time of referral and did not have signs of elevated ICP or because their parents did not give their consent. The mean age at primary vault expansion was 14 months (range: 2 months to 9 years). A total of 92 (55%) patients underwent surgery before the age of 1 year. The main reason for performing primary skull remodelling after the age of 1 year was a delay in referral. In 22 of the 167 (13%) a second vault expansion was needed, and in 1 a third vault expansion was needed. The indication for this secondary surgery was elevated ICP in eight, scheduled fronto-orbital surgery after initial occipital expansion without any sign of elevated ICP in one, and in five patients because of unsatisfactory aesthetic effect of the first vault expansion. Of the 22 patients with a second vault expansion result, three patients were referred for a second opinion following initial vault surgery that was performed by a surgeon who was inexperienced with the treatment of syndromic craniosynostosis. In 29 patients (12 Apert and 17 Crouzon/ Pfeiffer syndrome) 37 midface advancements were conducted. Complications caused by midface advancement were previously described by Nout et al.¹⁶. The type and timing of the midface advancements are described in table 3. A ventriculoperitoneal shunt was placed in 13 patients (three Apert, nine Crouzon/ Pfeiffer, and one Muenke syndrome) because progressive ventricular dilatation was present and intracranial volume was more than appropriate.

34. ICP

35. A complete fundoscopic assessment was performed in 164 patients; of these 55 (33%) were diagnosed with elevated ICP on at least one occasion. The mean age at the first diagnosis of elevated ICP was 3.5 years (range: 5 months to 18.3 years). Forty-two were diagnosed based on the presence of papilledema and 13 based on the presence of papilledema and a positive invasive ICP measurement. Invasive measurements were made when papilledema

1. **Table 4:** Prevalence of papilledema before and after the first vault expansion

| | Preoperative ¹ | Postoperative ² | Total |
|----------------------|---------------------------|----------------------------|--------------|
| 2. Apert | 2/ 22 (9%) | 11/ 31 (35%) | 12/ 36 (33%) |
| 3. Crouzon/ Pfeiffer | 24/ 45 (53%) | 8/ 40 (20%) | 29/ 55 (53%) |
| 4. Muenke | 1/ 28 (4%) | 1/ 24 (4%) | 2/ 38 (5%) |
| 5. Saethre-Chotzen | 5/ 26 (19%) | 4/ 24 (17%) | 8/ 38 (21%) |


6. ¹Number of patients with papilledema divided by the number of patients tested for papilledema

7. ²Includes new onset and recurrent cases of papilledema

8.
9. was present without any clinical or radiological evidence for elevated ICP. The prevalence
10. of papilledema varied strongly before and after first vault expansion and among different
11. syndromes (table 4). The 1-year cumulative incidence (CI) of first occurrence of papill-
12. edema varied strongly between different syndromes and in time (figure 1).

13.
14. **OSA**

15. Because of a high suspicion for respiratory problems (e.g., snoring, difficulty in breathing
16. during sleep or apneas during sleep) in 66 patients, a screening for OSA with nocturnal
17. pulse oximetry was done. In 30 (18%) of the 167 patients, OSA was diagnosed. Patients
18. with Apert and Crouzon/ Pfeiffer syndrome had a much higher prevalence of OSA than
19. patients with Muenke and Saethre-Chotzen syndrome, and if OSA was present in patients
20. with Muenke and Saethre-Chotzen syndrome it was only mild (table 5).



35. **Figure 1:** 1-year cumulative incidence (CI) of first occurrence of papilledema per syndrome*

36. * includes only patients checked for papilledema at least once every 3 years, Apert syndrome n = 32, Crouzon/
37. Pfeiffer syndrome n = 47, Muenke syndrome n = 36, Saethre-Chotzen syndrome n = 36

I. **Table 5:** Number of patients with OSA per syndrome

| | Mild | Moderate | Severe | Total |
|----------------------|---------|----------|---------|--------------|
| 2. Apert | 4 (11%) | 3 (8%) | 4 (11%) | 11/ 36 (31%) |
| 3. Crouzon/ Pfeiffer | 8 (15%) | 4 (7%) | 3 (5%) | 15/ 55 (27%) |
| 4. Muenke | 2 (5%) | 0 | 0 | 2/ 38 (5%) |
| 5. Saethre-Chotzen | 2 (5%) | 0 | 0 | 2/ 38 (5%) |

7. **Table 6:** Prevalence of refractive errors, strabismus and impaired hearing

| | Refractive error | Strabismus | Impaired hearing |
|-----------------------|------------------|---------------|------------------|
| 9. Apert | 22/ 29 (76%) | 27/ 29 (93%)* | 21/ 29 (72%) |
| 10. Crouzon/ Pfeiffer | 16/ 41 (39%) | 27/ 43 (63%) | 20/ 40 (50%) |
| 11. Muenke | 17/ 35 (49%) | 14/ 36 (39%) | 24/ 36 (67%) |
| 12. Saethre-Chotzen | 14/ 27 (52%) | 13/ 35 (37%) | 13/ 35 (37%) |

13. * statistical significant compared to all other syndromes

15. Sight

16. In 132 patients information of sight was available. Refractive errors were reported in 69
 17. (52%) patients, 18 were myopic and 51 hyperopic (table 6). In 48 (70%) patients it was
 18. corrected with glasses. Astigmatism was reported in five (4%), anisometropia in five (4%),
 19. and severe visual loss in four (3%). The four patients with severe visual loss were previ-
 20. ously reported by Bartels et al.¹⁷. Strabismus was diagnosed in 81 patients. Patients with
 21. Apert syndrome had significantly ($p < 0.001$) more strabismus than all patients with other
 22. syndromes (table 6).

24. Hearing

25. Hearing loss was reported in 78 of 140 (56%) patients. Conductive hearing loss was re-
 26. ported in 62 (44%), sensorineural hearing loss (SNHL) in six (4%) and mixed hearing
 27. loss was reported in 10 (7%) of the patients. The prevalence was the highest in Apert and
 28. Muenke syndrome (table 6). Of the 16 patients with SNHL, four had Apert syndrome,
 29. five had Crouzon/ Pfeiffer syndrome and seven had Muenke syndrome. Conductive hear-
 30. ing loss was present in 20 patients with Apert syndrome, in 19 patients with Crouzon/
 31. Pfeiffer syndrome, in 20 patients with Muenke and in 13 patients with Saethre-Chotzen
 32. syndrome. Eighteen of the 140 (13%) patients needed a hearing aid: four patients with
 33. Apert syndrome, nine with Crouzon/ Pfeiffer syndrome, three with Muenke syndrome
 34. and two with Saethre-Chotzen syndrome

1. **DISCUSSION**

2.

3. This study highlights the high prevalence of elevated ICP in patients with Apert, Crouzon/
 4. Pfeiffer and Saethre-Chotzen syndrome. OSA is prevalent in Apert and Crouzon/ Pfeiffer
 5. syndrome and hearing and visual problems are frequent in all of the syndromes. This
 6. retrospective description of our population guides us to a diagnosis-specific screening and
 7. treatment protocol (table 7).

8.

9. **Table 7:** Overview of diagnosis-specific screening and treatment protocol

| 10. | Clinical diagnosis | Apert | Crouzon/ Pfeiffer | Muenke | Saethre-Chotzen | Comment |
|-----|--|--|---|--|---|---|
| 11. | Genetic research | FGFR 2 | FGFR 2 | 1 st P250R
FGFR 3 | 1 st TWIST
2 nd P250R | No FGFR 1 analysis included |
| 12. | | | | 2 nd TWIST | FGFR 3 | |
| 13. | Fundoscopy | Yearly up till 6 years | Yearly up till 6 years.
In patients without craniosynostosis every 3 months during the first 2 years | At age of 2 years | Yearly up till 6 years | At first visit and pre-surgery in all patients. Papilledema without clinical or radiological symptoms: invasive ICP measurement |
| 14. | | | | | | |
| 15. | | | | | | |
| 16. | | | | | | |
| 17. | | | | | | |
| 18. | Polysomnography and/or pulse-oximetry | Yearly till 6 years. For older patient only if anamnestic breathing difficulties are present. Yearly after surgical treatment of moderate or severe OSA | | If anamnestic breathing difficulties are present | If anamnestic breathing difficulties are present | If OSA is diagnosed: inspection of tonsils and endoscopy of upper airway |
| 19. | | | | | | |
| 20. | | | | | | |
| 21. | Hearing | Otoscopy and tympanometry at all ages. Otoacoustic Emission (OAE) till 4 years. Pure tone audiometry in patients of 4 years and older. If a hearing deficit is found on OAE or pure tone audiometry, Brainstem Response Audiometry is indicated. | | | | |
| 22. | | | | | | |
| 23. | | | | | | |
| 24. | Sight | At first visit: screening for strabismus, if present; further ophthalmic work up is needed. When possible given child's development, information about visual acuity is required. | | | | |
| 25. | (3D-)CT scan | Prior to any craniofacial surgery in all patients | | | | |
| 26. | MRI | At age 0 and 4
If papilledema is present | | | | |
| 27. | | | | | | |
| 28. | First cranial vault remodelling | Occipital expansion between 6 and 9 months (if synostosis is present).
If severe OSA or severe exorbitism is present: monobloc + distraction | | Fronto-orbital advancement between 9 and 12 months | Fronto-orbital advancement between 6 and 9 months | |
| 29. | | | | | | |
| 30. | Elevated ICP in follow-up | Occipital expansion with distraction or biparietal widening based on shape of skull | | Occipital remodelling | | |
| 31. | | | | | | |
| 32. | | | | | | |
| 33. | Midface advancement (monobloc or le Fort III with distraction) | Relative indication: between age 9 and 12 (and le Fort I at 18) or at 18 | | Not indicated | | |
| 34. | | | | | | |
| 35. | | | | | | |
| 36. | Psychological testing | At the age of 1.5; 3.5; 6; 8; 12; 15 and 18 years | | | | |
| 37. | | | | | | |
| 38. | | | | | | |
| 39. | | | | | | |

1. All patients need genetic analysis to establish the diagnosis, for selective screening on
2. related abnormalities, genetic counseling and research. Given the fact that we never en-
3. countered a mutation in the FGFR 1 gene, we have now stopped routine analysis of this
4. gene (table 1).

5. In general, all patients undergo vault expansion within their first year of life^{18, 19}, but
6. surgery is scheduled earlier whenever papilledema is detected. According to our current
7. protocol, initial vault expansion in patients with Apert or Crouzon/ Pfeiffer syndrome
8. is occipital remodelling. This way we leave the fronto-orbital area untouched, which
9. facilitates a monobloc at a later stage. In Muenke and Saethre-Chotzen syndrome, we
10. choose to perform a fronto-orbital advancement, to expand the cranial volume and restore
11. the appearance of their upper face. Given the very low risk on elevated ICP in Muenke
12. syndrome and reports on the disappointing aesthetic results requiring additional surgery
13. ²⁰⁻²², we suggest to postponement of surgery for these patients (table 7).

14. A monobloc with distraction is chosen as primary surgery whenever patients suffer from
15. severe OSA and/or severe exophthalmus.

16. Some patients with Crouzon/ Pfeiffer syndrome may not develop craniosynostosis at
17. all or postnatal. These patients should be seen at an interval of 3 months within the first 2
18. years and vault surgery is indicated whenever elevated ICP is detected.

19. Despite early vault expansion, the prevalence of postoperative new onset elevated ICP
20. remained high in our and other studies especially for patients with the Apert, Crouzon/
21. Pfeiffer and Saethre-Chotzen syndrome^{18,23}. The craniofacial group from London has
22. presented similar findings in patients with the Apert syndrome², in whom vault expansion
23. was only performed once signs of elevated ICP were detected. Despite surgery at a later
24. age, these patients experienced a similar risk on re-occurrence of elevated ICP at about 5
25. years of age. Apparently, expansion of the skull does prevent and treat elevated ICP for a
26. few years. The second episode with elevated ICP about the age of 4-5 years is not related to
27. a craniocerebral disproportion because most of the brain growth has already taken place.
28. Other possible factors that can cause the second rise in ICP are OSA⁴, hydrocephalus and
29. venous hypertension.

30. To diagnose elevated ICP, we recommend yearly fundoscopy in Apert, Crouzon/ Pfeiffer
31. and Saethre-Chotzen syndrome up to the age of 6 and for Muenke up to the age of 2.
32. If papilledema is present, a computed tomography (CT) or magnetic resonance imaging
33. (MRI) is indicated to exclude progressive ventricular dilatation.

34. In this study, we probably have an underestimation of the prevalence of OSA due to
35. measuring only a selected group of patients with anamnestic breathing difficulties and due
36. to the use of pulse-oximetry instead of polysomnography. Pulse-oximetry is a diagnostic
37. test for straightforward OSA, but a negative pulse-oximetry cannot rule out OSA¹³. Ta-
38. king into account these limitations, we found OSA in more than 25% of the suspected
39. children with the Apert and Crouzon/ Pfeiffer syndrome and 5% in the children with

1. Saethre-Chotzen or Muenke syndrome. Because the high prevalence of OSA in Apert
2. and Crouzon/ Pfeiffer syndrome, we advocate yearly screening for OSA with polysom-
3. nography. Children with Saethre-Chotzen or Muenke syndrome should be tested when
4. difficulties in breathing during sleep are reported. Once the presence of OSA is confirmed,
5. additional work-up is indicated including inspection of the size of the tonsils and endos-
6. copy of the upper airways to determine the level(s) of obstruction. In a previous study
7. we have demonstrated that OSA in syndromic craniosynostosis can be caused by airway
8. obstruction at various levels and is therefore not always cured by a midface advancement
9. (Bannink 2009, submitted). Treatment of OSA should be individualized for each specific
10. patient, depending on severity of OSA, level of obstruction, contributing factors to OSA,
11. age of the patient and additional functional or psychosocial problems. Treatment may
12. consist of adjusting the sleeping position, nasal spray with steroids, respiratory support
13. (for instance with nocturnal oxygen, continuous positive airway pressure (CPAP) or
14. tracheal cannula), (adeno)tonsillectomy, maxillary or even mandibular advancement or
15. a monobloc procedure.

16. This retrospective study showed that impaired sight and hearing had a high prevalence
17. in all syndromes and should therefore be an integral part of follow-up. Regular screening
18. is therefore indicated.

19. Genetic analysis is necessary for counseling and screening on syndrome-specific anoma-
20. lies and functional deficits. Follow-up by a multidisciplinary team is needed till the age of
21. 18 years to guarantee the best possible outcome.

22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.


I. REFERENCES

1. Bannink N, Joosten KF, van Veelen ML, et al. Papilledema in patients with Apert, Crouzon, and Pfeiffer syndrome: prevalence, efficacy of treatment, and risk factors. *J Craniofac Surg* 2008; 19: 121-7.
2. Marucci DD, Dunaway DJ, Jones BM, Hayward RD. Raised intracranial pressure in Apert syndrome. *Plast Reconstr Surg* 2008; 122: 1162-8; discussion 69-70.
3. Gonzalez S, Hayward R, Jones B, Lane R. Upper airway obstruction and raised intracranial pressure in children with craniosynostosis. *Eur Respir J* 1997; 10: 367-75.
4. Hayward R, Gonzalez S. How low can you go? Intracranial pressure, cerebral perfusion pressure, and respiratory obstruction in children with complex craniosynostosis. *J Neurosurg* 2005; 102: 16-22.
5. Pijpers M, Poels PJ, Vaandrager JM, et al. Undiagnosed obstructive sleep apnea syndrome in children with syndromal craniofacial synostosis. *J Craniofac Surg* 2004; 15: 670-4.
6. Hertle RW, Quinn GE, Minguini N, Katowitz JA. Visual loss in patients with craniofacial synostosis. *J Pediatr Ophthalmol Strabismus* 1991; 28: 344-9.
7. Tay T, Martin F, Rowe N, et al. Prevalence and causes of visual impairment in craniosynostotic syndromes. *Clin Experiment Ophthalmol* 2006; 34: 434-40.
8. Jadico SK, Huebner A, McDonald-McGinn DM, et al. Ocular phenotype correlations in patients with TWIST versus FGFR3 genetic mutations. *J Aapos* 2006; 10: 435-44.
9. Church MW, Parent-Jenkins L, Rozzelle AA, et al. Auditory brainstem response abnormalities and hearing loss in children with craniosynostosis. *Pediatrics* 2007; 119: e1351-60.
10. Rajenderkumar D, Bamiou DE, Sirimanna T. Audiological profile in Apert syndrome. *Arch Dis Child* 2005; 90: 592-3.
11. Tuite GF, Chong WK, Evanson J, et al. The effectiveness of papilledema as an indicator of raised intracranial pressure in children with craniosynostosis. *Neurosurgery* 1996; 38: 272-8.
12. Wiegand C, Richards P. Measurement of intracranial pressure in children: a critical review of current methods. *Dev Med Child Neurol* 2007; 49: 935-41.
13. Brouillette RT, Morielli A, Leimanis A, et al. Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea. *Pediatrics* 2000; 105: 405-12.
14. Guilleminault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995; 127: 905-12.
15. Marcus CL, Omlin KJ, Basinki DJ, et al. Normal polysomnographic values for children and adolescents. *Am Rev Respir Dis* 1992; 146: 1235-9.
16. Nout E, Wolvius EB, van Adrichem LN, et al. Complications in maxillary distraction using the RED II device: a retrospective analysis of 21 patients. *Int J Oral Maxillofac Surg* 2006; 35: 897-902.
17. Bartels MC, Vaandrager JM, de Jong TH, Simonsz HJ. Visual loss in syndromic craniosynostosis with papilledema but without other symptoms of intracranial hypertension. *J Craniofac Surg* 2004; 15: 1019-22; discussion 23-4.
18. Renier D, Lajeunie E, Arnaud E, Marchac D. Management of craniosynostoses. *Childs Nerv Syst* 2000; 16: 645-58.
19. Mathijssen IM, Arnaud E. Benchmarking for craniosynostosis. *J Craniofac Surg* 2007; 18: 436-42.
20. Becker DB, Fundakowski CE, Govier DP, et al. Long-term osseous morphologic outcome of surgically treated unilateral coronal craniosynostosis. *Plast Reconstr Surg* 2006; 117: 929-35.
21. Honnebier MB, Cabiling DS, Hetlinger M, et al. The natural history of patients treated for FGFR3-associated (Muenke-type) craniosynostosis. *Plast Reconstr Surg* 2008; 121: 919-31.

- 1.
 - 2.
 - 3.
 - 4.
 - 5.
 - 6.
 - 7.
 - 8.
 - 9.
 - 10.
 - 11.
 - 12.
 - 13.
 - 14.
 - 15.
 - 16.
 - 17.
 - 18.
 - 19.
 - 20.
 - 21.
 - 22.
 - 23.
 - 24.
 - 25.
 - 26.
 - 27.
 - 28.
 - 29.
 - 30.
 - 31.
 - 32.
 - 33.
 - 34.
 - 35.
 - 36.
 - 37.
 - 38.
 - 39.
22. McCarthy JG, Glasberg SB, Cutting CB, et al. Twenty-year experience with early surgery for craniosynostosis: I. Isolated craniofacial synostosis--results and unsolved problems. *Plast Reconstr Surg* 1995; 96: 272-83.
23. Kress W, Schropp C, Lieb G, et al. Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. *Eur J Hum Genet* 2006; 14: 39-48.

Part IV


Quality of life and behavior






Chapter 7

Health-related quality of life in children and adolescents with syndromic craniosynostosis




Bannink N




Maliepaard M

Raat H



Joosten KFM

Mathijssen IMJ



I. **ABSTRACT**

2.

3. **Objective**

4. Syndromic craniosynostosis is a congenital disorder characterized by premature fusion of
5. calvarial sutures combined with other anomalies. The facial appearance is different and
6. patients may show physical impairment, mental or developmental disabilities, elevated
7. intracranial pressure and obstructive sleep apnea. The impact of this condition on daily
8. functioning has not been studied before. The aim of this study is to assess the health-related
9. quality of life in children and adolescents with syndromic or complex craniosynostosis and
10. to determine the impact of these syndromes on parents.

11.

12. **Methods**

13. A prospective study was performed in 111 children. Health-related quality of life was
14. measured by international standardised quality of life questionnaires, the Infant Toddler
15. Quality of Life Questionnaire (ITQoL), Child Health Questionnaire Parental Form 50
16. (CHQ-PF50), Child Health Questionnaire Child Form 87 (CHQ-CF87) and the Short
17. Form Health Survey (SF-36). For comparison, we used Dutch population norms of
18. health-related quality-of-life-scores.

19.

20. **Results**

21. Parents' scores for patients with syndromic or complex craniosynostosis were significant
22. lower than those for the norm population. Apert syndrome had the largest impact on the
23. different domains. Scores on the CHQ-PF50 scales for 'physical functioning', 'parental
24. impact emotional' and 'family activities' for these patients were significantly lower than
25. scores for patients with other syndromes, possibly due to the complexity of the syndrome,
26. which includes complex syndactyly, cognitive impairment and behavior problems. Parents
27. reported a reduced health-related quality of life for themselves, mostly psychosocial with
28. clearly significantly lower general health perceptions.

29.

30. **Conclusion**

31. Syndromic craniosynostosis has a large impact on the health-related quality of life of these
32. children and their parents, both physical and psychosocial.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Craniosynostosis, characterized by premature fusion of calvarial sutures, is a congenital
4. anomaly that occurs in 1 in 2500 births. In about 40% of cases, craniosynostosis is part
5. of a syndrome, such as Apert, Crouzon, Pfeiffer, Muenke or Saethre-Chotzen syndrome¹.
6. Fusion of two cranial sutures or more without a known fibroblast growth factor receptor
7. (FGFR) 1, 2, and 3, TWIST, or ephrin-B1 (EFNB1) mutation¹⁻³ is defined as complex
8. craniosynostosis.

9. Patients are at risk of elevated intracranial pressure (ICP), obstructive sleep apnea, hea-
10. ring and visual disorders, and delayed motor and language development⁴. All these could
11. affect the daily life of these patients and of their parents; however the impact has not been
12. studied so far.

13. The facial appearance of children with syndromic or complex craniosynostosis is clearly
14. different and they may show physical, mental or developmental disabilities. This study
15. aimed at assessing the health-related quality of life in children with syndromic or complex
16. craniosynostosis and additionally at determining the impact of these syndromes on the
17. daily functioning of their parents.

18.

19.

20. METHODS

21.

22. Study population

23. A prospective study was performed at the Erasmus MC-Sophia Children's Hospital, a
24. tertiary care university hospital. All patients between 2 and 18 years with syndromic or
25. complex craniosynostosis registered at the Dutch Craniofacial Center were invited be-
26. tween January 2007 and September 2008 to participate, along with their parents.

27.

28. Health-related quality of life questionnaires

29. Health-related quality of life of the past 4 weeks was measured with international stan-
30. dardized quality of life questionnaires. For children between the ages of 2 and 4 years, the
31. parents completed the Infant Toddler Quality of Life (ITQoL)⁵, and for children between
32. 4 and 18 years the Child Health Questionnaire Parental Form 50 (CHQ-PF50)⁶ was used.
33. Children aged between 12 and 18 years completed the Child Health Questionnaire Child
34. Form 87 (CHQ-CF87)⁷ themselves. Parents also completed a questionnaire on their own
35. health, the Short-Form Health Survey (SF-36)⁸ (see appendices 1-3).

36. Item scores per scale were summed up and transformed into a 0-100 score; the lower
37. the score, the poorer the subjective health status. For the CHQ-PF50, a 'physical sum-
38. mary score' and 'psychosocial summary score' were calculated; for the SF-36, a 'physical
39. component summary score' and 'mental component summary score' were calculated by

1. the sum of all scales except 'change in health', 'family activity' and 'family cohesion' based
2. on an exploratory factor-analytic model⁹. The 'change in health' scale differs from the
3. other scales in that it measures change over the past year. A score of 50 indicates no
4. change and a score of 100 maximal improvement. All questions were short and closed with
5. responses on Likert-scales. They were phrased to avoid difficult words where possible. The
6. confidentiality of the answers was guaranteed.

7. Data of the research group were compared with Dutch healthy population norms of
8. health-related quality-of-life-scores^{5, 7, 8}. Scores for patients with the different syndromes
9. were also compared with the norms and between the syndromes.

10.

11. **Potential predictive factors on health-related quality of life**

12. We compared scores for parents with and without the same craniosynostosis syndrome as
13. their child to evaluate how suffering from syndromic craniosynostosis themselves would
14. effect reporting on their children.

15. Furthermore, we determined the effect of obstructive sleep apnea (OSA) on health-
16. related quality of life. OSA was detected through a nocturnal ambulatory sleep study and
17. was defined as an obstructive apnea hypopnea index ≥ 1 (N. Bannink et al., unpublished
18. data, 2009).

19. Elevated intracranial pressure may have impact on health-related quality of life. It is
20. detected through fundoscopy, which reveals papilledema in those cases.

21.

22. **Statistical analysis**

23. Statistical analysis was performed with SPSS 16.0 for Windows (SPSS, Chicago, IL, USA)
24. and with GraphPad Prism 4.0 (GraphPad Prism Inc., CA, USA). The mean values of the
25. different domains with standard deviation were calculated. The independent t-test was
26. used to compare the children's and parents' quality of life with a sample of the Dutch
27. population^{5, 7}. The groups were large enough to use this test. Because of the small numbers
28. of patients in the syndromic subgroups, Z-scores were calculated and compared in an
29. analysis of variance (ANOVA) procedure.

30. Significant differences were defined as a p-value ≤ 0.05 . All quality-of-life domains were
31. expressed as mean and standard deviation. Pooled effect size of the difference between
32. study population and norm population was calculated for each domain, which is measured
33. by the difference between norm scores and patient scores divided by the pooled standard
34. deviation¹⁰.

35. To analyze the effects of OSA and ICP on each domain, multivariate analysis was per-
36. formed with age, sex, diagnosis, OSA and papilledema as independent variables.

37.

38.

39.

1. RESULTS

2.

3. Study population

4. A total of 136 patients with syndromic or complex craniosynostosis were approached, and
 5. 117 (86%) children and their parents gave informed consent. Of those, 111 (95%) returned
 6. the questionnaires; that is, 23 patients returned the ITQoL and 88 patients the CHQ-
 7. PF50. Twenty-nine of the 32 patients between 12 and 18 years completed the CHQ-CF87.
 8. The three other patients were unable to complete due to low mental capacity. One parent
 9. returned the CHQ-PF50 without answering all questions; the analysis therefore included
 10. 87 instead of 88 questionnaires.

11. All 110 parents (74% mothers) completed the SF-36. Their median age was 39 (23-61)
 12. years. As many as 85% of the mothers and 84% of the fathers were born in the Netherlands.
 13. The educational level of 6% was elementary school, of 72% secondary education and of
 14. 22% higher education or university.

15. The study group consisted of 53 boys (48%) and 57 girls. Eighteen patients had Apert
 16. syndrome, 26 Crouzon, 17 Muenke, 20 Saethre-Chotzen syndrome, and 29 had complex
 17. craniosynostosis. Their median age was 7 (2-18) years. A total of 95% was born in the
 18. Netherlands.

19.

20. Health-related consequences in children with syndromic or complex craniosynostosis 21. below 4 years of age

22. The mean ITQoL scores of the study population in comparison with the norm population
 23. scores are shown in table 1. Children under the age of 4 years were assigned significantly
 24. lower scores on the domains such as 'physical functioning', 'growth and development',
 25. 'general health perceptions' and 'parental impact: emotional and time'.

26.

27. Health-related consequences in children with syndromic or complex craniosynostosis 28. above 4 years of age

29. The mean CHQ-PF50 scores of the study population in comparison with the norm popu-
 30. lation are also shown in table 1. Children above 4 years of age were assigned lower scores
 31. on all domains except 'family cohesion' and 'change in health'.

32. Subgroup analysis of age groups 4-12 years (n = 55) and 12-18 years (n = 32) revealed no
 33. statistical differences in the scores in any domain. Families with a lower socioeconomic
 34. status reported a lower health-related quality of life of their children, but only on psycho-
 35. social domains.

36.

37. Syndrome-specific health-related consequences in children with syndromic or complex 38. craniosynostosis

39. Table 2 and figure 1 show the scores per syndrome in comparison with the norm popula-
 tion.

1. **Table 1:** The mean health-related quality-of-life scores with standard deviation of the ITQoL and the CHQ-PF50
 2. of our study population in comparison with the norm population

| | Children with
craniosynostosis | Norm
population | p-value ¹ | Effect size ²
d |
|--|-----------------------------------|--------------------|----------------------|-------------------------------|
| 4. <u>ITQoL (2-4 years)</u> | n = 23 | n = 314 | | |
| 5. Physical functioning (PF) | 86.1 (23.8) | 97.2 (9.8) | <0.0001** | 0.61 |
| 6. Growth and development (GD) | 79.9 (19.7) | 86.5 (10.6) | 0.0063** | 0.42 |
| 7. Bodily pain (BP) | 84.4 (18.0) | 83.8 (16.8) | 0.86 | -0.04 |
| 8. Temperament and moods (TM) | 78.7 (12.6) | 77.2 (10.5) | 0.51 | -0.13 |
| 9. General behavior (GB) | 75.3 (15.0) | 72.8 (12.7) | 0.36 | -0.18 |
| 10. Getting along (GA) | 72.2 (10.0) | 71.4 (8.8) | 0.69 | -0.08 |
| 11. General health perceptions (GH) | 67.8 (22.0) | 79.0 (14.5) | 0.0007** | 0.60 |
| 12. Parental impact: Emotional (PE) | 83.1 (19.7) | 92.1 (10.5) | 0.0002** | 0.57 |
| 13. Parental impact: Time (PT) | 84.9 (24.2) | 93.0 (11.0) | 0.0018** | 0.43 |
| 14. Family activity (FA) | 82.8 (22.5) | 86.2 (13.5) | 0.26 | 0.18 |
| 15. Family cohesion (FC) | 82.8 (23.0) | 75.3 (18.8) | 0.06 | -0.36 |
| 16. Change in health (CH) | 61.4 (21.4) | 56.1 (18.4) | 0.20 | -0.26 |
| 17. <u>CHQ-PF50 (4-18 years)</u> | n = 87 | n = 353 | | |
| 18. Physical functioning (PF) | 90.6 (16.4) | 99.1 (4.3) | <0.0001** | 0.72 |
| 19. Role functioning: Emotional/behavior (REB) | 87.2 (23.4) | 97.9 (7.2) | <0.0001** | 0.61 |
| 20. Role functioning: Physical (RP) | 87.9 (27.2) | 95.8 (15.6) | 0.0004** | 0.36 |
| 21. Bodily pain (BP) | 78.8 (25.4) | 85.7 (17.2) | 0.0044** | 0.31 |
| 22. General behavior (GB) | 73.6 (15.5) | 78.5 (13.1) | 0.0046** | 0.33 |
| 23. Mental health (MH) | 74.9 (15.8) | 81.4 (12.1) | <0.0001** | 0.45 |
| 24. Self-esteem (SE) | 73.6 (15.1) | 79.2 (11.0) | 0.0001** | 0.42 |
| 25. General health perceptions (GH) | 65.8 (23.9) | 82.9 (13.4) | <0.0001** | 0.87 |
| 26. Parental impact: Emotional (PE) | 72.3 (23.7) | 86.3 (15.2) | <0.0001** | 0.69 |
| 27. Parental impact: Time (PT) | 82.6 (26.7) | 94.0 (13.0) | <0.0001** | 0.54 |
| 28. Family activity (FA) | 80.3 (21.9) | 91.5 (11.9) | <0.0001** | 0.61 |
| 29. Family cohesion (FC) | 71.1 (19.7) | 72.2 (19.4) | 0.81 | 0.03 |
| 30. Change in health (CH) | 56.9 (19.7) | 56.1 (18.4) | 0.58 | -0.06 |
| 31. Physical summary (PHS) | 50.9 (10.4) | 56.4 (5.7) | <0.0001** | 0.81 |
| 32. Psychosocial summary (PSS) | 52.0 (9.6) | 53.2 (6.4) | <0.0001** | 0.43 |

33. ** p-value ≤ 0.01

34. ¹ 2-sided one-sample t-test of the scale scores between study population and norm population

35. ² pooled effect size d measured the difference in mean scores divided by the standard deviations of the parental group, 0.2 ≤ d < 0.5 indicated a small effect, 0.5 ≤ d < 0.8 a moderate effect, d ≥ 0.8 a large effect, a negative effect size meant a higher score with regard to the norm group¹⁰

36. *Apert syndrome*

37. The three 2- to 4-year-olds with Apert syndrome scored significantly lower than the norm
 38. at 'physical functioning', 'growth and development', 'general health perceptions', 'parental
 39. impact: time', and 'family activity'. They showed a significant 'change in health'. The 15
 40. children above 4 years of age were assigned significantly lower scores in each domain except
 41. 'family cohesion' and 'change in health'. Compared with children with other syndromes,

Table 2: The mean health-related quality-of-life scores with standard deviation of the ITQoL and the CHQ-PF50 per syndrome

| | Norm population | Apert | Crouzon/ Pfeiffer | Muenke | Saethre-Chotzen | Complex |
|---------------------------------|-----------------|-----------------|-------------------|---------------|-----------------|---------------|
| ITQoL (2-4 years) | n = 314 | n = 3 | n = 8 | n = 4 | n = 2 | n = 6 |
| Physical functioning (PF) | 97.2 (9.8) | 68.9 (25.5)** | 93.0 (16.2)** | 98.3 (3.3) | 100.0 (0.0) | 76.7 (35.3)** |
| Growth and development (GD) | 86.5 (10.6) | 74.2 (26.3)** | 85.5 (10.6) | 96.3 (7.5) | 87.5 (10.6) | 73.3 (25.3)** |
| Bodily pain (BP) | 83.8 (16.8) | 83.3 (8.3) | 89.4 (9.2) | 91.7 (9.6) | 95.8 (5.9) | 83.3 (13.9) |
| Temperament and moods (TM) | 77.2 (10.5) | 78.7 (14.8) | 83.1 (12.1) | 89.2 (10.4)* | 79.2 (3.9) | 76.4 (2.9) |
| General behavior (GB) | 72.8 (12.7) | 75.7 (21.7) | 81.0 (12.7) | 84.7 (5.6) | 73.8 (5.4) | 71.6 (9.6) |
| Getting along (GA) | 71.4 (8.8) | 73.9 (20.4) | 74.3 (6.9) | 78.9 (5.4) | 76.7 (2.4) | 69.6 (7.3) |
| General health perceptions (GH) | 79.0 (14.5) | 59.0 (31.8)* | 71.0 (19.5) | 91.3 (1.5) | 78.9 (16.2) | 67.2 (25.8) |
| Parental impact: Emotional (PE) | 92.1 (10.5) | 80.9 (16.9) | 83.8 (18.9)* | 99.1 (1.8) | 92.9 (10.1) | 88.1 (16.4) |
| Parental impact: Time (PT) | 93.0 (11.0) | 74.6 (22.5)** | 92.2 (10.7) | 98.8 (2.4) | 100.0 (0.0) | 79.4 (37.3)** |
| Family activity (FA) | 86.2 (13.5) | 68.1 (24.4)* | 89.0 (16.6) | 100.0 (0.0)* | 89.6 (8.8) | 87.5 (17.1) |
| Family cohesion (FC) | 75.3 (18.8) | 86.7 (23.1) | 87.3 (15.2) | 96.3 (7.5)* | 72.5 (17.7) | 90.0 (7.7) |
| Change in health (CH) | 56.1 (18.4) | 91.7 (14.4)** | 57.5 (12.1) | 50.0 (0.0) | 62.5 (17.7) | 58.3 (25.8) |
| CHQ-PF50 (4-18 years) | n = 353 | n = 15 | n = 18 | n = 13 | n = 18 | n = 23 |
| Physical functioning (PF) | 99.1 (4.3) | 83.1 (14.3)**# | 95.9 (10.4)** | 92.3 (12.7)** | 97.2 (5.5) | 85.0 (24.4)** |
| Role functioning: | | | | | | |
| Emotional/behavior (REB) | 97.9 (7.2) | 82.2 (22.9)** | 86.4 (27.4)** | 85.5 (21.5)** | 95.7 (10.2) | 85.5 (28.5)** |
| Role functioning: Physical (RP) | 95.8 (15.6) | 78.8 (35.9)** | 89.8 (27.5) | 88.5 (22.9) | 94.4 (17.1) | 86.9 (29.7)* |
| Bodily pain (BP) | 85.7 (17.2) | 75.3 (29.9)* | 83.9 (23.8) | 74.6 (31.3)* | 73.3 (21.7)** | 83.9 (22.9) |
| General behavior (GB) | 78.5 (13.1) | 64.9 (15.7)** | 77.6 (15.9) | 69.2 (5.5)* | 74.4 (12.1) | 77.3 (16.1) |
| Mental health (MH) | 81.4 (12.1) | 69.0 (13.4)** | 77.5 (16.9) | 74.5 (20.3)* | 74.7 (14.5)* | 76.9 (15.1) |
| Self-esteem (SE) | 79.2 (11.0) | 68.0 (12.9)** | 71.9 (15.4)** | 70.5 (18.4)** | 74.1 (14.5) | 79.9 (13.9) |
| General health perceptions (GH) | 82.9 (13.4) | 50.6 (29.0)** | 74.7 (20.5) | 65.6 (26.6)** | 68.0 (15.7)** | 67.5 (23.8)** |
| Parental impact: Emotional (PE) | 86.3 (15.2) | 56.7 (22.3)**## | 80.6 (16.4) | 61.4 (29.2)** | 80.1 (15.9) | 75.0 (26.5)** |
| Parental impact: Time (PT) | 94.0 (13.0) | 72.6 (23.7)** | 84.6 (27.0)** | 84.3 (26.1)* | 88.9 (22.9) | 81.6 (31.4)** |
| Family activity (FA) | 91.5 (11.9) | 63.1 (23.2)**## | 87.9 (19.2) | 67.1 (18.5)** | 70.3 (21.5)** | 79.3 (24.0)** |
| Family cohesion (FC) | 72.2 (19.4) | 71.5 (20.1) | 70.8 (16.1) | 80.8 (20.5) | 87.9 (14.0)** | 73.9 (22.3) |
| Change in health (CH) | 56.1 (18.4) | 63.3 (22.9) | 63.9 (21.4) | 48.1 (18.9) | 52.8 (8.1) | 55.4 (21.3) |
| Physical summary (PHS) | 56.4 (5.7) | 46.6 (11.9)** | 54.3 (9.3) | 49.1 (10.3)** | 53.5 (4.7)* | 49.6 (12.6)** |
| Psychosocial summary (PSS) | 53.2 (6.4) | 47.3 (9.2)** | 52.7 (9.7) | 50.0 (12.9) | 53.9 (7.1) | 54.0 (9.4) |

2-sided one-sample t-test of the scale scores between each syndrome and the norm population

* p-value ≤ 0.05

** p-value ≤ 0.01

2-sided one-sample t-test of the scale scores between each syndrome and the other syndromes

p-value ≤ 0.05

p-value ≤ 0.01




Figure 1: The mean health-related quality-of-life scores of the CHQ-PF50 per syndrome

those with Apert syndrome had significantly lower scores at ‘physical functioning’, ‘parental impact: emotional’ and ‘family activity’. No correlation with age was found.

The nine children with a S252W mutation scored lower at each domain on the CHQ than the four children with a P253R mutation, and significantly lower at ‘role functioning: emotional/ behavior’ (mean 74.1 vs. 100.0, $p = 0.01$), ‘mental health’ (mean 62.8 vs. 85.0, $p = 0.03$) and ‘self-esteem’ (mean 61.9 vs. 80.2, $p = 0.02$).

Crouzon and Pfeiffer syndrome

The 2- to 4-year-olds with Crouzon or Pfeiffer syndrome scored significantly lower at ‘physical functioning’ and ‘parental impact: emotional’. Their scores did not differ very much from the norm. Those above 4 years scored significantly lower at ‘physical functioning’, ‘role functioning: emotional/ behavior’, ‘self-esteem’, ‘general health perceptions’, and ‘parental impact: time’.

Muenke syndrome

The under 4-year-olds with Muenke syndrome scored significantly higher at ‘temperament and moods’ and ‘family activity and cohesion’. Scores for those above 4 years were almost the same as for children with Apert syndrome, apart from better scores on ‘role functioning: physical’ and ‘parental impact: time’.

1. *Saethre-Chotzen syndrome*

2. The under 4-year-olds with Saethre-Chotzen syndrome scored according to the norm on
3. all domains. The older children scored significantly lower on 'bodily pain', 'mental health',
4. 'general health perceptions', and 'family activity' and significantly higher on 'family cohe-
5. sion'.
6.

7. *Complex craniosynostosis*

8. The under 4-year-olds with complex craniosynostosis scored significantly lower at 'physi-
9. cal functioning', 'growth and development' and 'parental impact: time'. Those above 4
10. years scored significantly lower at 'physical functioning', 'role functioning: emotional/
11. behavior and physical', 'general health perceptions', 'parental impact: emotional and time'
12. and 'family activity'.
13.

14. **Potential predictive factors on health-related quality of life**

15.

16. *Hereditary craniosynostosis*

17. Scores of the five parents of 2- to 4-year-olds who suffered from the same syndrome as
18. their child were more in agreement with the norm on all quality-of-life domains of their
19. children, except 'change in health', than parents without the syndrome (n=18). Significant
20. differences were seen in the following domains: 'physical functioning' (mean 98.7 vs. 82.6,
21. $p = 0.02$), 'growth and development' (mean 93.5 vs. 76.1, $p = 0.02$), 'bodily pain' (mean
22. 96.7 vs. 81.0, $p = 0.01$), 'parental impact: emotional (mean 97.1 vs. 79.2, $p = 0.004$) and
23. time' (mean 99.0 vs. 81.0, $p = 0.01$) and 'family activity' (mean 96.7 vs. 78.9, $p = 0.01$).
24.

25. Parents of children above 4 years of age, 24 with the same syndrome and 63 without,
26. showed no differences in this respect.
26.

27. *Obstructive sleep apnea*

28. Thirty-seven of all children had OSA, of whom six suffered from Apert syndrome (16%),
29. 12 from Crouzon syndrome (32%) and nine from complex craniosynostosis (24%). After
30. multivariate analysis OSA was an independent predictor for the domain 'change in health'
31. on the CHQ only.
32.

33. *Elevated ICP*

34. Nineteen children had elevated ICP, of whom 13 suffered from Crouzon syndrome, one
35. from Apert syndrome, three from Saethre-Chotzen syndrome and two from complex
36. craniosynostosis. ICP was an independent predictor for the domains 'parental impact:
37. emotional', 'family activity' and 'change in health' on the ITQoL and 'physical functioning',
38. 'general behavior', 'general health perceptions', 'parental impact: time' and 'family activity'
39. on the CHQ.

1. **Health-related consequences reported by patients themselves**

2. The 29 children between 12 and 18 years of age who completed the CHQ-CF87 scored
3. almost similar to the norm. They scored significantly lower at 'general health perceptions'
4. (mean 68.3 vs. 75.0, $p = 0.03$) and 'family cohesion' (mean 66.4 vs. 76.0, $p = 0.03$). In
5. comparison with their parents two domains were significantly different. Parents reported
6. more limitations due to physical health ('role functioning: physical') and more behavioral
7. problems ('general behavior') than their children.

8.
9. **Health-related consequences in parents**

10. The results of the SF-36, completed by parents, are shown in table 3. They reported more
11. limitations in work or other daily activities. The 'mental component summary' score was
12. lower in comparison with the norm population. Parents of the under 4-year-olds reported
13. significantly lower scores on 'physical functioning' (mean 55.0 vs. 95.8, $p = 0.03$) and 'role
14. limitations due to physical functioning' (mean 45.0 vs. 78.5, $p = 0.03$) when they had the
15. same syndrome as their child. Parents of children above the age of 4 years who suffered
16. from the same syndrome scored similar to those without any syndrome.

17.

18.

19. **DISCUSSION**

20.

21. In this large, selected group of children with only syndromic or complex craniosynostosis,
22. health-related quality of life was significantly lower than in the norm population. For all
23. syndromes, scores at 'general health perceptions' were significantly lower. Apert syndrome
24. had the largest impact on the different domains. Two earlier studies reported quality of
25. life of a small group of children with craniosynostosis. Warschausky et al.¹¹ compared 27
26. children with primary cleft lip and/ or palate and 28 children with other craniofacial diag-
27. noses. There were only five children with Apert syndrome, Crouzon syndrome or complex
28. craniosynostosis. The children with other craniofacial diagnoses perceived significantly
29. more general health concerns; but no specific physical or mental health concerns were
30. reported. Boltshauser et al.¹² evaluated behavior and quality of life in 30 children with
31. isolated sagittal craniosynostosis. Parents reported behavior to be within the normal range
32. and health-related quality of life was comparable with the norms, except for lower scores
33. on positive emotional functioning.

34. For the two age groups, 2-4 years and 4-18 years, in which we used different question-
35. naires, we found comparably low scores in similar domains. There was no significant
36. correlation between age and the results of questionnaires.

37. Subgroup analysis for the different syndromes showed that parents of 2- to 4-year-olds
38. with Apert syndrome and complex craniosynostosis reported lower health-related qua-
39. lity of life for their children. The low scores on 'physical functioning' and 'growth and

I. **Table 3:** The mean health-related quality-of-life scores with standard deviation of the SF-36 of the parents

| 2. | Parents | Norm population | p-value ¹ | Effect size ²
d | |
|-----|----------------------------------|-----------------|----------------------|-------------------------------|-------|
| 3. | | | | | |
| 4. | <u>SF-36</u>
n = 110 | n = 314 | | | |
| 5. | Physical functioning (PF) | 86.5 (24.7) | 87.0 (21.8) | 0.21 | 0.13 |
| 6. | Role functioning: Physical (RP) | 74.2 (27.9) | 81.6 (30.3) | 0.03* | 0.25 |
| 7. | Social functioning (SF) | 78.0 (24.4) | 84.2 (22.5) | 0.01** | 0.27 |
| 8. | Bodily pain (BP) | 82.8 (26.3) | 75.3 (22.9) | 0.004** | -0.30 |
| 9. | Mental health (MH) | 74.0 (17.3) | 76.2 (18.2) | 0.28 | 0.12 |
| 10. | Role functioning: Emotional (RE) | 76.6 (22.9) | 85.5 (39.9) | 0.03* | 0.27 |
| 11. | General health perceptions (GH) | 59.9 (21.8) | 73.6 (29.6) | <0.0001** | 0.53 |
| 12. | Physical component summary (PCS) | 50.3 (7.8) | 50.3 (8.2) | 0.26 | 0.03 |
| 13. | Mental component summary (MCS) | 48.0 (6.9) | 51.3 (10.3) | 0.01** | 0.35 |

13. * p-value ≤ 0.05

14. ** p-value ≤ 0.01

15. ¹ 2-sided one-sample t-test of the scale scores between parents and the norm population

16. ² pooled effect size d measured the difference in mean scores divided by the standard deviations of the parental group, 0.2 ≤ d < 0.5 indicated a small effect, 0.5 ≤ d < 0.8 a moderate effect, d ≥ 0.8 a large effect, a negative effect size meant a higher score with regard to the norm group¹⁰

17.
18.
19. development' might be explained by the higher complexity of these conditions than in the
20. other syndromes. Whereas no scores on comparable domains differed between the two age
21. groups and were all significantly lower than the norm, the score on the domain 'change in
22. health' did not significantly differ from the norm in the older age group. A likely explanation
23. is improved function of the hand after surgical correction of the complex syndactyly
24. in the younger age group.

25. Scores for the older children with Apert syndrome or Muenke syndrome differed most
26. significantly from the norms, with significantly higher scores in 11 out of the 13 domains
27. and 10 out of the 13 domains, respectively. This might be because children with Apert
28. syndrome are more prone to mental retardation and behavioral problems, such as autism.
29. Muenke syndrome was always considered a mild type of syndromic craniosynostosis,
30. given the low risk of elevated ICP or OSA; however, in the present study, children with
31. this syndrome showed many problems on physical and emotional domains, possibly related
32. to headache and behavior problems. Furthermore, we found a relatively low impact
33. on health-related quality of life for patients with Crouzon or Pfeiffer syndrome, despite
34. their distinct facial features. They showed better intelligence and motor development than
35. children with the other syndromes and seemed to have fewer behavioral problems. On
36. the other hand, they have the highest risk to develop craniosynostosis-related problems
37. such as elevated ICP, OSA and tonsillar herniation^{13,14}. These findings support the assumption
38. that behavioral disturbances and lowered mental capacities in Apert and Muenke
39. syndrome are inborn and not a consequence of elevated ICP. In the group with complex

1. craniosynostosis, significant higher scores were found on the domains 'physical impair-
2. ment' and 'high parental impact'. These children tend to have more associated problems
3. such as developmental retardation. For all syndromes, scores on the domain 'general
4. health perceptions' were significantly lower, probably due to the chronic character of the
5. syndromes and the uncertainty about future developments.

6. Scores for children with Apert syndrome were also much lower than those for children
7. with other syndromes. The children with a S252W mutation had a lower health-related
8. quality of life. These children had more severe skull and facial abnormalities than children
9. with a P253R mutation, who are characterized by more severe syndactyly. Possibly mental
10. retardation and behavior problems were important factors for the lower scores.

11. Parents who suffered from the same syndrome as their child reported better scores than
12. their children at all domains. Perhaps they recognize their own character in their child and
13. consider this to be normal. However, denial of the problems seen in their own child might
14. be an explanation as well.

15. In multivariate analysis, OSA was the only independent predictor for the domain
16. 'change in health', possibly associated with its treatment. Furthermore, elevated ICP was
17. an independent predictor for lower scores on several domains. This might be explained
18. by the fact that this condition could result in behavioral changes that influence scores.
19. Further, once it is detected, extra hospital visits are necessary, which may cause more
20. parental concerns.

21. Interestingly, parents of children aged 12-18 years reported more problems in different
22. domains than their children. Children seem to cope with the disabilities, minimizing
23. concerns about functioning and health¹⁵. Parents may have been influenced by their
24. own mental health and the concerns about the syndrome of their child. Therefore, it is
25. important to collect information from both to get an impression about the health-related
26. quality of life because they may have different views and consequences for support are
27. different^{15, 16}.

28. Parents themselves also scored their quality of life lower at different domains, mainly
29. psychosocial. Their child's condition seems to have a major impact. There was a difference
30. on physical domains between parents suffering from syndromic craniosynostosis and those
31. without, but only if their child was below 4 years. Treatment is most intense in the first
32. years due to vault expansion and requires very regular visits to the outpatient clinic. This
33. might influence the physical condition of the parents with syndrome.

34. A major strength of this study is the large study population of children with syndromic
35. or complex craniosynostosis. The health-related quality-of-life questionnaires are standard
36. measures used to assess the quality of life, but a limitation is the use of these questionnaires
37. in children with syndromic or complex craniosynostosis without validation in this specific
38. population. Another possible limitation could be that outcomes for the two age groups are
39. not completely comparable because different questionnaires were used.

1. In conclusion, syndromic craniosynostosis has an important impact on health-related
2. quality of life of these children and their families. The impact is not only most obvious
3. for children with Apert syndrome, but also clear-cut for children with Muenke, Crouzon,
4. Pfeiffer, or Saethre-Chotzen syndrome and complex craniosynostosis. The impact on daily
5. functioning does not differ much at the different ages between 2 and 18 years. Parents
6. themselves also experienced restrictions in quality of life.

7.
8.

9. **ACKNOWLEDGEMENTS**

10.

11. We thank J.M. Landgraf of HealthAct CHQ, Boston, USA for permission to use the
12. health-related quality-of-life questionnaires.

13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.

I. **APPENDIX 1**

2.

3. **ITQoL scales, items per scale and score interpretation^a**

4. The ITQoL consists of 103 items with 4, 5 or 6 response options. The items are arranged
5. into 10 multi-item scales and 2 single-item scales: 'physical functioning', growth and de-
6. velopment', 'bodily pain', 'temperaments and moods', 'general behavior', 'getting along',
7. 'general health perceptions', 'parental impact: emotional', 'parental impact: time', 'family
8. activity', 'family cohesion' and 'change in health'.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

| Scale | Number of items | Description low score | Description high score |
|---------------------------------|-----------------|--|---|
| Physical functioning (PF) | 10 | Child is limited a lot in performing physical activities such as eating, sleeping, grasping, and playing due to health problems | Child performs all types of physical activities such as eating, sleeping, grasping, and playing without limitations due to health problems |
| Growth and development (GD) | 10 | Parent is very dissatisfied with development (physical growth, motor, language, cognitive), habits (eating, feeding, sleeping) and overall temperament | Parent is very satisfied with development (physical growth, motor, language, cognitive), habits (eating, feeding, sleeping) and overall temperament |
| Bodily pain (BP) | 3 | Child has extremely severe, frequent and limiting bodily pain/discomfort | Child has no pain or limitations due to pain/discomfort |
| Temperament and moods (TM) | 18 | Child has very often certain moods and temperaments, such as sleeping/eating difficulties, crankiness, fussiness unresponsiveness and lack of playfulness and alertness | Child never has certain moods and temperaments, such as sleeping/eating difficulties, crankiness, fussiness unresponsiveness and lack of playfulness and alertness |
| General behavior (GB) | 13 | Parent believes child's behavior is poor and likely to get worse | Parent believes child's behavior is excellent and will continue to be so |
| Getting along (GA) | 15 | Child very often exhibits behavior problems, such as not following directions, hitting, biting others, throwing tantrums, and being easily distracted, while positive behaviors, such as ability to cooperate, appear sorry, and adjustment to new situations are seldom shown | Child never exhibits behavior problems, such as not following directions, hitting, biting others, throwing tantrums, and being easily distracted, while positive behaviors, such as ability to cooperate, appear sorry, and adjustment to new situations are frequently shown |
| General health perceptions (GH) | 12 | Parent believes child's health is poor and likely to get worse | Parent believes child's health is excellent and will continue to be so |
| Parental impact: Emotional (PE) | 7 | Parent experiences a great deal of emotional worry/concern as a result of child's physical and/or psychosocial health and/or growth and development | Parent does not experience feelings of emotional worry/concern as a result of child's physical and/or psychosocial health and/or growth and development |
| Parental impact: Time (PT) | 7 | Parent experiences a lot of limitations in time available for personal needs due to child's physical and/or psychosocial health and/or growth and development | Parent does not experience limitations in time available for personal needs due to child's physical and/or psychosocial health and/or growth and development |
| Family activity (FA) | 6 | The child's health and/or growth and development very often limits and interrupts family activity or is a source of family tension | The child's health and/or growth and development never limits and interrupts family activities or is a source of family tension |
| Family cohesion (FC) | 1 | Family's ability to get along is rated 'poor' | Family's ability to get along is rated 'excellent' |
| Change in health (CH) | 1 | Child's health is much worse now than 1 year ago | Child's health is much better now than 1 year ago |

^a reproduced with permission from the principal author J.M. Landgraf, 1994

I. **APPENDIX 2**

2.

3. **CHQ-PF50 scales, items per scale and score interpretation^a**

4. The CHQ-PF50 consists of 50 items with 4, 5 or 6 response options. The items are arranged
5. into 11 multi-item scales and 2 single-item scales: 'physical functioning', 'role functioning:
6. emotional/ behavior', 'role functioning: physical', 'bodily pain', 'general behavior', 'mental
7. health', 'self-esteem', 'general health perceptions', 'parental impact: emotional', 'parental
8. impact: time', 'family activity', 'family cohesion' and 'change in health'⁶.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

| Scale | Number of items | Description low score | Description high score |
|--|-----------------|---|--|
| Physical functioning (PF) | 6 | Child is limited a lot in performing all physical activities, including self-care due to health | Child performs all types of physical activities, including the most vigorous, without limitations due to health |
| Role functioning: Emotional/behavior (REB) | 3 | Child is limited a lot in schoolwork or activities with friends as a result of emotional or behavior problems | Child has no limitations in schoolwork or activities with friends as a result of emotional or behavior problems |
| Role functioning: Physical (RF) | 2 | Child is limited a lot in schoolwork or activities with friends as a result of physical health | Child has no limitations in schoolwork or activities with friends as a result of physical health |
| Bodily pain (BP) | 2 | Child has extremely severe, frequent and limiting bodily pain | Child has no pain or limitations due to pain |
| General behavior (GB) | 6 | Child very often exhibits aggressive, immature, delinquent behavior | Child never exhibits aggressive, immature, delinquent behavior |
| Mental health (MH) | 5 | Child has feelings of anxiety and depression all of the time | Child feels peaceful, happy and calm all of the time |
| Self-esteem (SE) | 6 | Child is very dissatisfied with abilities, looks, family/peer relationships and life overall | Child is very satisfied with abilities, looks, family/peer relationships and life overall |
| General health perceptions (GH) | 6 | Parent believes child's health is poor and likely to get worse | Parent believes child's health is excellent and will continue to be so |
| Parental impact: Emotional (PE) | 3 | Parent experiences a great deal of emotional worry/concern as a result of child's physical and/or psychosocial health | Parent does not experience feelings of emotional worry/concern as a result of child's physical and/or psychosocial health |
| Parental impact: Time (PT) | 3 | Parent experiences a lot of limitations in time available for personal needs due to child's physical and/or psychosocial health | Parent does not experience limitations in time available for personal needs due to child's physical and/or psychosocial health |
| Family activity (FA) | 6 | The child's health very often limits and interrupts family activities or is a source of family tension | The child's health never limits and interrupts family activities nor is a source of family tension |
| Family cohesion (FC) | 1 | Family's ability to get along is rated 'poor' | Family's ability to get along is rated 'excellent' |
| Change in health (CH) | 1 | Child's health is much worse now than 1 year ago | Child's health is much better now than 1 year ago |

* reproduced with permission from the principal author J.M. Landgraf, 1994

The CHQ-CF87 consists of 87 items with 4, 5 or 6 response options. The items are arranged into 10 multi-item scales and 2 single-item scales: 'physical functioning', 'role functioning: emotional', 'role functioning: behavior', 'role functioning: physical', 'bodily pain', 'general behavior', 'mental health', 'self esteem', 'general health perceptions', 'family activity', 'family cohesion' and 'change in health'⁷.

I. **APPENDIX 3**

2.

3. **SF-36: scales, items per scale and score interpretation**

4. The SF-36 consists of 36 items with 3, 4, 5 or 6 response options. The items are arranged
 5. into 7 multi-item scales: ‘physical functioning’, ‘role limitations due to physical function-
 6. ing’, ‘social functioning’, ‘bodily pain’, ‘mental health’, ‘role limitations emotional’ and
 7. ‘general health perceptions’^{38, 17}.

8.

| 9. | Scale | Number of items | Description low score | Description high score |
|-----|----------------------------------|-----------------|---|--|
| 10. | Physical functioning (PF) | 10 | Very limited in performing all physical activities, including bathing or dressing due to health | Performs all types of physical activities, including the most vigorous, without limitations due to health |
| 11. | Role functioning: Physical (RF) | 4 | Problems with work or other daily activities as a result of physical health | No problems with work or other daily activities as a result of physical health |
| 12. | Social functioning (SF) | 2 | Extreme and frequent interference with normal social activities due to physical or emotional problems | Performs normal social activities without interference with normal social activities due to physical or emotional problems |
| 13. | Bodily pain (BP) | 2 | Very severe and extremely limiting bodily pain | No pain or limitations due to pain |
| 14. | Mental health (MH) | 5 | Feelings of nervousness and depression all of the time | Feels peaceful, happy, and calm all of the time |
| 15. | Role functioning: Emotional (RE) | 3 | Problems with work or other daily activities as a result of emotional problems | No problems with work or other daily activities as a result of emotional problems |
| 16. | General health perceptions (GH) | 5 | Evaluates personal health as poor and believes it is likely to get worse | Evaluates personal health as excellent |

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

I. REFERENCES

1. Lajeunie E, Heuertz S, El Ghouzzi V, et al. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet* 2006;14:289-298.
2. Kress W, Schropp C, Lieb G, et al. Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. *Eur J Hum Genet* 2006;14:39-48.
3. Twigg SR, Matsumoto K, Kidd AM, et al. The origin of EFNB1 mutations in craniofrontonasal syndrome: frequent somatic mosaicism and explanation of the paucity of carrier males. *American journal of human genetics* 2006;78:999-1010.
4. de Jong T, Bannink N, Bredero-Boelhouwer HH, et al. Long-term functional outcome in 167 patients with syndromic craniosynostosis; defining a syndrome-specific risk profile. *J Plast Reconstr Aesthet Surg* 2009
5. Raat H, Landgraf JM, Oostenbrink R, et al. Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQOL) in a general population and respiratory disease sample. *Qual Life Res* 2007;16:445-460.
6. Landgraf JM, Maunsell E, Speechley KN, et al. Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results. *Qual Life Res* 1998;7:433-445.
7. Raat H, Landgraf JM, Bonsel GJ, et al. Reliability and validity of the child health questionnaire-child form (CHQ-CF87) in a Dutch adolescent population. *Qual Life Res* 2002;11:575-581.
8. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *Journal of clinical epidemiology* 1998;51:1055-1068.
9. Anagnostopoulos F, Niakas D, Tountas Y. Comparison between exploratory factor-analytic and SEM-based approaches to constructing SF-36 summary scores. *Qual Life Res* 2009;18:53-63.
10. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. *Medical care* 2003;41:582-592.
11. Warschausky S, Kay JB, Buchman S, et al. Health-related quality of life in children with craniofacial anomalies. *Plastic and reconstructive surgery* 2002;110:409-414; discussion 415-406.
12. Boltshauser E, Ludwig S, Dietrich F, et al. Sagittal craniosynostosis: cognitive development, behavior, and quality of life in unoperated children. *Neuropediatrics* 2003;34:293-300.
13. Cinalli G, Spennato P, Sainte-Rose C, et al. Chiari malformation in craniosynostosis. *Childs Nerv Syst* 2005;21:889-901.
14. Gonzalez S, Hayward R, Jones B, et al. Upper airway obstruction and raised intracranial pressure in children with craniosynostosis. *Eur Respir J* 1997;10:367-375.
15. Stancin T, Drotar D, Taylor HG, et al. Health-related quality of life of children and adolescents after traumatic brain injury. *Pediatrics* 2002;109:E34.
16. Eiser C, Morse R. A review of measures of quality of life for children with chronic illness. *Archives of disease in childhood* 2001;84:205-211.
17. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical care* 1992;30:473-483.



Chapter 8

Reliability and validity of the obstructive sleep apnea (OSA)-18 survey in healthy children and children with syndromic or complex craniosynostosis

Bannink N

Maliepaard M

Raat H

Joosten KFM

Mathijssen IMJ

Submitted

1. **ABSTRACT**

2.

3. **Objective**

4. Obstructive sleep apnea (OSA) affects the child's quality of life. Rosenfeld developed a
5. quality of life questionnaire, the OSA-18, on obstructive sleep apnea for children with
6. OSA not caused by specific craniofacial syndromes. With regard to the use of the OSA-18
7. in children with syndromic and complex craniosynostosis, we assessed the internal consis-
8. tency, test-retest reliability and discriminative validity of the OSA-18 in these children; we
9. also applied the OSA-18 in healthy children to obtain reference values.

10.

11. **Methods**

12. The OSA-18 was translated into Dutch using the procedure of multiple forward and
13. backward-translations. Test-retest reliability and internal consistency were examined. In
14. a prospective study, the craniosynostosis patients underwent an ambulatory polysomno-
15. graphy to diagnose OSA. The ability of the OSA-18 to discriminate between subgroups
16. of patients with or without OSA was evaluated. We compared OSA-18 scores of children
17. with syndromic or complex craniosynostosis with scores in healthy children.

18.

19. **Results**

20. The Cronbach's alpha was ≥ 0.70 for the total OSA-18 score and for most of the domains
21. in both the craniosynostosis and general population. In the craniosynostosis group the
22. test-retest intraclass correlation coefficients were ≥ 0.70 , except for the domain 'physi-
23. cal suffering' with 0.69. The discriminative validity of the domains 'sleep disturbance',
24. 'physical suffering', 'caregiver concerns' and total OSA-18 score was significant between
25. the general and craniosynostosis population.

26.

27. **Conclusion**

28. This study supports the reliability and validity of the OSA-18 in children with syndromic
29. or complex craniosynostosis.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Obstructive sleep apnea (OSA) is a clinical syndrome characterized by difficulty in breathing, snoring and apneas during sleep due to a partial or complete obstruction of the upper airway. The gold standard for diagnosing OSA is polysomnography¹. Leaving OSA untreated may result in major physical and functional impairment due to the disturbed sleep patterns, for instance failure to thrive, recurrent infections, feeding difficulties, disturbed cognitive functions (attention deficit, impaired concentration and memory), delay of development, cor pulmonale and sudden death².

10. Obstructive sleep apnea affects the child's quality of life, because of fatigue during the day, disturbed cognitive functions and the implications of treatment. Sleep problems, physical symptoms related to adenotonsillar hypertrophy, behavioral aspects and fatigue or impaired concentration are domains of quality of life that are of particular relevance. R.M. Rosenfeld has developed a disease-specific quality of life questionnaire for healthy children with OSA due to adenotonsillar hypertrophy, the OSA-18³. It consists of 18 age-independent items grouped into five domains: 'sleep disturbance', 'physical suffering', 'emotional distress', 'daytime problems' and 'caregiver concerns'. The OSA-18 has been shown to be reliable and valid to measure the impact of OSA in American children with a history of snoring and disrupted sleep for three months or longer, who were referred for polysomnography and who had enlarged tonsils or adenoids.

21. In previous studies of OSA and quality of life only children without specific syndromes were studied; children with OSA based on underlying syndromes, such as craniofacial abnormalities, were excluded. This study aims at evaluating the OSA-18 in children with syndromic and complex craniosynostosis. These patients have a 40% risk for OSA^{4,5,6} mainly during the first six years of life due to midface hypoplasia and collapse of the pharynx, but other factors such as adenotonsillar hypertrophy and mandibular hypoplasia may be involved as well^{7,6}.

28. In this study we assessed the internal consistency and the test-retest reliability and the discriminative validity of the OSA-18 in children with syndromic or complex craniosynostosis. We compared OSA-18 scores of these children with scores in healthy children.

31.

32.

33. METHODS

34.

35. Before the start of this study, authorisation was granted by the medical ethics committee (MEC-2005-273) of the Erasmus Medical Center.

37.

38.

39.

I. **Craniosynostosis population**

2. A prospective study was carried out in the Erasmus MC-Sophia Children's Hospital, a
3. tertiary care university hospital in Rotterdam. Patients with syndromic (genetically con-
4. firmed) or complex craniosynostosis registered at the Dutch Craniofacial Center were
5. invited to participate in the study between January 2007 and March 2009. Syndromic
6. craniosynostosis included Apert, Crouzon, Pfeiffer, Muenke or Saethre-Chotzen syn-
7. drome and is characterized by the premature fusion of calvarial sutures with additional
8. congenital malformations⁸. Fusion of two cranial sutures or more without a known FGFR
9. (fibroblast growth factor receptor) 1, 2, 3 or TWIST gene mutation^{8,9} was defined as
10. complex craniosynostosis.

11.

12. **General population**

13. A convenience sample of parents of healthy children was approached at day-care centers,
14. primary and secondary schools and sport clubs in Rotterdam, Rijswijk and Leiden in the
15. Netherlands.

16.

17. **OSA-18 survey**

18. First, we translated the OSA-18 to the Dutch language with permission of R.M. Rosenfeld
19. using a procedure with multiple forward and back-translations¹⁰. Three independent per-
20. sons have translated the survey from English to Dutch and thereafter we asked two native
21. speakers for back-translation to English as check.

22. All parents were asked to complete the survey, the parent form. They decided whether
23. the father or the mother should do that. After several months the same survey was sent to
24. a random sample of parents to be completed by the same person to assess the test-retest
25. reliability.

26. The total OSA-18 score, subdivided in 5 domains, is the sum of scores for all 18 items
27. with a score ranging from 18 to 126. The domains 'sleep disturbance', 'physical suffering',
28. and 'caregiver concerns' consisted each of four items and the domains 'emotional distress'
29. and 'daytime problems' of three. Each item can be answered with 1 (never) to 7 (always).
30. Additionally it provided a 10-point visual analogous scale with specific semantic anchors
31. (appendix 1).

32. Additionally children between 12 and 18 years completed a child form of the question-
33. naire themselves. Six items of the OSA-18 were excluded in the self-report child form,
34. the OSA-12. In the domain 'sleep disturbance' children cannot report pauses in their
35. breathing and gasping sounds during sleep by themselves and therefore the domain 'sleep
36. disturbance' consisted two items. The domain 'caregiver concerns', which consists 4 items,
37. cannot be used as well in the child form. The total OSA-12 score ranged from 12 to 84.

38. An additional questionnaire was given regarding items on socio-demographic variables
39. as age, sex, school performance and the presence of sickness, allergy, behavior problems,

1. adenotonsillectomy, use of medication and the presence of cough and use of nose drops,
2. nasal or inhalation corticosteroids in the preceding four weeks. These items were needed
3. to exclude OSA in the general population.

4.

5. **Polysomnography**

6. The craniosynostosis population underwent a polysomnography to diagnose obstructive
7. sleep apnea. Polysomnography was done ambulatory with Embletta Portable Diagnostic
8. System and analyzed with Somnologica for Embletta software 3.3 ENU (Medcare Flaga,
9. Reykjavik, Iceland). Thoracic and abdominal movements, nasal flow, saturation, and pulse
10. were monitored. The minimal total sleep time was 360 minutes. Obstructive apnea was
11. defined as absence of airflow (measured by a nasal cannula) or out-of-phase movement of
12. thorax and abdomen (scored as X flow) and hypopnea as $\geq 50\%$ reduction in nasal flow
13. signal amplitude or X flow signal amplitude, both for more than two breaths^{11, 12}. The X
14. flow signal was the sum of the amplitudes of the thoracic and abdominal movements^{11, 12}
15. and was used when nasal airflow was insufficient. Mixed apnea was defined as a type of
16. obstructive apnea with a central component that mostly preceded the obstructive pattern,
17. for more than two breaths. Central apneas were not included in this study. Desaturation
18. was defined as $\geq 4\%$ decrease with respect to the baseline value.

19. The severity of OSA was expressed in an obstructive apnea hypopnea index (OAHI), the
20. hourly number of obstructive and mixed apneas in combination with the hourly number
21. of hypopneas followed by desaturation. A score < 1 is considered to be normal, between 1-5
22. is defined as mild OSA, between 6 and 25 as moderate OSA, and > 25 as severe OSA^{13, 14}.

23.

24. **Analysis**

25.

26. *Reliability*

27. Reliability refers to the stability or reproducibility of survey results. Internal consistency
28. was examined per domain and for the total OSA-I8 score in the craniosynostosis and
29. general population. The Cronbach's alpha was used to calculate this internal consistency
30. and a value ≥ 0.70 was considered as adequate both in children with syndromic or complex
31. craniosynostosis, as in healthy children.

32. The test-retest reliability in the sample of the craniosynostosis population was evaluated
33. by applying the paired t-test of the means at the group level and by intraclass correlation
34. coefficients (ICC) at the individual level. ICCs ≥ 0.70 were considered as adequate.

35.

36. *Validity*

37. Validity is the degree to which the survey measures what it purports to measure³. We tested
38. the discriminative validity by comparing domains and the total OSA-I8 scores in the
39. general and in the craniosynostosis population. We hypothesized that the craniosynostosis

1. population reported higher mean scores, i.e. a lower quality on life due to OSA than the
2. general population. In addition, in the population children with syndromic or complex
3. craniosynostosis we evaluated the ability of the OSA-18 to discriminate between patients
4. with and without OSA; we hypothesized that OSA patients have higher mean scores than
5. the non OSA patients.

6.

7. All analyses were performed with SPSS 16.0 for Windows (SPSS, Chicago, IL). The num-
8. bers were given in median and range. All domains were expressed as mean and standard
9. deviation. The independent t-test was used to compare the craniosynostosis with the
10. general population. The groups were large enough to use this test. Because of the small
11. numbers of patients in the OSA subgroups Z-scores were calculated and compared in an
12. ANOVA procedure.

13. Significant differences were defined as a p-value ≤ 0.05 . Pooled effect size of the diffe-
14. rence between craniosynostosis and general population was calculated for each domain.
15. Pooled effect size is measured by the difference between norm scores and patient scores
16. divided by the pooled standard deviation¹⁵.

17.

18.

19. **RESULTS**

20.

21. **Craniosynostosis population**

22. In total 163 patients with syndromic or complex craniosynostosis and their parents were
23. approached, of whom 141 (87%) children and their parents gave informed consent for
24. this research project. Of them 119 (73%) returned the questionnaires and underwent a
25. polysomnography. Of these 119 parents 34 had children between 12 and 18 years of age and
26. 29 of them completed the child form themselves and underwent a polysomnography. The
27. others were unable to do so, due to low mental capacity.

28. The characteristics of the craniosynostosis population are shown in table 1. The median
29. age of the parents, who completed the questionnaires, was 39 (23-61) years and 88% of
30. them were born in the Netherlands. A sample consisting of 64 out of the 72 (89%) parents,
31. who received the OSA-18 twice, completed the survey as retest after a mean time of 6.3
32. (sd 3.1) months (range 1-16 months). The median age of the children, who completed the
33. child form, was 14 (12-18) years.

34.

35. **General population**

36. After distribution of 1500 questionnaires, parents of 459 healthy children returned the
37. questionnaire, the parent form. The median age of the respondent, who completed the
38. questionnaire, was 41 (17-55) years and 91% were born in the Netherlands. Of these 459
39. returned questionnaires children themselves completed also the child form in 162 cases

1. **Table 1:** Characteristics of the craniosynostosis and general population

| 2. | | Craniosynostosis | General | p-value |
|-----|-------------------------------|-------------------|------------|---------|
| 3. | | population | population | |
| | | n = 119 | n = 459 | |
| 4. | Completed by | | | |
| 5. | Mother | 104 (87%) | 402 (87%) | ns |
| 6. | Father | 15 (13%) | 50 (11%) | |
| | Other | | 7 (2%) | |
| 7. | Age respondent | 23-61 | 17-55 | ns |
| 8. | range | | | |
| | median | 39 | 41 | |
| | Education respondent | | | |
| 9. | Low | 7 (6%) | 7 (1.5%) | 0.00** |
| 10. | Middle | 78 (65.5%) | 251 (55%) | |
| | High | 31 (26%) | 198 (43%) | |
| 11. | Unknown | 3 (2.5%) | 3 (0.5%) | |
| 12. | Age child | 2-18 | 2-18 | 0.04* |
| 13. | range | | | |
| | median | 8 | 9 | |
| 14. | Sex child | 56 (47%) | 239 (52%) | ns |
| | boy | | | |
| | girl | 63 (53%) | 220 (48%) | |
| 15. | Syndrome/ sex (boy/ girl) | | | |
| 16. | Apert | 19 (16%) (9/ 10) | | |
| | Crouzon/ Pfeiffer | 31 (26%) (14/ 17) | | |
| 17. | Muenke | 18 (15%) (8/ 10) | | |
| 18. | Saethre-Chotzen | 21 (18%) (8/ 13) | | |
| | Complex craniosynostosis | 30 (25%) (17/ 13) | | |
| 19. | Obstructive sleep apnea child | | | |
| 20. | Non | 75 (63%) | | |
| | Mild | 37 (31%) | | |
| 21. | Moderate | 7 (6%) | | |

22. ns not significantly different

23. * p-value \leq 0.05

24. ** p-value \leq 0.01

25.

26.

27. (median age 14 (12-18) years). The craniosynostosis and general population were compa-
 28. rable, shown in table 1. However, the educational level of the parents was lower in the
 29. craniosynostosis population with regard to the general population ($p = 0.00$).

30.

31. Obstructive sleep apnea

32. Based on the calculated obstructive apnea hypopnea index (OAHI) 44 patients (37%) were
 33. diagnosed as having obstructive sleep apnea; 37 mild with a mean OAHI of 2.3 (sd 1.1) and
 34. 7 moderate with a mean OAHI of 9.0 (sd 5.1) with a maximum index of 20. Severe OSA
 35. was not diagnosed in this craniosynostosis population at the moment of the study.

36.

37. Internal consistency

38. With regard to parent-completed questionnaires, in the study and general population the
 39. Cronbach's alpha for almost all domains and for the total OSA-18 score was ≥ 0.70 . The

1. exceptions were the domains 'daytime problems' in the non OSA craniosynostosis group
 2. (0.63) and 'sleep disturbance' in the general (0.56) and craniosynostosis (0.62) population,
 3. as shown in table 2.

4. With regard to child-completed questionnaires, the Crohnbach's alpha for three domains
 5. and for the total OSA-12 score was ≥ 0.70 , except for the domain 'sleep disturbance'. In
 6. the OSA subgroup (n = 7) the Crohnbach's alpha was < 0.70 for 'physical suffering',
 7. 'emotional distress' and the total OSA-12 score.

8.

9. Test-retest reliability in the craniosynostosis population

10. With regard to parent-completed questionnaires in the craniosynostosis population the
 11. test-retest reliability was shown in table 3. The domains showed no statistically different
 12. mean scores between the test and retest. The intraclass correlations were ≥ 0.70 , except the
 13. domain 'physical suffering' with 0.69. OSA treatment in the interim was only performed
 14. in two patients.

15.

16. **Table 2:** Internal consistency in the craniosynostosis versus general population of the parent and child form

| 17. Parent form | Items | General population | Craniosynostosis population Crohnbach's α | | |
|-----------------|--------------------|----------------------|--|----------|--------|
| 18. | n | Crohnbach's α | Total group/ | Non OSA/ | OSA |
| 19. | | n = 459 | n = 119 | n = 75 | n = 44 |
| 20. | Sleep disturbance | 0.56 | 0.62 | 0.73 | 0.83 |
| 21. | Physical suffering | 0.83 | 0.83 | 0.76 | 0.89 |
| 22. | Emotional distress | 0.81 | 0.86 | 0.79 | 0.92 |
| 23. | Daytime | 0.70 | 0.70 | 0.63 | 0.79 |
| 24. | problems | | | | |
| 24. | Caregiver | 0.77 | 0.91 | 0.88 | 0.94 |
| 25. | concerns | | | | |
| 25. | Total OSA-18 | 0.85 | 0.89 | 0.84 | 0.95 |
| 26. | score | | | | |
| 27. Child form | Items | General population | Craniosynostosis population Crohnbach's α | | |
| 28. | n | Crohnbach's α | Total group/ | Non OSA/ | OSA |
| 29. | | n = 162 | n = 29 | n = 22 | n = 7 |
| 30. | Sleep disturbance | 0.25 | 0.58 | 0.67 | 0.29 |
| 31. | Physical suffering | 0.78 | 0.79 | 0.83 | 0.65 |
| 32. | Emotional distress | 0.74 | 0.76 | 0.78 | 0.65 |
| 33. | Daytime | 0.71 | 0.85 | 0.79 | 0.97 |
| 34. | problems | | | | |
| 34. | Total OSA-12 | 0.81 | 0.84 | 0.87 | 0.60 |
| 34. | score | | | | |

35. OSA obstructive sleep apnea

36.

37.

38.

39.

Table 3: Test-retest reliability of the parent form in a sample of the craniosynostosis population

| Parent form | Test
mean (sd)
n = 64 | Retest
mean (sd)
n = 64 | p-value ¹ | ICC |
|--------------------|-----------------------------|-------------------------------|----------------------|------|
| Sleep disturbance | 9.90 (5.81) | 9.08 (4.96) | 0.49 | 0.93 |
| Physical suffering | 11.88 (5.77) | 12.12 (5.66) | 0.86 | 0.69 |
| Emotional distress | 6.67 (3.64) | 7.49 (4.02) | 0.97 | 0.82 |
| Daytime problems | 7.02 (3.61) | 7.73 (3.58) | 0.73 | 0.77 |
| Caregiver concerns | 7.98 (5.41) | 7.92 (4.88) | 0.94 | 0.71 |
| Total OSA-18 score | 42.71 (19.15) | 43.51 (16.96) | 0.56 | 0.82 |

sd standard deviation

ICC intraclass correlation coefficient

¹ 2-sided paired t-test of the mean between the test and retest, time between test and retest: mean 6.3 (3.1) months, range 1-16 months

Table 4: Discriminative validity in the craniosynostosis versus general population of the parent and child form

| Parent form | General
population
mean (sd)
n = 459 | Craniosynostosis
population
mean (sd)
n = 119 | Cranio vs General
p-value ¹ | Cranio vs General
(pooled) effect size ²
(d) |
|--------------------|---|--|---|---|
| Sleep disturbance | 5.8 (2.4) | 8.9 (4.8) | 0.000** | 0.81 |
| Physical suffering | 8.1 (4.3) | 11.1 (5.8) | 0.000** | 0.60 |
| Emotional distress | 6.2 (3.1) | 6.5 (3.4) | 0.35 | 0.10 |
| Daytime problems | 6.2 (3.1) | 6.8 (3.5) | 0.12 | 0.17 |
| Caregiver concerns | 5.2 (2.4) | 7.0 (4.2) | 0.000** | 0.52 |
| Total OSA-18 score | 31.2 (10.4) | 39.9 (16.7) | 0.000** | 0.63 |
| Child form | General
population
mean (sd)
n = 162 | Craniosynostosis
population
mean (sd)
n = 29 | Cranio vs General
p-value ¹ | Cranio vs General
(pooled) effect size ²
(d) |
| Sleep disturbance | 3.7 (1.8) | 5.6 (3.3) | 0.006** | 0.71 |
| Physical suffering | 9.0 (4.4) | 9.9 (5.3) | 0.37 | 0.19 |
| Emotional distress | 5.9 (3.4) | 5.4 (2.9) | 0.43 | 0.15 |
| Daytime problems | 7.7 (4.0) | 7.7 (4.3) | 0.99 | 0.00 |
| Total OSA-12 score | 26.4 (9.9) | 28.4 (11.6) | 0.39 | 0.19 |

sd standard deviation

** p-value ≤ 0.01

¹ 2-sided paired t-test of the means between the study population and the norm

² pooled effect size d measured the difference in mean scores divided by the standard deviations of the study group, $0.2 \leq d < 0.5$ indicated a small effect, $0.5 \leq d < 0.8$ a moderate effect, $d \geq 0.8$ a large effect, a negative effect size meant a higher score with regard to the norm group¹⁵

I. **Table 5:** Discriminative validity of obstructive sleep apnea in the craniosynostosis population of the parent and child form

| Parent form | Non OSA
mean (sd) | Mild OSA
mean (sd) | Moderate OSA
mean (sd) | Mild vs
Non OSA
p-value ¹ | Moderate vs
Non OSA
p-value ¹ | Mild vs Non
OSA
(pooled)
effect size ² | Moderate vs
Non OSA
(pooled)
effect size ² |
|--------------------|----------------------|-----------------------|---------------------------|--|--|--|--|
| | n = 75 | n = 37 | n = 7 | | | | |
| Sleep disturbance | 8.1 (4.2) | 9.1 (5.0) | 15.0 (6.3) | 0.34 | 0.03* | 0.21 | 1.29 |
| Physical suffering | 10.6 (5.1) | 10.9 (6.2) | 17.7 (6.2) | 0.80 | 0.02* | 0.05 | 1.26 |
| Emotional distress | 6.3 (3.1) | 6.7 (3.8) | 8.5 (4.4) | 0.72 | 0.28 | 0.07 | 0.57 |
| Daytime problems | 6.6 (3.3) | 6.7 (3.6) | 8.7 (4.9) | 0.89 | 0.31 | 0.03 | 0.50 |
| Caregiver concerns | 6.6 (3.8) | 7.5 (4.9) | 8.2 (4.0) | 0.35 | 0.40 | 0.20 | 0.39 |
| Total OSA-18 score | 38.0 (13.0) | 41.0 (20.8) | 55.0 (20.4) | 0.45 | 0.10 | 0.17 | 0.99 |
| Child form | Non OSA
mean (sd) | Mild OSA
mean (sd) | Moderate OSA
mean (sd) | Mild vs
Non OSA
p-value ¹ | Moderate vs
Non OSA
p-value ¹ | Mild vs Non
OSA
(pooled)
effect size ² | Moderate vs
Non OSA
(pooled)
effect size ² |
| | n = 22 | n = 5 | n = 2 | | | | |
| Sleep disturbance | 5.2 (3.2) | 4.8 (2.5) | 11.0 (1.4) | 0.73 | 0.04* | 0.18 | 2.30 |
| Physical suffering | 10.0 (5.3) | 10.2 (4.9) | 9.5 (7.8) | 0.90 | 0.96 | 0.07 | 0.05 |
| Emotional distress | 5.6 (3.1) | 5.2 (1.6) | 6.0 (4.2) | 0.84 | 0.88 | 0.08 | 0.16 |
| Daytime problems | 7.7 (4.1) | 7.2 (4.8) | 11.5 (7.8) | 0.90 | 0.60 | 0.07 | 0.65 |
| Total OSA-12 score | 28.4 (12.1) | 25.8 (7.1) | 38.0 (9.9) | 0.62 | 0.37 | 0.23 | 0.89 |

OSA obstructive sleep apnea

sd standard deviation

* p-value ≤ 0.05

¹ 2-sided paired t-test of the means between the degrees of severity of OSA

² pooled effect size d measured the difference in mean scores divided by the standard deviations of the study group, $0.2 \leq d < 0.5$ indicated a small effect, $0.5 \leq d < 0.8$ a moderate effect, $d \geq 0.8$ a large effect, a negative effect size meant a higher score with regard to the norm group¹⁵

Discriminative validity

With regard to parent-completed questionnaires the mean scores between the general and the craniosynostosis population were significantly different in the domains 'sleep disturbance', 'physical suffering', 'caregiver concerns' and total OSA-i18 score with higher scores, i.e. lower quality of life, in the craniosynostosis population (table 4). The ability of the OSA-i18 to discriminate between the degrees of severity of OSA was significant in the first two domains (table 5). Patients with moderate OSA (OAH1 ≥ 5) discriminated

1. significantly from the children without OSA on the two domains 'sleep disturbance' and
2. 'physical suffering'. The total OSA-18 score had a positive trend ($p = 0.10$) (table 5).
3. With regard to child-completed questionnaires, the mean scores in the general and the
4. study population were significantly different in the domain 'sleep disturbance' (table 4).
5. Children with moderate OSA ($\text{OAHI} \geq 5$) discriminated significantly from the children
6. without OSA on the domain 'sleep disturbance' (table 5).

7.
8.

9. **DISCUSSION**

10.

11. Until now, the OSA-18 was used for healthy children with OSA due to adenotonsillar hypertrophy without specific syndromes. In this study norm scores of the general
12. population were provided for clinical studies. We showed that the OSA-18 completed
13. by parents is also reliable to measure the quality of life of children with syndromic or
14. complex craniosynostosis and to measure the impact of obstructive sleep apnea on the
15. health-related quality of life in the craniosynostosis population; the results supported the
16. internal consistency and test-retest reliability. The results on the test and retest were very
17. consistent; the dynamic character of obstructive sleep apnea did not influence the scores.

18. The OSA-18 domains 'sleep disturbance', 'physical suffering', 'caregiver concerns' and
19. the total score discriminated significantly between children with syndromic or complex
20. craniosynostosis and the general population independent of the presence of OSA whereas
21. the domains 'emotional distress' and 'daytime problems' did not. Children with syndromic
22. or complex craniosynostosis had more sleep related problems and physical symptoms due
23. to the severe anatomical malformations of the nasal cavity resulting in nasal obstruction
24. and to a higher prevalence of OSA in comparison with the general population. Caregiver
25. concerns were probably related to having a child with a syndrome with the additional
26. problems. For the child form the domain 'sleep disturbance' discriminated between the
27. craniosynostosis and the general population. This difference is mainly based on the fre-
28. quency of a good bit, most or all of the time (answers 5, 6 or 7 on item 1 of the OSA-18)
29. loud snoring during the past 4 weeks: 26% in the craniosynostosis population ($n = 29$)
30. versus 1% in the general population ($n = 162$).

31. In general, parents of children with syndromic craniosynostosis reported a lower quality of
32. life compared to parents of children in the general population. But, with the use of the OSA-
33. 18 survey it was possible to discriminate between the presence of moderate OSA and mild
34. or no OSA on two domains, 'sleep disturbance' and 'physical suffering'. This means that if
35. the child is suffering from moderate OSA the impact on quality of life is the largest (table 5).

36. In the child-completed questionnaires children scored higher than the general popula-
37. tion on 'sleep disturbance', but not on other domains. A reason for these comparable
38. scores on the other domains might be that children with syndromic or complex cranio-
39.

1. synostosis tend to minimize their concerns about functioning and health¹⁶⁻¹⁸, they reported
2. their quality of life as better than their parents did. It might also be possible that children
3. aged between 12 and 18 in the general population scored higher on different items, due to
4. their puberty, more than the children in the craniosynostosis population. In that case the
5. general scores were higher than expected resulting in a smaller difference in mean scores
6. between the general and craniosynostosis population. Another point is the completion of
7. the questionnaires; maybe children in the general population really completed the survey
8. by themselves and children in the craniosynostosis population talked to their parents
9. about some questions, for example about loud snoring, resulting in the different scores on
10. the domain 'sleep disturbance'.

11. To unravel differences in the scores between parents and children a comparison was
12. made using the paired-samples t-test between the scores of the parents about their child
13. and the scores of children themselves in the general and the craniosynostosis population
14. in the selections in whom the parent and the child form were available. In the craniosy-
15. nostosis population (n = 29) the answers on all 12 items were comparable (not significantly
16. different) between parent and child. In the general population (n = 162) the answers on 6
17. items (restless sleep, mouth breathing, frequent colds, nasal discharge, aggressive behavior
18. and difficulty getting out of bed) were statistically significant different between parent and
19. child, the other 6 were comparable. So, in the general population children and parents
20. had different views about above-mentioned items in contrast with the craniosynostosis
21. population. This difference may be due to more communication between parents and
22. craniosynostosis patients regarding their sleep and health.

23. Overall, the OSA-18 completed by parents is more reliable and valid than the OSA-12
24. child form. We will recommend using the OSA-18 survey anyhow for all children.

25. A limitation is the small number of moderate OSA patients, and for this reason we
26. used the Z-scores for the independent t-test. The educational level of the respondents
27. was significantly lower in the craniosynostosis population than in the general population,
28. which can influence the OSA-18 results. However this study showed that the OSA-18
29. survey is reliable, also in this population.

30.
31. In conclusion, the OSA-18 can be used in future studies to evaluate the disease-specific
32. impact of obstructive sleep apnea, also in children with syndromic or complex craniosy-
33. nostosis.

34.

35.

36. **ACKNOWLEDGEMENTS**

37.

38. We thank R.M. Rosenfeld for permission to translate the OSA-18 into the Dutch language
39. and to use this questionnaire in The Netherlands.

I. REFERENCES

2. 1. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Arch Pediatr Adolesc Med.* 2005;159:775-785.
- 3.
4. 2. Nixon GM, Brouillette RT. Sleep. 8: paediatric obstructive sleep apnoea. *Thorax.* 2005;60:511-516.
5. 3. Franco RA, Jr., Rosenfeld RM, Rao M. First place--resident clinical science award 1999. Quality of life for children with obstructive sleep apnea. *Otolaryngol Head Neck Surg.* 2000;123:9-16.
6. 4. Pijpers M, Poels PJ, Vaandrager JM, et al. Undiagnosed obstructive sleep apnea syndrome in children with syndromal craniofacial synostosis. *J Craniofac Surg.* 2004;15:670-674.
7. 5. Hoeve LJ, Pijpers M, Joosten KF. OSAS in craniofacial syndromes: an unsolved problem. *Int J Pediatr Otorhinolaryngol.* 2003;67 Suppl 1:S111-113.
8. 6. Lo LJ, Chen YR. Airway obstruction in severe syndromic craniosynostosis. *Ann Plast Surg.* 1999;43:258-264.
9. 7. Hoeve HL, Joosten KF, van den Berg S. Management of obstructive sleep apnea syndrome in children with craniofacial malformation. *Int J Pediatr Otorhinolaryngol.* 1999;49 Suppl 1:S59-61.
10. 8. Lajeunie E, Heuertz S, El Ghouzzi V, et al. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet.* 2006;14:289-298.
11. 9. Kress W, Schropp C, Lieb G, et al. Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. *Eur J Hum Genet.* 2006;14:39-48.
12. 10. Silva VC, Leite AJ. Quality of life in children with sleep-disordered breathing: evaluation by OSA-18. *Rev Bras Otorinolaringol (Engl Ed).* 2006;72:747-756.
13. 11. Preuthiphan A, Chantarojanasiri T, Suwanjutha S, et al. Can parents predict the severity of childhood obstructive sleep apnoea? *Acta Paediatr.* 2000;89:708-712.
14. 12. Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol.* 1996;13:198-207.
15. 13. Guilleminault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr.* 1995;127:905-912.
16. 14. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg.* 2003;129:1281-1284.
17. 15. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. *Medical care.* 2003;41:582-592.
18. 16. Stancin T, Drotar D, Taylor HG, et al. Health-related quality of life of children and adolescents after traumatic brain injury. *Pediatrics.* 2002;109:E34.
19. 17. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. *Health technology assessment (Winchester, England).* 2001;5:1-157.
20. 18. Theunissen NC, Vogels TG, Koopman HM, et al. The proxy problem: child report versus parent report in health-related quality of life research. *Qual Life Res.* 1998;7:387-397.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.



Chapter 9

Obstructive sleep apnea-specific quality of life (OSA-18) and behavioral problems in children with syndromic or complex craniosynostosis

Bannink N

Maliepaard M

Raat H

Joosten KFM

Mathijssen IMJ

Submitted

1. **ABSTRACT**

2.

3. **Objective**

4. This study aimed at evaluating the impact of syndromic craniosynostosis on quality of life,
5. assessing the association between presence of craniosynostosis syndrome and prevalence
6. of behavioral problems and assessing the impact of obstructive sleep apnea (OSA) in syn-
7. dromic craniosynostosis compared to healthy controls and the association with behavior.

8.

9. **Methods**

10. A prospective study was carried out using the OSA-18 survey and Child Behavior Checklist
11. (CBCL) in 119 syndromic craniosynostosis patients and 459 controls. The craniosynostosis
12. population underwent a ambulatory polysomnography to diagnose OSA.

13.

14. **Results**

15. The domains 'sleep disturbance', 'physical suffering', 'caregiver concerns' and total OSA-18
16. score were significantly higher in the craniosynostosis group than in controls. After sub-
17. group analysis 67% and 50% of boys with Apert and Muenke syndrome showed behavioral
18. problems. The correlation between obstructive apnea hypopnea index and total OSA-18
19. and CBCL score was significant. Mean scores for the domains 'sleep disturbance' and
20. 'physical suffering' were significantly higher in moderate OSA.

21.

22. **Conclusion**

23. Children with syndromic craniosynostosis reported lower quality of life measured with
24. OSA-18 than controls. Behavioral problems were common in boys with Apert and Muenke
25. syndrome. Obstructive sleep apnea reduced the quality of life of craniosynostosis children.
26. OSA-18 and CBCL scores are correlated with OSA severity.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. INTRODUCTION

2.

3. Apert, Crouzon, Pfeiffer, Muenke and Saethre-Chotzen syndrome are craniosynostosis
4. syndromes caused by FGFR (fibroblast growth factor receptor) 1, 2, 3 mutations and
5. TWIST gene mutations or deletions. These syndromes are characterized by the premature
6. fusion of calvarial sutures, brain anomalies, characteristic facial features, hand and feet
7. malformations and hearing deficits amongst others^{1, 2}. Fusion of two cranial sutures or
8. more without a known mutation^{1, 2} is defined as complex craniosynostosis. Patients with
9. a syndromic or complex craniosynostosis are at risk for obstructive sleep apnea due to
10. midface hypoplasia and collapse of the pharynx, but other factors such as adenotonsillar
11. hypertrophy may be involved as well^{3, 4}. They can also have behavioral problems, such as
12. attention deficit hyperactive disorder and autism^{5, 6}. The prevalence and severity of the
13. behavioral problems among patients with craniosynostosis syndromes are unknown, but
14. the problems seem to occur more frequent in comparison with the general population.

15. Obstructive sleep apnea (OSA) is characterized by difficulties in breathing, snoring and
16. apneas during sleep due to a partial or complete obstruction of the upper airway. OSA is
17. associated with major physical and functional impairment due to disturbed sleep patterns,
18. for instance failure to thrive, recurrent infections, feeding difficulties, disturbed cognitive
19. functions (attention deficit, impaired concentration and memory), delay of development,
20. cor pulmonale and sudden death⁷. OSA can be treated pharmacologically (e.g. with
21. intranasal corticosteroids or antibiotics), surgically (e.g. with adenotonsillectomy (ATE)
22. or midface advancement), or non-surgically (e.g. with nocturnal oxygen or continuous or
23. bi-level positive airway pressure (CPAP or BiPAP))^{3, 8, 9}.

24. Obstructive sleep apnea may affect the child's quality of life because of these physical
25. and functional consequences and the treatment. Previously a disease-specific quality of life
26. survey was developed and validated, the OSA-18, for healthy children who got OSA due
27. to adenotonsillar hypertrophy¹⁰.

28. This study aimed (a) at evaluating the impact of syndromic craniosynostosis on quality
29. of life, (b) at assessing the association between the presence of a craniosynostosis syndrome
30. and the prevalence of behavioral problems and (c) at assessing the impact of obstructive
31. sleep apnea on the quality of life in a population of patients with syndromic craniosy-
32. nostosis compared to healthy controls and the association with the presence of behavioral
33. problems.

34.

35.

36. METHODS

37.

38. Authorisation was granted by the medical ethics committee (MEC-2005-273) of the
39. Erasmus Medical Center.

1. **Craniosynostosis population**

2. A prospective study was carried out in the Erasmus MC-Sophia Children's Hospital, a
 3. tertiary care university hospital in Rotterdam. Patients with syndromic (genetically
 4. confirmed) or complex craniosynostosis between the age of 2 and 18 years treated at the
 5. Dutch Craniofacial Center between January 2007 and March 2009 were included (table
 6. 1). Parents were asked to complete the OSA-I8 survey and the Child Behavior Checklist
 7. (CBCL).

8.

9. **General population**

10. Parents of healthy children between the age of 2 and 18 years were approached at day-
 11. care centers, primary and secondary schools and sports clubs in Rotterdam, Rijswijk and
 12. Leiden (table 1). They were asked to complete the OSA-I8 survey on their child and to
 13. return this to the hospital. A child with Down syndrome was excluded. No child had
 14. anamnestic complaints suggestive of OSA. Behavioral problems were not excluded.

15.

16. **Table 1:** Characteristics of the craniosynostosis and general population

| 17. | | Craniosynostosis
population
n = 119 | General
population
n = 459 | p-value |
|-----|--|---|----------------------------------|---------|
| 19. | Completed by | | | |
| 20. | Mother | 104 (87%) | 402 (87%) | ns |
| 21. | Father | 15 (13%) | 50 (11%) | |
| 21. | Other | | 7 (2%) | |
| 22. | Age respondent range
(years) median | 23-61
39 | 17-55
41 | ns |
| 23. | Education respondent | | | |
| 24. | Low | 7 (6%) | 7 (1.5%) | 0.00** |
| 25. | Middle | 78 (65.5%) | 251 (55%) | |
| 26. | High | 31 (26%) | 198 (43%) | |
| 26. | Unknown | 3 (2.5%) | 3 (0.5%) | |
| 27. | Age child range
(years) median | 2-18
8 | 2-18
9 | 0.04* |
| 28. | Sex child boy | 56 (47%) | 239 (52%) | ns |
| 29. | girl | 63 (53%) | 220 (48%) | |
| 30. | Syndrome/ sex (boy/ girl) | | | |
| 31. | Apert | 19 (16%) (9/ 10) | | |
| 32. | Crouzon/ Pfeiffer | 31 (26%) (14/ 17) | | |
| 33. | Muenke | 18 (15%) (8/ 10) | | |
| 33. | Saethre-Chotzen | 21 (18%) (8/ 13) | | |
| 34. | Complex | 30 (25%) (17/ 13) | | |
| 34. | Obstructive sleep apnea child | | | |
| 35. | Non | 75 (63%) | | |
| 36. | Mild | 37 (31%) | | |
| 36. | Moderate | 7 (6%) | | |

37. ns not significantly different

38. * p-value \leq 0.05

39. ** p-value \leq 0.01

1. OSA-18 survey

2. The questionnaire consisted of 18 age-independent items grouped into five domains: ‘sleep
3. disturbance’, ‘physical suffering’, ‘emotional distress’, ‘daytime problems’ and ‘caregiver
4. concerns’. Each item had seven optional answers ranging from 1 (never) to 7 (always). The
5. total OSA-18 score was the sum of the 18 items and ranged from 18 to 126. It also provided
6. a 10-point visual analog scale with specific semantic anchors¹⁰ (appendix 1). Total scores
7. less than 60 suggest a small impact on health-related quality of life, scores between 60 and
8. 80 a moderate impact and scores above 80 a large impact¹⁰.

9. Prior to this study the internal consistency, test-retest reliability and discriminative
10. validity of the translated OSA-18 survey in healthy children and children with syndromic
11. or complex craniosynostosis were demonstrated (Bannink et al., unpublished data, 2010).

12.

13. Child Behavior Checklist

14. The standardized Child Behavior Checklist (CBCL) was used to measure the parent-
15. reported child problem-behavior frequency. The CBCL is a widely used norm-referenced
16. measure (Rescorla, Manual for the ASEBA Preschool Forms & Profiles¹¹ and Achenbach,
17. Manual for the Child Behavior Checklist/4-18 & Profile¹²). The CBCL 1.5-5 years consisted
18. of 100 items and the CBCL 6-18 years of 113 items. Each item is scored as 0, not true;
19. 1, somewhat or sometimes true; and 2, very true or often true. The known Dutch norm
20. scores were used as cut-off values. Scores < 95th percentile are scores in the normal range.
21. Scores ≥ 95th percentile but < 98th percentile were defined as scores in the borderline and
22. ≥ 98th percentile as scores in the clinical range, so these scores are considered as abnormal.

23. The CBCL provided age- (1.5-5, 6-11 and 12-18 years) and gender-specific scores for in-
24. ternalizing, externalizing and total problems. Internalizing scores were based on the three
25. domains ‘anxiety’, ‘withdrawal’ and ‘somatic complaints’. Externalizing scores were based
26. on ‘rule-breaking behavior’ and ‘aggressive behavior’. The total score is a combination of
27. the two scores plus ‘social’, ‘thought’ and ‘attention problems’, and ‘other problems’ (e.g.
28. overeating, overtired).

29. Behavioral problems were defined as the presence of scores in the (borderline) clinical
30. range¹¹. The results were analyzed in the craniosynostosis population and per syndrome.

31.

32. Polysomnography

33. The children of the craniosynostosis population underwent a polysomnography, the gold
34. standard to diagnose obstructive sleep apnea. Polysomnography was done ambulatory
35. with Embletta Portable Diagnostic System and analyzed with Somnologica for Embletta
36. software 3.3 ENU (Medcare Flaga, Reykjavik, Iceland). Thoracic and abdominal move-
37. ments, nasal flow, saturation, and pulse were monitored. The required minimal total sleep
38. time was 360 minutes. Obstructive apnea was defined as absence of airflow (measured by
39. a nasal cannula) or out-of-phase movement of thorax and abdomen (scored as X flow) and

1. hypopnea as $\geq 50\%$ reduction in nasal flow signal amplitude or X flow signal amplitude,
2. both for more than two breaths¹³⁻¹⁵. The X flow signal was the sum of the amplitudes of the
3. thoracic and abdominal movements^{14, 15} and was used when nasal airflow was insufficient.
4. Mixed apnea was defined as a type of obstructive apnea with a central component that
5. mostly preceded the obstructive pattern, for more than two breaths. Central apneas were
6. not included in this study. Desaturation was defined as $\geq 4\%$ decrease with respect to the
7. baseline value.

8. The degree of OSA was expressed in an obstructive apnea hypopnea index (OAHI), the
9. hourly number of obstructive and mixed apneas in combination with the hourly number
10. of hypopneas followed by desaturation. A score < 1 is considered to be normal, between
11. 1 and 5 is defined as mild OSA, between 6 and 25 as moderate OSA, and > 25 as severe
12. OSA^{16, 17}.

13.

14. **Statistical analysis**

15. All analyses were performed with SPSS 16.0 for Windows (SPSS, Chicago, IL). The analy-
16. ses were performed in several subgroups, in boys and girls and in each craniosynostosis
17. syndrome separately. The independent t-test was used to compare the means of the dif-
18. ferent craniosynostosis syndromes with the general population. The correlations between
19. OSA-I8, CBCL and OAHI were assessed. Significant differences were defined as a p-value
20. ≤ 0.05 . The numbers were given in median and range.

21.

22.

23. **RESULTS**

24.

25. **Craniosynostosis population**

26. A total of 163 patients with syndromic or complex craniosynostosis were approached, of
27. whom 141 (87%) children and their parents gave informed consent for this research project.
28. Of them 119 (73%) returned the OSA-I8 survey and underwent a polysomnography. Out
29. of these 119 the parents of two girls did not complete the CBCL, due to very low mental
30. capacity of one child (several items could not be answered) and due to a logistic reason in
31. the other.

32. Most of the questionnaires, namely 87% were completed by mothers compared to 13%
33. completed by fathers and 88% of them were born in the Netherlands. The craniosynostosis
34. group consisted of 56 boys (47%) and 63 girls (table 1).

35.

36. **General population**

37. Parents of 459 healthy children returned the questionnaire. Also in this healthy population
38. most of the questionnaires (87%) were completed by mothers and 91% of the respondents

39.

1. were born in the Netherlands. The reference group consisted of 239 boys (52%) and 220
2. girls (table 1).

3.

4. OSA-18 survey

5. The quality of life measured with the OSA-18 in patients with a syndromic or complex cra-
6. niosynostosis was lower than that measured in the general population (table 2). The mean
7. total OSA-18 score in the craniosynostosis population was 39.9 (sd 16.7). The maximum
8. score was 100. A score above 60 was present in 12%, above 80 in 3%. The mean OSA-18
9. score in the general population was 31.2 (sd 10.4) with a score above 60 in 2% and above
10. 80 in none of the healthy children.

11. The domains 'sleep disturbance', 'physical suffering', and 'caregiver concerns' and the
12. total OSA-18 score were significantly higher in the craniosynostosis group than in the ge-
13. neral population ($p = 0.000$). Specifically children with Apert, Crouzon/ Pfeiffer syndrome
14. and complex craniosynostosis scored significantly higher than the general population on
15. all these domains. Children with Muenke syndrome scored significantly higher on 'sleep
16. disturbance' (table 2).

17.

18. **Table 2:** Means of the OSA-18 scores in the craniosynostosis population and per syndrome in comparison with
19. the general population

| | General
population | Craniosynostosis
population | Apert | Crouzon/
Pfeiffer | Muenke | Saethre-
Chotzen | Complex |
|--------------------------------|-----------------------|--------------------------------|---------------------|----------------------|---------------------|---------------------|---------------------|
| | mean (sd)
n = 459 | mean (sd)
n = 119 | mean (sd)
n = 19 | mean (sd)
n = 31 | mean (sd)
n = 18 | mean (sd)
n = 21 | mean (sd)
n = 30 |
| 23. Sleep
24. disturbance | 5.8 (2.4) | 8.9 (4.8)** | 12.7 (5.2)*** | 9.3 (7.1)** | 8.8 (5.3)* | 7.8 (5.1) | 7.2 (3.1)* |
| 25. Physical
26. suffering | 8.1 (4.3) | 11.1 (5.8)** | 14.7 (6.3)*** | 10.8 (6.1)** | 8.7 (4.6) | 9.7 (5.8) | 11.1 (5.1)** |
| 27. Emotional
28. distress | 6.2 (3.1) | 6.5 (3.4) | 6.7 (3.7) | 5.9 (4.1) | 6.5 (3.2) | 6.1 (2.7) | 7.1 (3.4) |
| 29. Daytime
30. problems | 6.2 (3.1) | 6.8 (3.5) | 7.5 (3.4) | 6.0 (3.7) | 7.7 (4.6) | 7.1 (3.1) | 6.3 (3.1) |
| 31. Caregiver
32. concerns | 5.2 (2.4) | 7.0 (4.2)** | 8.3 (3.9)** | 6.9 (5.5)* | 6.3 (4.1) | 6.2 (2.9) | 6.9 (4.1)* |
| 33. Total OSA-
34. 18 score | 31.2 (10.4) | 39.9 (16.7)** | 49.8 (16.8)**^ | 39.0 (19.0)* | 38.2 (19.2) | 37.4 (14.4) | 37.9 (14.5)* |

sd standard deviation

* p-value ≤ 0.05

** p-value ≤ 0.01

35. + scores were significantly higher in Apert syndrome in comparison with Muenke, Saethre-Chotzen syndrome
36. and complex craniosynostosis

37. # scores were significantly higher in Apert syndrome in comparison with all other four syndromes

38. ^ scores were significantly higher in Apert syndrome in comparison with Saethre-Chotzen syndrome and complex
39. craniosynostosis

1. Within the group of children with syndromic or complex craniosynostosis Apert
 2. syndrome scored significantly higher than the other syndromes on different domains as
 3. demonstrated in table 2.

4.

5. Child Behavior Checklist

6. The prevalence of behavioral problems is 32% in boys with syndromic or complex cranio-
 7. synostosis and 16% in girls (table 3). The total CBCL score between 1.5 and 5 years was 31.8
 8. (sd 17.9) in boys and 28.1 (sd 27.7) in girls and between 6 and 18 years 38.1 (sd 29.6) in boys
 9. and 28.4 (sd 14.6) in girls. The maximum score was 144.

10. Table 3 also showed the results of the CBCL scores per syndrome. Of the boys with
 11. Apert syndrome 67% scored in the (borderline) clinical range in contrast with none of the
 12. girls. This 67% prevalence of behavioral problems in boys is significantly higher than in
 13. Crouzon/ Pfeiffer syndrome and complex craniosynostosis. Boys with Muenke syndrome
 14. also scored high (50%) in the (borderline) clinical range.

15.

16. Obstructive sleep apnea

17. Out of the 119 patients 44 (37%) were diagnosed with an obstructive sleep apnea; 37 mild
 18. with a mean OAH1 of 2.3 (sd 1.1) and 7 moderate with a mean OAH1 of 9.0 (sd 5.1) with
 19. a maximum index of 20.

20.

21.

Table 3: The numbers and percentages of the CBCL scores in the (borderline) clinical range in the
 22. craniosynostosis population and per syndrome in boys and girls

| | Craniosynostosis
population
(borderline)
clinical range
n (%) | Apert
(borderline)
clinical range
n (%) | Crouzon/
Pfeiffer
(borderline)
clinical range
n (%) | Muenke
(borderline)
clinical range
n (%) | Saethre-
Chotzen
(borderline)
clinical range
n (%) | Complex
(borderline)
clinical range
n (%) |
|--------------------------------|---|--|---|---|--|--|
| 23. Boy | n = 56 | n = 9 | n = 14 | n = 8 | n = 8 | n = 17 |
| 24. Internalizing
25. score | 14 (25) | 4 (44) | 3 (21) | 3 (38) | 1 (13) | 3 (18) |
| 26. Externalizing
27. score | 12 (21) | 4 (44)* | 1 (7) | 3 (38) | 1 (13) | 3 (18) |
| 28. Total score | 18 (32) | 6 (67)* | 3 (21) | 4 (50) | 2 (25) | 3 (18) |
| 29. Girl | n = 61 | n = 10 | n = 16 | n = 10 | n = 12 | n = 13 |
| 30. Internalizing
31. score | 12 (20) | 0 (0) | 2 (13) | 4 (40)^ | 4 (33)* | 2 (15) |
| 32. Externalizing
33. score | 5 (8) | 0 (0) | 1 (6) | 1 (10) | 3 (25) | 0 (0) |
| 34. Total score | 10 (16) | 0 (0) | 1 (6) | 3 (30) | 3 (25) | 3 (23) |

35. - scores were significantly higher in Apert syndrome in comparison with Crouzon/ Pfeiffer syndrome

36. # scores were significantly higher in Apert syndrome in comparison with Crouzon/ Pfeiffer syndrome and
 37. complex craniosynostosis

38. ^ scores were significantly higher in Muenke syndrome in comparison with Apert syndrome

39. + scores were significantly higher in Saethre-Chotzen syndrome in comparison with Apert syndrome

1. Obstructive sleep apnea in the patients with syndromic or complex craniosynostosis
 2. had impact on the quality of life. There was a significant positive correlation between
 3. the total OSA-18 score and the OAHI ($r = 0.34$, $p = 0.000$), also after exclusion of the
 4. patients without OSA ($r = 0.40$, $p = 0.009$) (figure 1). Patients without OSA had a mean
 5. total OSA-18 score of 38.0, with mild OSA 41.0 and with moderate OSA 55.0 (figure 2).
 6. All patients with a total OSA-18 score above 80 had OSA, and 9 out of 14 (64%) with a
 7. total score above 60.

8. The domains 'sleep disturbance' and 'physical suffering' were significantly higher in the
 9. moderate OSA group than in the non OSA and than in the mild OSA group ($p \leq 0.05$),
 10. but not in the mild OSA group in comparison with the non OSA group.

11. The degree of obstructive sleep apnea also has impact on behavior. The correlation
 12. between the total CBCL score in children between 6 and 18 years and the OAHI was
 13. significant ($r = 0.38$, $p = 0.001$), also after exclusion of the patients without OSA ($r = 0.55$,
 14. $p = 0.008$) (figure 3).

15. Overall, there is a significant correlation between the total OSA-18 score and the total
 16. CBCL score in children between 1.5 and 5 years and 6 and 18 years (figure 4), also after
 17. exclusion of the patients without OSA ($r = 0.73$, $p = 0.000$).

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.


32.

33.

34.

35.

36.




37.


38.

39.

Figure 1: Correlation between total OSA-18 score and the OAHI in the total group after exclusion of children without obstructive sleep apnea
 OAHI obstructive apnea hypopnea index



15. **Figure 2:** Mean total OSA-18 scores with standard deviation over three groups with no, mild and moderate
16. obstructive sleep apnea
17. sd standard deviation



1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.

Total OSA-18 score




Figure 4: Correlation between the total CBCL score of the children between the age of 6 and 18 and the total OSA-18 score

DISCUSSION

This is the first study using a disease-specific quality of life score (OSA-18) in which comparison is made between children with syndromic or complex craniosynostosis suffering from obstructive sleep apnea and a general healthy population of Dutch children. The total OSA-18 score was significantly higher in the syndromic craniosynostosis population than in the general population (table 2), which meant a lower quality of life. Explanations can be the higher prevalence of OSA in this group compared to the low prevalence (2-5%) in the general population¹⁵ and the impact of having syndromic or complex craniosynostosis independent of the presence of OSA¹⁸. In the craniosynostosis population the total OSA-18 score (mean 43.4) of the OSA group was higher in comparison with the non OSA group (mean 38.0). Per domain the scores on 'sleep disturbance', 'physical suffering', and 'caregiver concerns' were significantly higher in the craniosynostosis than in the general population.

Within the group of children with syndromic or complex craniosynostosis, children with Apert syndrome showed the highest total OSA-18 score (table 2). This is in accordance with the lowest health-related quality of life in comparison with the other syndromes¹⁸ and a high prevalence of OSA (42%) seen in Apert syndrome.

1. There was a significant positive correlation between the total OSA-18 score and the
 2. OAH1. However, within the group of children with mild OSA a considerable number of
 3. children had a high OSA-18 score. This could be due to high scores on some specific items
 4. within the domains, which can be related to syndromic craniosynostosis. These items are
 5. snoring, mouth breathing, nasal discharge, aggressive or hyperactive behavior and poor
 6. attention span or concentration. These items were also higher scored in children with
 7. syndromic craniosynostosis without OSA. Overall the domains 'sleep disturbance' and
 8. 'physical suffering' were scored significantly higher in children with moderate OSA and
 9. these two domains might be used in clinical practice for evaluating the severity of OSA. A
 10. significant correlation between the mean OSA-18 score and the severity of OSA was also
 11. found in healthy children with OSA due to adenotonsillar hypertrophy¹⁰.

12. We found a high prevalence of behavioral problems, especially in boys with syndromic
 13. or complex craniosynostosis. Furthermore we found a positive correlation between the
 14. total CBCL score and the OAH1 and the total OSA-18 score. Within the group of chil-
 15. dren with syndromic or complex craniosynostosis it was remarkable that boys with Apert
 16. and Muenke syndrome showed the highest prevalence of behavioral problems, whereas
 17. none of the girls with Apert syndrome scored these problems. In Apert syndrome OSA
 18. is much more present in boys (78%) than in girls (10%) and the intelligence of boys with
 19. Apert syndrome is significantly lower than that of girls, which can influence the behavior
 20. (Maliepaard et al., unpublished data). In Muenke syndrome the behavioral problems may
 21. be more intrinsic and possibly related to their P250R mutation than be associated with
 22. OSA. The prevalence of OSA in Muenke syndrome is with 28% low in comparison with
 23. the other syndromes. Previously, studies on behavioral problems were mostly performed
 24. in children with isolated craniosynostosis. Boltshauser et al.¹⁹ reported in 30 children with
 25. isolated sagittal craniosynostosis a normal behavior whereas Kelleher et al.²⁰ reported in
 26. 63 children with trigonocephaly that 37% of the parents expressed concerns about their
 27. child's behavior. In children with Apert syndrome Sarimski et al.^{5, 6} reported in the majo-
 28. rity of the children clinically significant social problems and attention deficit, the total
 29. CBCL scores were only in 8 out of 25 children with Apert in the clinical range.

30. In this study it can be questioned what the additional influence of OSA is next to
 31. having syndromic craniosynostosis on the presence of behavioral problems in the different
 32. syndromes. Goldstein et al.⁹ reported that non-syndromic healthy children with OSA
 33. demonstrated a high prevalence of behavioral and emotional problems measured by the
 34. standardized CBCL, which changed after adenotonsillectomy. A positive correlation was
 35. found between the OSA-18 total scores and the CBCL scores⁹. After adenotonsillectomy
 36. both scores improved²¹. In children with the diagnosis ADHD in combination with mild
 37. OSA the apnea hypopnea index, the OSA-18 'sleep disturbance' domain and the ADHD-
 38. rating scale total and inattentive scores improved significantly more in the group treated
 39. for OSA by adenotonsillectomy than the group treated for their ADHD by methylphe-

1. nidate²². Concerning children with syndromic or complex craniosynostosis future studies
2. have to elaborate the impact of OSA treatment on the OSA-18 score and CBCL score for
3. each specific syndrome separately.

4.
5. In conclusion, children with syndromic craniosynostosis reported a lower quality of life
6. measured with the OSA-18 compared to healthy controls. Behavioral problems were highly
7. prevalent and most common in boys with Apert and Muenke syndrome. Obstructive sleep
8. apnea reduced the quality of life of children with syndromic craniosynostosis. The OSA-18
9. and CBCL scores are correlated with the severity of OSA, but the additional influence of
10. OSA on behavior is unclear in craniosynostosis.

11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.

I. **APPENDIX 1**


2.

3. **OSA-18 Quality of Life Survey**

4. Instructions. For each question below, please circle the number that best describes how
 5. often each symptom or problem has occurred during the past 4 weeks. Please circle only
 6. one number per question. Thank you.

| | None
of the
time | Hardly
any of
the
time | A
little
of the
time | Some
of the
time | A good
bit of
the
time | Most
of
the
time | All
of
the
time |
|-----|---|---------------------------------|-------------------------------|------------------------|---------------------------------|---------------------------|--------------------------|
| 7. | | | | | | | |
| 8. | | | | | | | |
| 9. | | | | | | | |
| 10. | <u>SLEEP DISTURBANCE</u> | | | | | | |
| | During the past 4 weeks, how often has your child had... | | | | | | |
| 11. | | | | | | | |
| | ...loud snoring? | | | | | | |
| 12. | | | | | | | |
| | ...breath holding spells or pauses in breathing at night? | | | | | | |
| 13. | | | | | | | |
| | ...choking or gasping sounds while asleep? | | | | | | |
| | ...restless sleep or frequent awakenings from sleep? | | | | | | |
| 14. | <u>PHYSICAL SYMPTOMS</u> | | | | | | |
| | During the past 4 weeks, how often has your child had... | | | | | | |
| 15. | | | | | | | |
| | ...mouth breathing because of nasal obstruction? | | | | | | |
| 16. | | | | | | | |
| | ...frequent colds or upper respiratory infections? | | | | | | |
| 17. | | | | | | | |
| | ...nasal discharge or runny nose? | | | | | | |
| 18. | | | | | | | |
| | ...difficulty in swallowing foods? | | | | | | |
| 19. | <u>EMOTIONAL DISTRESS</u> | | | | | | |
| | During the past 4 weeks, how often has your child had... | | | | | | |
| 20. | | | | | | | |
| | ...mood swings or temper tantrums? | | | | | | |
| 21. | | | | | | | |
| | ...aggressive or hyperactive behavior? | | | | | | |
| | ...discipline problems? | | | | | | |
| 22. | <u>DAYTIME PROBLEMS</u> | | | | | | |
| | During the past 4 weeks, how often has your child had... | | | | | | |
| 23. | | | | | | | |
| | ...excessive daytime drowsiness or sleepiness? | | | | | | |
| 24. | | | | | | | |
| | ...poor attention span or concentration? | | | | | | |
| 25. | | | | | | | |
| | ...difficulty getting out of bed in the morning? | | | | | | |
| 26. | <u>CAREGIVER CONCERNS</u> | | | | | | |
| | During the past 4 weeks, how often have the above problems... | | | | | | |
| 27. | | | | | | | |
| | ...caused you to worry about your child's general health? | | | | | | |
| 28. | | | | | | | |
| | ...created concern that your child is not getting enough air? | | | | | | |
| 29. | | | | | | | |
| | ...interfered with your ability to perform daily activities? | | | | | | |
| 30. | | | | | | | |
| | ...made you frustrated? | | | | | | |

31. **OVERALL, HOW WOULD YOU RATE YOUR CHILD'S QUALITY OF LIFE AS A**
 32. **RESULT OF THE ABOVE PROBLEMS?**
 33. (Circle one number)




I. REFERENCES

2. 1. Kress W, Schropp C, Lieb G, et al. Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. *Eur J Hum Genet* 2006;14:39-48.
3. 2. Lajeunie E, Heuertz S, El Ghouzzi V, et al. Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. *Eur J Hum Genet* 2006;14:289-298.
4. 3. Hoeve HL, Joosten KF, van den Berg S. Management of obstructive sleep apnea syndrome in children with craniofacial malformation. *Int J Pediatr Otorhinolaryngol* 1999;49 Suppl 1:S59-61.
5. 4. Lo LJ, Chen YR. Airway obstruction in severe syndromic craniosynostosis. *Ann Plast Surg* 1999;43:258-264.
6. 5. Sarimski K. Children with Apert syndrome: behavioral problems and family stress. *Developmental medicine and child neurology* 1998;40:44-49.
7. 6. Sarimski K. Social adjustment of children with a severe craniofacial anomaly (Apert syndrome). *Child: care, health and development* 2001;27:583-590.
8. 7. Nixon GM, Brouillette RT. Sleep. 8: paediatric obstructive sleep apnoea. *Thorax* 2005;60:511-516.
9. 8. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2002;109:704-712.
10. 9. Goldstein NA, Fatima M, Campbell TF, et al. Child behavior and quality of life before and after tonsillectomy and adenoidectomy. *Arch Otolaryngol Head Neck Surg* 2002;128:770-775.
11. 10. Franco RA, Jr., Rosenfeld RM, Rao M. First place--resident clinical science award 1999. Quality of life for children with obstructive sleep apnea. *Otolaryngol Head Neck Surg* 2000;123:9-16.
12. 11. Rescorla LA. Assessment of young children using the Achenbach System of Empirically Based Assessment (ASEBA). *Mental retardation and developmental disabilities research reviews* 2005;11:226-237.
13. 12. Achenbach TM, Edelbrock CS. Behavioral problems and competencies reported by parents of normal and disturbed children aged four through sixteen. *Monographs of the Society for Research in Child Development* 1981;46:1-82.
14. 13. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Archives of pediatrics & adolescent medicine* 2005;159:775-785.
15. 14. Preutthipan A, Chantarojanasiri T, Suwanjutha S, et al. Can parents predict the severity of childhood obstructive sleep apnoea? *Acta Paediatr* 2000;89:708-712.
16. 15. Ward SL, Marcus CL. Obstructive sleep apnea in infants and young children. *J Clin Neurophysiol* 1996;13:198-207.
17. 16. Guilleminault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995;127:905-912.
18. 17. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg* 2003;129:1281-1284.
19. 18. Bannink N, Maliopaard M, Raat H, et al. Health-related quality of life in children and adolescents with syndromic craniosynostosis. *J Plast Reconstr Aesthet Surg*
20. 19. Boltshausen E, Ludwig S, Dietrich F, et al. Sagittal craniosynostosis: cognitive development, behavior, and quality of life in unoperated children. *Neuropediatrics* 2003;34:293-300.
21. 20. Kelleher MO, Murray DJ, McGillivray A, et al. Behavioral, developmental, and educational problems in children with nonsyndromic trigonocephaly. *J Neurosurg* 2006;105:382-384.
22. 21. Tran KD, Nguyen CD, Weedon J, et al. Child behavior and quality of life in pediatric obstructive sleep apnea. *Arch Otolaryngol Head Neck Surg* 2005;131:52-57.
23. 22. Huang YS, Guilleminault C, Li HY, et al. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study. *Sleep Med* 2007;8:18-30.

Part V


Discussion and summary





Chapter 10

Discussion and future perspectives



1. DISCUSSION

2.

3. The main aim of this thesis was to assess the importance and impact of obstructive sleep
4. apnea (OSA) in children with syndromic or complex craniosynostosis. **Main findings** are:

5. • The prevalence of obstructive sleep apnea in children with syndromic or complex cra-
6. niosynostosis is 42%.

7. • When parents do not notice difficulty in breathing of their child during sleep the pre-
8. sence of moderate or severe obstructive sleep apnea can almost be excluded.

9. • Home cardiorespiratory monitoring is feasible to diagnose obstructive sleep apnea;
10. nevertheless there are concerns about the nasal flow recordings. Analysis of the X flow
11. signal gives additional information.

12. • Endoscopy before midface advancement in patients with obstructive sleep apnea is
13. recommended to identify level of airway obstruction and to help predict respiratory
14. improvement after midface advancement.

15. • There is a high (52-56%) prevalence of functional problems such as refractive errors and
16. hearing loss in all types of syndromic or complex craniosynostosis. The prevalence of
17. papilledema in Crouzon/ Pfeiffer syndrome is 53%; in Apert syndrome it is 33%.

18. • Syndromic craniosynostosis has a large impact on the health-related quality of life of
19. these children and their parents, both physical and psychosocial.

20. • The OSA-18, a disease-specific quality of life questionnaire, has good reliability and
21. validity for patients with syndromic craniosynostosis. Obstructive sleep apnea reduced
22. the quality of life of children with syndromic craniosynostosis and the OSA-18 scores are
23. correlated with disease severity.

24. • The prevalence of behavioral problems in boys with syndromic or complex craniosyn-
25. nostosis is 32%; in girls it is 16%. Boys with Apert syndrome (67%) or Muenke syndrome
26. (50%) had more behavioral problems than children with the other syndromes.

27.

28.

29. COMMENTS ON FINDINGS

30.

31. This thesis describes a large study in children with syndromic or complex craniosynostosis,
32. who were treated by the multidisciplinary team at the craniofacial center in Rotterdam.

33. It is divided into a retrospective and prospective part. Prospectively, 190 children and
34. their parents were approached consecutively, and 164 gave informed consent. Thus the
35. participation rate was 86%. This high rate made it possible to differentiate the outcomes
36. per syndrome. The records of 167 children with syndromic craniosynostosis were reviewed
37. retrospectively regarding the presence of elevated intracranial pressure (ICP), obstructive
38. sleep apnea, functional problems and the different treatments.

39.

1. Prevalence of obstructive sleep apnea

2. Obstructive sleep apnea is an important feature in children with syndromic craniosynostosis. On the basis of an obstructive apnea hypopnea index ≥ 1 the prevalence of OSA was 42% in the total prospective study group, 47% in Apert syndrome, 42% in Crouzon/Pfeiffer, 35% in Muenke, 28% in Saethre-Chotzen syndrome, and 50% in complex craniosynostosis. This is in accordance with the 40% risk to develop OSA in children with Apert, Crouzon and Pfeiffer syndrome reported in the literature¹⁻³. Of the OSA patients 82% had mild and 18% had moderate OSA. Apert syndrome occurred in half of those with moderate OSA; each of the other syndromes in 12.5% of the other half. The prospective study revealed no new cases with severe OSA. On the other hand, some cases of severe OSA were described in the group of patients studied retrospectively in **chapter 4**. The latter patients were older than 18 years at the time of the study and therefore not included in the prospective study.

14. Polysomnography in the prospective study resulted in a higher prevalence of OSA than that found previously in the retrospective analyzed patients, of whom the majority had undergone nocturnal pulse oximetry only (**chapter 6**). Obstructive and mixed apneas without desaturation were not registered with pulse oximetry, as this technique only records desaturation.

19. After informed consent all children aged between 0 and 18 years underwent a polysomnography. The mean age at inclusion and thus the age at OSA diagnosis with polysomnography differed between the children with OSA and the children without OSA: 5.5 and 9.7 years, respectively. This would seem to imply that in the majority of children with syndromic craniosynostosis OSA will develop at a young age. The older patients did not develop OSA or had already been treated. The exact age of OSA onset is currently not clear; yearly follow up from the first year of life during at least six years might provide a clue.

27. Screening tool

28. In the past, parents and physicians of children with syndromic or complex craniosynostosis did not recognize respiratory difficulties as separate entity. Parents or caregivers did not report and physicians did not ask for breathing problems at the outpatient clinic. We evaluated the use of an established screening tool for OSA, the Brouillette score, which is based on three questions⁴ (**chapter 2**). This study showed that informing of difficulty in breathing in itself is sensitive to screen for moderate or severe OSA. This single question is a simplification of the Brouillette score. Information about snoring is not specific due to its high prevalence (77%). The question about presence of apneas is specific but not sensitive and thus may result in missing cases.

37. In conclusion, if the child has no difficulty in breathing moderate or severe OSA is not very likely to be present. If difficulties in breathing are reported a polysomnography is recommended.

1. Diagnostic method

2.

3. *Polysomnography*

4. There are four levels of polysomnography^{5, 6}.

5. Level 1, full polysomnography, is the gold standard and this is performed in a sleep
6. laboratory with a technician in attendance. It records sleep stages (REM and non-REM
7. sleep and arousals), respiratory effort, airflow, oxygen saturation, electrocardiogram, body
8. position and limb movements.

9. Level 2 records the same variables, but can be performed outside of the sleep laboratory
10. without a technician.

11. Level 3 is the method used in the prospective study described in this thesis. A portable
12. monitor records four physiologic variables, i.e. two respiratory variables (respiratory
13. movement and airflow), a cardiac variable (heart rate or an electrocardiogram), and arte-
14. rial oxyhemoglobin saturation via pulse oximetry. Sleep stages and arousals cannot be
15. recorded^{5, 6}.

16. Level 4 is the simplest portable monitor, which records arterial oxyhemoglobin satura-
17. tion and/ or airflow^{5, 6}. Brouillette et al.⁷ used nocturnal pulse oximetry to diagnose OSA
18. in healthy children with a high positive predictive value, but a negative oximetry result
19. could not rule out the presence of OSA. In children with syndromic craniosynostosis
20. moderate or severe OSA is almost unlikely with a negative oximetry.

21. **Chapter 3** described the use of level 3 polysomnography in children with syndromic or
22. complex craniosynostosis. OSA was diagnosed with 40.5% successful recordings (minimal
23. total sleep time of 360 minutes with artefact-free signals). This is a better result than that
24. of a previous study performed in children who snore, in whom only 29% of the home
25. cardiorespiratory recordings were successful⁸. Moss et al.⁹ studied the use of abbreviated
26. home polysomnography in 50 primary school children. In 89% of the recordings the total
27. sleep time without movement or artifacts was at least four hours. However, it is two hours
28. less than our definition of a successful measurement. In general, a polysomnography las-
29. ting a minimum of six hours is advocated for the accurate diagnosis of OSA.

30.

31. *Limitations in the use of ambulatory polysomnography*

32. - Use of nasal cannula

33. The nasal cannula is the most important limitation of polysomnography in children
34. with syndromic craniosynostosis. Shifting during sleep or intolerance may cause failure.
35. Another causative factor is the absence of nasal passage when the nasal cavity is severely
36. malformed¹⁰.

37. - X flow as alternative for nasal flow

38. We showed that the X flow can be helpful to diagnose OSA in the absence of nasal flow. We
39. were the first to report this use of the X flow in ambulatory polysomnography in children.

1. A limitation of this method is underestimation of the degree of OSA by missing a part of
2. the obstructive apneas, possibly due to shifting of the trace belts. This method should be
3. properly validated in comparison with level 1 polysomnography. An alternative solution to
4. bypass the nasal obstruction is the use of a mouth thermistor to record oral airflow.

5. - Additional measurements

6. Guilleminault et al.^{11, 12} recommended to measure esophageal pressure (indirect measure
7. of the intrathoracic pressure, which gives information on respiratory efforts) and the
8. transcutaneous or end tidal CO₂ next to arousal and sleep stages detection. This method
9. allows to distinguish OSA from upper airway resistance syndrome (UARS)¹². Furthermore
10. the relation between elevated intracranial pressure and OSA or UARS can be determined
11. more accurately.

12. - Uniform definitions for polysomnography in children

13. Another limitation in children is the lack of a uniform definition to analyze a polysomno-
14. graphy (table 1)^{7, 8, 13-15}. The common definition of OSA is an AHI ≥ 1 based on the number
15. of obstructive apneas and hypopneas followed by desaturation for at least two breaths. In
16. our studies this definition was used as well. There is less consensus about the definitions
17. of mild, moderate and severe OSA (table 2). In our study we used the definition of Guil-
18. leminault et al.¹⁶ Children were classified as having mild obstructive sleep apnea if they
19. had an AHI of 1 to 5 events per hour of sleep, as moderate OSA with an AHI of between 6
20. and 25 events per hour of sleep, and as severe with more than 25 events per hour.

21. Central apneas were not included in the AHI, because many children, especially the
22. very young, show central irregularity of breathing^{17, 18}, which has no association with OSA.

23. Another definition is the lowest observed saturation in addition to the number of apneas
24. and hypopneas per hour^{19, 20}. There are however no studies in children who showed a
25. higher morbidity using these criteria. It might be argued that very low saturations warrant
26. more or earlier treatment than mild desaturations, but this has to be determined.

27.

28. **Treatment**

29. Patients who underwent a polysomnography are discussed by a multidisciplinary team
30. consisting of a pediatrician, plastic surgeon, otorhinolaryngologist, oral and maxillofacial
31. surgeon, and nurse specialist. If OSA is not diagnosed, a strategy of annual screening is
32. decided on, unless symptoms of OSA developed in between.

33. If OSA is diagnosed, the otorhinolaryngologist is asked to inspect the adenoid and
34. tonsils. In mild or moderate cases conservative medical therapy (e.g. xylometazolin, anti-
35. biotics, nasal corticosteroids) or adenotonsillectomy (ATE) are the first treatment options.

36. If these do not improve OSA or in severe OSA, continuous or bi-level positive airway
37. pressure (CPAP or BiPAP) can be initiated. In some children oxygen therapy might be
38. helpful. A tracheostomy might be necessary in very young children with severe OSA who
39. present with breathing problems throughout the day.

Table 1: Overview of different studies about definitions to analyze a polysomnography

| N of patients, diagnosis | Mean age (yrs) ± sd (range) | TST in hrs | Obstructive apnea (O) | Central apnea (C) | Mixed apnea (M) | Hypopnea (H) | Obstructive sleep apnea | Desaturation |
|---|---|------------|--|--|--|---|-------------------------|--------------|
| Brouillette et al. ⁷ , 2000 | 349 patients referred for PSG
median 4.5 (2.9-7.1) | 8.1 ± 1.4 | ≥ 1 breath | ≥ 1 breath | ≥ 1 breath | associated with desaturation | O+M+H ≥ 1 | ≥ 4% |
| Guilleminault et al. ¹³ , 2004 | 400 patients suspected for OSA + 60 controls
6.5 ± 4.0 (2.0-12.1) | ≥ 8.5 | > 2 breaths, independent of desaturation/EEG arousal | > 2 breaths independent of desaturation/EEG arousal | > 2 breaths independent of desaturation/EEG arousal | ≥ 2 breaths independent of desaturation/EEG arousal | O+M+H > 1.5 | ≥ 3% |
| Marcus et al. ¹⁴ , 1992 | 50 healthy children
9.7 ± 4.6 (1.1-17.4) | 6.0 ± 1.6 | any length | associated with desaturation < 90%, irrespective of length | central component: ≥ 4 sec/ ≥ 2 breaths, obstructive: any length | - | O > 1 | > 4% |
| Poels et al. ⁸ , 2003 | 24 patients scheduled for ATE
4.2 ± 1.6 | ≥ 6.5 | ≥ 10 sec | ≥ 10 sec | ≥ 10 sec | ≥ 10 sec | O+C+M+H ≥ 1 | ≥ 4% |
| Verhulst et al. ¹⁵ , 2007 | 60 healthy children
11.7 ± 2.6 (7.1-16.6) | 7.8 ± 0.8 | > 2 breaths independent of desaturation | ≥ 10 sec or of any length associated with desaturation | central and obstructive component | associated with desaturation/EEG arousal | O+M+H > 1 | > 3% |
| This study:
Bannink et al., 2010 | 65 patients syndromic/complex craniosynostosis
median 8.5 (0.2-18.7) | ≥ 6 | > 2 breaths independent of desaturation | > 2 breaths associated with desaturation | > 2 breaths independent of desaturation | > 2 breaths associated with desaturation | O+M+H ≥ 1 | ≥ 4% |

1. **Table 2:** Overview of different studies about the severity of OSA

| | Mild (events/hour) | Moderate (events/hour) | Severe (events/hour) |
|---|----------------------------|----------------------------|--------------------------|
| 2. Guilleminault et al. ¹⁶ , 1995 | | | |
| 3. AHI | 1-5 | 6-24 | >25 |
| 4. Guideline New Zealand*, 2005 | | | |
| 5. Apnea index | 1-4 | 5-9 | >10 |
| 6. Saturation in association with obstruction | Nadir 87-91% | Nadir 76-85% | Nadir <75% |
| 7. Hypoventilation | 10-24% of total sleep time | 25-49% of total sleep time | >50% of total sleep time |
| 8. Goroza et al. ¹⁶ , 2009 | | | |
| 9. AHI | 5-15 | 16-30 | >30 |
| 10. Lowest saturation | Nadir 81-90% | Nadir 71-80% | Nadir ≤ 70% |
| 11. This study, Bannink et al, 2010 | | | |
| 12. AHI | 1-5 | 6-25 | >25 |

13. * best practice evidence based guideline, assessment of sleep disordered breathing in childhood, 2005, Pediatric Society of New Zealand

14.
15.
16. Surgical treatment to enlarge the upper airway with midface advancement can also
17. be valuable to treat OSA. Patients with Apert, Crouzon and Pfeiffer syndrome have an
18. intrinsic growth retardation of the maxilla²¹ and restriction of normal transverse growth
19. of the mandible, possibly secondary to cranial base abnormalities²². However, midface
20. advancement does not always result in improvement of OSA^{21, 23, 24}.

21. **Chapter 4** showed a favorable short-term effect of monobloc or le Fort III with distrac-
22. tion in only six of eleven (55%) patients with Apert, Crouzon or Pfeiffer syndrome. In a
23. study by Witherow et al.²⁴, severe OSA treated with tracheostomy or CPAP was resolved
24. after monobloc with external distraction in six of fourteen (43%) patients suffering from
25. Apert, Crouzon or Pfeiffer syndrome. The other eight patients remained dependent on
26. tracheostomy or CPAP. Arnaud et al.²¹ showed that removal of tracheostomy was possible
27. after monobloc with internal distraction in four of six (67%) severe cases with Apert,
28. Crouzon or Pfeiffer syndromes. Nelson et al.²³ studied eighteen patients with syndromic
29. bilateral coronal synostosis and OSA; respiratory support was discontinued after midface
30. advancement in eleven patients (73%). Five patients were decanulated and CPAP was
31. stopped in six. With a monobloc the midface (including the maxilla) and the forehead are
32. advanced; with a le Fort III the midface is advanced, which resulted in improvement of the
33. naso- and oropharynx (figure 1)²⁵. A lower obstruction at the level of the hypopharynx may
34. be responsible for unsuccessful midface advancement. Other treatment modalities should
35. be considered as well, such as an advancement of the mandible.

36. Endoscopy of the upper airways by the otorhinolaryngologist before starting OSA treat-
37. ment is recommended. In adults endoscopy is possible under propofol to induce the obstruc-
38. tive sleep situation. Children need to be in lying position at the outpatient clinic. When this
39. is not possible, usually in very young children, it might be done under general anesthesia.




Figure 1: Le Fort III and monobloc as treatment modalities to improve the upper airway volume

Furthermore, the age at which the midface is advanced is essential, seeing that due to persistent maxillary growth retardation this intervention has only a temporary effect when performed at young age²⁶. Then, at the age of 18, a second but simpler advancement (le Fort I) is needed. During adolescence it will be better to postpone the midface advancement if possible, because of the psychological consequences of this large surgical intervention, the period of distraction and the change of the child's face.

Other treatment options for OSA are a mandibular repositioning appliance (MRA), a surgically assisted rapid maxillary expansion (SARME) or a correction of the nasal septum. The treatment of OSA must be individualized, dependent on age, severity of OSA, cranio-facial syndrome and level of obstruction (table 3).

Multidisciplinary approach

In this prospective study all children underwent at least one polysomnography; children below the age of seven more frequently on a yearly basis. In 35 multidisciplinary meetings 321 polysomnographies were evaluated. In 246 polysomnographies (77%) no or mild OSA without clinical symptoms was diagnosed and follow-up was arranged. In 78 polysomnographies (24%) mild OSA with clinical symptoms or moderate OSA was diagnosed and treatment was scheduled (table 4). Treatments were mostly (81%) needed in patients with Apert, Crouzon or Pfeiffer syndrome. This study also includes patients who were treated for OSA in the past and underwent a PSG in the follow-up program. In the past few years a new treatment was needed in 24% of those.

Airway volume measurements

In **chapter 4** we showed that it was possible to analyze computed tomography (CT) scans and measure volumes of two separate anatomical defined areas, the nasal cavity and rhinopharynx, and the oro- and hypopharynx. These airway volume measurements can show the improvement in airway after midface advancement and can determine the narrowest point of the airway. Volume changes in the pharyngeal airway were also found after

Table 3: Policy of the multidisciplinary team after performing a polysomnography

| Age | Mild OSA | Moderate/ severe OSA | Remarks |
|-----------|------------------------------|--|--|
| 0-1 yr | Conservative medical therapy | Nasal corticosteroids, nocturnal oxygen, NPT, tracheostomy | |
| 1-6 yrs | Conservative medical therapy | ATE, nasal corticosteroids, nocturnal oxygen, CPAP/ BiPAP, monobloc (as first vault expansion or in presence of elevated ICP) | PSG 6 weeks post ATE, 3 months post monobloc, repeat PSG yearly |
| 6-12 yrs | Conservative medical therapy | ATE, nasal corticosteroids, nocturnal oxygen, CPAP/ BiPAP, monobloc (in presence of elevated ICP)/ le Fort III | PSG 6 weeks post ATE, 3 months post advancement, repeat PSG yearly |
| 12-15 yrs | Conservative medical therapy | Nasal corticosteroids, nocturnal oxygen, CPAP/ BiPAP, monobloc* (in presence of elevated ICP)/ le Fort III*, other options | PSG 3 months post advancement, repeat PSG yearly |
| 15-18 yrs | Conservative medical therapy | Nasal corticosteroids, nocturnal oxygen, CPAP/ BiPAP, monobloc (in presence of elevated ICP)/ le Fort III, mandibular advancement, other options | PSG 3 months post advancement, repeat PSG yearly |

Table 4: Treatment protocol of obstructive sleep apnea

| Policy after 321 polysomnographies | n (%) |
|---------------------------------------|------------|
| Follow-up | 246 (76.6) |
| Consultation of otorhinolaryngologist | 17 (5.3) |
| Endoscopy of upper airways | 20 (6.2) |
| Nasal corticosteroids | 7 (2.2) |
| Adenotonsillectomy | 11 (3.4) |
| CPAP | 4 (1.2) |
| Midface/ mandibular advancement | 7 (2.2) |
| Correction of nasal septum | 1 (0.3) |
| Diagnostics for elevated ICP | 8 (2.5) |

mandibular advancement²⁷. Per surgical treatment this method can reproduce the level of improvement in the upper airway and it will be possible to choose the best treatment for each patient individually.

Functional problems

In **chapters 5 and 6** functional problems in syndromic craniosynostosis were discussed. The prevalence of papilledema in patients with Apert, Crouzon, or Pfeiffer syndrome is high, not only before but also after vault expansion. From 4% of patients with Muenke syndrome to 53% of patients with Crouzon/ Pfeiffer syndrome showed a first, preoperative episode of elevated intracranial pressure. It can be related to craniocerebral disproportion and can be adequately treated or prevented with early vault expansion. However,

1. the second episode is also frequently seen at the age of about 4 years, but its causative
 2. factors are less clear. It can be related to OSA, hydrocephalus or venous hypertension²⁸⁻³⁰.
 3. The prevalence of papilledema after the first vault expansion was 17% in Saethre-Chatzen
 4. syndrome, 20% in Crouzon/ Pfeiffer and 35% in Apert syndrome. Marucci et al.³¹ reported
 5. the same prevalence in Apert syndrome. Only in Muenke syndrome there is a low risk
 6. of papilledema, i.e. 4%. Annual fundoscopy is recommended to screen for papilledema.
 7. If found present, a CT angiography can be performed to evaluate the ventricles and the
 8. venous outflow. A polysomnography to exclude OSA is needed to explore the possible
 9. cause of elevated ICP. Fundoscopy is of particular importance given the low reliability of
 10. clinical symptoms related to elevated ICP³².

11. Other functional problems, such as refractive errors and hearing loss, should be diag-
 12. nosed early, through screening. Treatment of hearing loss is necessary for an adequate
 13. development of speech.

14.

15. **Quality of life**

16. Syndromic craniosynostosis has a large impact on the health-related quality of life of
 17. the children and their parents, both physical and psychosocial. This phenomenon was
 18. explored in **chapter 7**. Apert syndrome has the largest impact. But also patients with
 19. Muenke syndrome scored significantly lower than the norm, despite the lower risk for
 20. elevated ICP and OSA in comparison with Apert and Crouzon or Pfeiffer syndrome.
 21. OSA was an independent predictor for the domain 'change in health' on the Child Health
 22. Questionnaire (CHQ) only, possibly associated with the improvement after OSA treat-
 23. ment. Furthermore, elevated ICP was an independent predictor for lower scores on several
 24. domains: 'parental impact: emotional', 'family activity' and 'change in health' on the
 25. Infant Toddler Quality of Life questionnaire (ITQoL) and 'physical functioning', 'general
 26. behavior', 'general health perceptions', 'parental impact: time' and 'family activity' on the
 27. CHQ. This might be explained by the fact that elevated ICP could result in behavioral
 28. changes that influence these scores.

29. **Chapter 8** showed the reliability and validity of the OSA-18, a disease-specific quality
 30. of life questionnaire, in children with syndromic or complex craniosynostosis. Its use
 31. is described in **chapter 9**. OSA seems to have consequences for quality of life. In these
 32. patients the OSA-18 score is also correlated with the severity of OSA. The domains 'sleep
 33. disturbance' and 'physical suffering' can be used to evaluate the impact of OSA on quality
 34. of life. In future research we will ask parents to complete the OSA-18 before and after
 35. treatment. Comparing these scores with polysomnography results we could measure the
 36. exact impact of OSA in syndromic craniosynostosis.

37. The OSA-18 showed no correlation with the presence of elevated ICP. Patients with
 38. papilledema scored not significantly higher at the different domains than those without
 39. papilledema.

1. **Behavior**

2. Behavioral problems were common in children with syndromic or complex craniosynostosis, as presented in **chapter 9**. The prevalence of behavioral problems is 32% in boys and 16% in girls. Sixty-seven percent of the boys with Apert syndrome scored in the (borderline) clinical range versus none of the girls. In Muenke syndrome also half of the boys scored in the (borderline) clinical range. In Apert syndrome OSA occurs more in boys (78%) than in girls (10%). Further the intelligence of boys with Apert syndrome is significantly lower than that of girls with Apert syndrome (Maliepaard et al., unpublished data); this can influence behavior. In Muenke syndrome the behavioral problems may be more intrinsic and are possibly related to the P250R FGFR3 mutation rather than associated with OSA. Previous studies were mostly performed in isolated craniosynostosis, only Sarimski^{33, 34} reported behavioral problems in patients with Apert syndrome.

13. The total Child Behavior Checklist (CBCL) score of the children between the ages of 6 and 18 clearly correlated with the total OSA-18 score ($p = 0.000$). Boys aged 2-18 years with total CBCL scores in the abnormal range had significantly higher mean scores ($p < 0.05$) on all domains of the OSA-18 and the total OSA-18 score, girls only on the domains 'emotional distress' and 'daytime problems'. In boys the same was found for the externalizing CBCL scores in the abnormal range and for internalizing CBCL scores in the abnormal range: significantly higher means were found on the domains 'sleep disturbance', 'emotional distress', 'caregiver concerns' and the total OSA-18 score. In girls with abnormal internalizing and externalizing CBCL scores only the domain 'emotional distress' had significantly higher scores.

23. From the above results we may deduce that the 'emotional distress' domain can serve as a first screening for the presence of behavioral problems in children with syndromic or complex craniosynostosis. Dependent on age and sex we can formulate cut-off points for the 'emotional distress' score. Only above these points the complete CBCL questionnaire is needed. Setting a cut-off point of 6, for example, would imply that 45 CBCLs were indicated in this study population, of which 24 were scored in the (borderline) clinical range. The negative predictive value is 93% in boys and 91% in girls; six were missed. For externalizing scores in the abnormal range the domain 'emotional distress' had a negative predictive value of 100% in both boys and girls. Seventy-seven questionnaires could have been saved, and thus efficiency at the outpatient clinic in tracing behavioral problems could have been higher.

34. The CBCL showed no correlation with the presence of elevated ICP. Only one of seven boys and one of twelve girls with papilledema scored in the (borderline) clinical range on the total CBCL score. After this analysis with a small number of patients with papilledema we cannot confirm that elevated ICP resulted in behavioral problems.

38.
39.

1. Overall, obstructive sleep apnea in children with syndromic or complex craniosynostosis
 2. is characterized by difficulty in breathing during sleep and an obstructive apnea hypopnea
 3. index (OAHI) ≥ 1 . But complaints during the day, such as frequent colds, and the conse-
 4. quences for behavior and quality of life are also important for evaluation of the severity in
 5. specific patients and for the decision how to treat.

6.

7.

8. **FUTURE PERSPECTIVES**

9.

10. - Improved recognition of the clinical symptoms of mild obstructive sleep apnea

11. The presence of OSA must be suspected in each child with syndromic or complex cranio-
 12. synostosis. Information from parents about difficulty in breathing is a good screening tool
 13. to exclude moderate or severe OSA in these children, but not mild OSA. There is a need
 14. for a screening tool that can be used to detect mild OSA.

15. - Better definition of mild, moderate and severe obstructive sleep apnea

16. The clinical consequences of mild obstructive sleep apnea are not well understood in chil-
 17. dren with syndromic and complex craniosynostosis. To gain more insight into the (patho)
 18. physiologic consequences of OSA, future studies should address the relations of OSA
 19. severity with heart rate variability, pulse transit time, sleep quality and arousal detection.
 20. Furthermore, markers of inflammation and oxidative stress will have to be determined to
 21. find a relation with the severity of OSA.

22. - Improvement of ambulatory polysomnography as diagnostic method

23. Polysomnography carried out at home is a great step forward. However, nasal flow is
 24. difficult to register. As alternative methods may serve the X flow or a mouth thermistor for
 25. recording of oral airflow. In ambulatory polysomnography, professionals could remotely
 26. monitor parents attaching the sensors with the use of a webcam rather than going to the
 27. patients' home themselves to attach the sensors. In case monitoring raises doubt about the
 28. procedure or when the diagnosis OSA is made, a full polysomnography in the hospital is
 29. necessary.

30. - Further determination of the relation between obstructive sleep apnea, elevated intra-
 31. cranial pressure and functional problems

32. The detection of elevated intracranial pressure is difficult. Papilledema is a late sign³².
 33. Transorbital sonography of the optic nerve can show dilatation of the optic nerve sheath
 34. diameter. A rise in ICP directly affects the perioptic nerve space resulting in an increase
 35. of the diameter³⁵⁻³⁷. Ultrasounds were performed in the craniosynostosis group and these
 36. will be analyzed in relation to the presence of papilledema. We will study the value of
 37. this method to detect elevated ICP more early in comparison with the development of
 38. papilledema.

39.

1. The cause for elevated ICP is not only craniocerebral disproportion. The possible
2. relationship between elevated ICP and Chiari malformation or ventricular dilatation is
3. evaluated in these children with syndromic or complex craniosynostosis. To explore the
4. venous hypertension hypothesis the size of the jugular foramen³⁸ will be measured on
5. CT angiography scan in our study population. In addition, the natural course of ICP
6. in craniosynostosis and the exact relationship with OSA will be studied by combining
7. polysomnography with intracranial pressure monitoring.
8. - Further evaluation of the relation between physical sequelae, obstructive sleep apnea,
9. elevated intracranial pressure and quality of life and behavior
10. Quality of life was measured using the Child Health Questionnaire Parental Form 50
11. (CHQ-PF50) above the age of 4 and the Infant Toddler Quality of Life questionnaire
12. below 4 years. To compare the health-related quality of life in these children after a few
13. years and to evaluate the impact of momentous events such as going to school we will
14. ask the parents, who completed the ITQoL in this study, to complete the CHQ-PF 50.
15. As teachers may note problems from comparison with classmates, parents are unaware of
16. before. Teachers will also be asked to complete the CBCL to compare behavioral problems
17. reported by parents and teachers.
18. Muenke syndrome is not well understood. This syndrome was recognized recently. Until
19. now it was seen as a mild anomaly, but our studies brought out many problems in these
20. children. Not all persons with the P250R FGFR3 mutation have craniosynostosis and it
21. is not clear if they have the same problems as the patients with craniosynostosis. Maybe
22. we can use them as controls to see the impact of the premature fusion of the calvarial
23. sutures. The health-related quality of life of children with Muenke syndrome is lower and
24. behavioral problems were frequently seen. Perhaps there is a relation between these two
25. findings. The risk for elevated ICP is very low, but a third of patients will develop OSA in a
26. mild form. It might well be that the behavioral problems are intrinsic. On the other hand
27. mild OSA might be underestimated and the condition could then also result in behavioral
28. problems and a lower quality of life. Psychological tests will help to unravel the sort of
29. behavioral problems and the need for treatment.
30. Mental development in all children with syndromic or complex craniosynostosis will
31. be determined by psychological tests. More attention to quality of life and behavior is
32. needed at the outpatient clinic and support of children and their parents is necessary.
33. Each child with syndromic or complex craniosynostosis should be seen by a psychologist
34. minimally once. The best age for testing seems to be eight years; at that age accurate tes-
35. ting is possible. Furthermore, in most children any problems, such as anxiety, behavioral
36. problems and learning disabilities will have developed before that age, so there is time for
37. intervention.
38. - Longitudinal follow-up of treatment for OSA
- 39.

1. Treatment should be individualized and the level of obstruction must be the determining
2. factor. The effect of each treatment should be analyzed by change and hopefully improve-
3. ment of the OAHl, the functional outcome and quality of life measured by the ITQoL
4. or CHQ and by the OSA-18. Enlargement of the upper airway volume after surgical
5. treatment, such as midface advancement, should be evaluated with three dimensional
6. volume measurements before and after surgery.

7.

8. With the initiation of this large prospective study in 2006, a lot of these future aims
9. can be explored as part of the ongoing research in our center. The aim of this study
10. and the ongoing studies is to improve the care of patients with syndromic and complex
11. craniosynostosis. The early recognition of possible problems related to their syndrome is
12. important. This enables to start with treatment as soon as possible, thus diminishing the
13. negative consequences and offering these children optimal chances in life.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

I. REFERENCES


2. 1. Hoeve LJ, Pijpers M, Joosten KF. OSAS in craniofacial syndromes: an unsolved problem. *Int J Pediatr Otorhinolaryngol* 2003;67 Suppl 1:S111-113.
3. 2. Lo LJ, Chen YR. Airway obstruction in severe syndromic craniosynostosis. *Ann Plast Surg* 1999;43:258-264.
4. 3. Pijpers M, Poels PJ, Vaandrager JM, et al. Undiagnosed obstructive sleep apnea syndrome in children with syndromal craniofacial synostosis. *J Craniofac Surg* 2004;15:670-674.
5. 4. Brouillette R, Hanson D, David R, et al. A diagnostic approach to suspected obstructive sleep apnea in children. *J Pediatr* 1984;105:10-14.
6. 5. Collop NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med* 2007;3:737-747.
7. 6. Ferber R, Millman R, Coppola M, et al. Portable recording in the assessment of obstructive sleep apnea. ASDA standards of practice. *Sleep* 1994;17:378-392.
8. 7. Brouillette RT, Morielli A, Leimanis A, et al. Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea. *Pediatrics* 2000;105:405-412.
9. 8. Poels PJ, Schilder AG, van den Berg S, et al. Evaluation of a new device for home cardiorespiratory recording in children. *Arch Otolaryngol Head Neck Surg* 2003;129:1281-1284.
10. 9. Moss D, Urschitz MS, von Bodman A, et al. Reference values for nocturnal home polysomnography in primary schoolchildren. *Pediatric research* 2005;58:958-965.
11. 10. Lowe LH, Booth TN, Joglar JM, et al. Midface anomalies in children. *Radiographics* 2000;20:907-922; quiz 1106-1107, 1112.
12. 11. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. *Arch Pediatr Adolesc Med* 2005;159:775-785.
13. 12. Guilleminault C, Pelayo R, Leger D, et al. Recognition of sleep-disordered breathing in children. *Pediatrics* 1996;98:871-882.
14. 13. Guilleminault C, Li K, Khramtsov A, et al. Breathing patterns in prepubertal children with sleep-related breathing disorders. *Arch Pediatr Adolesc Med* 2004;158:153-161.
15. 14. Marcus CL, Omlin KJ, Basinki DJ, et al. Normal polysomnographic values for children and adolescents. *Am Rev Respir Dis* 1992;146:1235-1239.
16. 15. Verhulst SL, Schrauwen N, Haentjens D, et al. Reference values for sleep-related respiratory variables in asymptomatic European children and adolescents. *Pediatric pulmonology* 2007;42:159-167.
17. 16. Guilleminault C, Pelayo R, Clerk A, et al. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. *J Pediatr* 1995;127:905-912.
18. 17. Oliveira AJ, Nunes ML, Fojo-Olmos A, et al. Clinical correlates of periodic breathing in neonatal polysomnography. *Clin Neurophysiol* 2004;115:2247-2251.
19. 18. Weintraub Z, Cates D, Kwiatkowski K, et al. The morphology of periodic breathing in infants and adults. *Respiration physiology* 2001;127:173-184.
20. 19. Goroza E, Sagy M, Sagy N, et al. Severity assessment of obstructive sleep apnea syndrome (OSAS) in pediatric patients. *Clinical pediatrics* 2009;48:528-533.
21. 20. Matsumoto E, Tanaka E, Tabe H, et al. Sleep architecture and the apnoea-hypopnoea index in children with obstructive-sleep apnoea syndrome. *Journal of oral rehabilitation* 2007;34:112-120.
22. 21. Arnaud E, Marchac D, Renier D. Reduction of morbidity of the frontofacial monobloc advancement in children by the use of internal distraction. *Plastic and reconstructive surgery* 2007;120:1009-1026.

1. 22. Boutros S, Shetye PR, Ghali S, et al. Morphology and growth of the mandible in Crouzon, Apert, and Pfeiffer syndromes. *J Craniofac Surg* 2007;18:146-150.
2. 23. Nelson TE, Mulliken JB, Padwa BL. Effect of midfacial distraction on the obstructed airway in patients with syndromic bilateral coronal synostosis. *J Oral Maxillofac Surg* 2008;66:2318-2321.
3. 24. Witherow H, Dunaway D, Evans R, et al. Functional outcomes in monobloc advancement by distraction using the rigid external distractor device. *Plastic and reconstructive surgery* 2008;121:1311-1322.
4. 25. Burstein FD, Cohen SR, Scott PH, et al. Surgical therapy for severe refractory sleep apnea in infants and children: application of the airway zone concept. *Plastic and reconstructive surgery* 1995;96:34-41.
5. 26. Fearon JA. Halo distraction of the Le Fort III in syndromic craniosynostosis: a long-term assessment. *Plastic and reconstructive surgery* 2005;115:1524-1536.
6. 27. Vos WG, De Backer WA, Verhulst SL. Correlation between the severity of sleep apnea and upper airway morphology in pediatric and adult patients. *Current opinion in allergy and clinical immunology*;10:26-33.
7. 28. Hayward R. Venous hypertension and craniosynostosis. *Childs Nerv Syst* 2005;21:880-888.
8. 29. Hayward R, Gonzalez S. How low can you go? Intracranial pressure, cerebral perfusion pressure, and respiratory obstruction in children with complex craniosynostosis. *J Neurosurg* 2005;102:16-22.
9. 30. Taylor WJ, Hayward RD, Lasjaunias P, et al. Enigma of raised intracranial pressure in patients with complex craniosynostosis: the role of abnormal intracranial venous drainage. *J Neurosurg* 2001;94:377-385.
10. 31. Marucci DD, Dunaway DJ, Jones BM, et al. Raised intracranial pressure in Apert syndrome. *Plastic and reconstructive surgery* 2008;122:1162-1168; discussion 1169-1170.
11. 32. Tuite GF, Chong WK, Evanson J, et al. The effectiveness of papilledema as an indicator of raised intracranial pressure in children with craniosynostosis. *Neurosurgery* 1996;38:272-278.
12. 33. Sarimski K. Children with Apert syndrome: behavioral problems and family stress. *Developmental medicine and child neurology* 1998;40:44-49.
13. 34. Sarimski K. Social adjustment of children with a severe craniofacial anomaly (Apert syndrome). *Child: care, health and development* 2001;27:583-590.
14. 35. Helmke K, Hansen HC. Fundamentals of transorbital sonographic evaluation of optic nerve sheath expansion under intracranial hypertension II. Patient study. *Pediatr Radiol* 1996;26:706-710.
15. 36. Helmke K, Hansen HC. Fundamentals of transorbital sonographic evaluation of optic nerve sheath expansion under intracranial hypertension. I. Experimental study. *Pediatr Radiol* 1996;26:701-705.
16. 37. Wiegand C, Richards P. Measurement of intracranial pressure in children: a critical review of current methods. *Developmental medicine and child neurology* 2007;49:935-941.
17. 38. Rich PM, Cox TC, Hayward RD. The jugular foramen in complex and syndromic craniosynostosis and its relationship to raised intracranial pressure. *AJNR Am J Neuroradiol* 2003;24:45-51.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.



Chapter 11

Summary



1. SUMMARY

2.

3. The aim of this thesis is to assess the importance and impact of obstructive sleep apnea in
4. children with syndromic or complex craniosynostosis. The topics of interest are the preva-
5. lence, diagnostics and treatment outcome of obstructive sleep apnea and the influence on
6. prevalence of papilledema, health-related quality of life and general behavior.

7.

8. Background information on syndromic craniosynostosis is given in **chapter 1**. Cranio-
9. synostosis is characterized by the premature fusion or agenesis of calvarial sutures and in
10. about 40% of the cases (1:6.250) the craniosynostosis is part of a syndrome, such as Apert,
11. Crouzon, Pfeiffer, Muenke or Saethre-Chotzen syndrome. Complex craniosynostosis is
12. defined as fusion of two or more cranial sutures without known FGFR (fibroblast growth
13. factor receptor) or TWIST mutation.

14. Patients with syndromic and complex craniosynostosis are at risk for elevated intracra-
15. nial pressure (ICP) and obstructive sleep apnea (OSA). Factors suggested to contribute
16. to elevated ICP in craniosynostosis are craniocerebral disproportion, ventriculomegaly or
17. hydrocephalus, venous hypertension and obstructive sleep apnea. In craniosynostosis the
18. first treatment or prevention of elevated ICP is surgical decompression to expand the skull
19. within the first year of life.

20. Obstructive sleep apnea is a clinical syndrome due to partial or complete upper airway
21. obstruction characterized by difficulty in breathing, snoring and apneas during sleep
22. resulting in sleep fragmentation, hypoxia and hypercapnia. A questionnaire on presence
23. of symptoms can be helpful to screen for OSA, but the gold standard to diagnose presence
24. and severity of OSA is polysomnography (PSG). The obstructive apnea hypopnea index
25. (OAHl) is used to differentiate in severity. OSA treatment is dependent on its severity,
26. cause and level of obstruction.

27. **Chapter 2** described the prediction of the presence of OSA in children with syndromic
28. or complex craniosynostosis by their parents. The OSA score, known as Brouillette score,
29. can be used to screen for the presence of OSA and consists of the three items: breathing
30. difficulty, apnea and snoring. The single question 'difficulty in breathing during sleep'
31. showed a sensitivity of 64% and a high negative predictive value of 91% in comparison with
32. polysomnography. So, if the child has no difficulty in breathing during sleep, the presence
33. of moderate or severe OSAS can almost certainly be excluded and polysomnography is not
34. necessary. The question about snoring does not have any additional value, because it was
35. shown that 77% of the children snore. This is mainly due to a narrow nasal cavity.

36. The feasibility of a home cardiorespiratory monitor in these children to diagnose OSA at
37. home is presented in **chapter 3**. Overall, 40.5% of the recordings were suitable for calcula-
38. ting an OAHl with all signals being present. The most important limitation is the absence
39. of nasal flow. In children with syndromic or complex craniosynostosis we speculate that

1. the main reason for the failing signal of the nasal cannula is the absence of nasal passage
2. due to the severe anatomical malformations of the nasal cavity, leading to almost complete
3. obstruction of the upper airway and as a consequence preferred mouth breathing. Another
4. important reason for absence of nasal flow is that not all children accept the nasal cannula.
5. The sum of the amplitudes of the thoracic and abdominal movements (X flow) seems a
6. valuable alternative assessment, when complete recording of the nasal flow signal was not
7. achieved. Using X flow as screening method raised the overall success rate from 40.5% to
8. 75%.
9. The long-term respiratory outcome of midface advancement in patients with Apert,
10. Crouzon or Pfeiffer syndrome suffering from moderate or severe OSA, requiring oxygen,
11. continuous positive airway pressure (CPAP), or tracheostomy is assessed in **chapter 4**.
12. Despite midface advancement, long-term respiratory support (dependency on CPAP or
13. tracheostomy) was maintained in five of the eleven studied patients. In all patients without
14. respiratory improvement or with relapse after surgery, endoscopy showed obstruction
15. at the level of the rhino- or hypopharynx. Dynamic pharyngeal collapse can affect the
16. respiratory outcome of midface advancement. Therefore endoscopy of the upper airway
17. before midface advancement is recommended to identify any level of airway obstruction
18. that may interfere with respiratory improvement after midface advancement.
19. The prevalence of functional problems in children with syndromic craniosynostosis
20. is reported in **chapter 5 and 6**. The prevalence of papilledema in patients with Apert,
21. Crouzon or Pfeiffer syndrome is high (51%), not only before cranial decompression (38%)
22. but also after surgery (43%). Clinical symptoms, such as headache and vomiting, were
23. poor predictors for the presence of papilledema. Complex craniosynostosis, exorbitism
24. and ventricular dilatation were factors associated with papilledema. Given the high
25. prevalence of papilledema annual fundoscopy is highly recommended (chapter 5). Other
26. functional problems such as refractive errors and hearing loss are highly prevalent (52-56%)
27. in all types of syndromic or complex craniosynostosis. Genetic analysis is necessary for
28. counseling and screening on syndrome specific anomalies and functional deficits. Follow-
29. up by a multidisciplinary team is needed till the age of 18 years to obtain the best possible
30. outcome. A diagnosis-specific screening and treatment protocol is given (chapter 6).
31. **Chapter 7** describes the health-related quality of life in children and adolescents with
32. syndromic or complex craniosynostosis. Parents' scores for these patients were significant
33. lower than those for the norm population; syndromic craniosynostosis has a large impact
34. on the health-related quality of life, both physical and psychosocial. Apert syndrome had
35. the largest impact on the different domains.
36. To evaluate the disease-specific impact of obstructive sleep apnea in the general popula-
37. tion and also in children with syndromic or complex craniosynostosis, a disease-specific
38. quality of life questionnaire, the OSA-18 survey, is tested. The internal consistency, test-
39. retest reliability and discriminative validity of the OSA-18 in the craniosynostosis popula-

1. tion are assessed in **chapter 8**. The OSA-18 was found to be a reliable and valid method.
2. It can be used in future studies.

3. **Chapter 9** reports the impact of OSA on quality of life in syndromic and complex cra-
4. niosynostosis and the prevalence of behavioral problems. The correlation between OAH
5. and the total OSA-18 and CBCL scores was significant. The domains 'sleep disturbance'
6. and 'physical suffering' were significantly higher in patients with moderate OSA and can
7. be used to evaluate the impact of OSA on their quality of life. Within the craniosynostosis
8. group children with Apert syndrome showed the highest total OSA-18 score. A high
9. prevalence of behavioral problems was found, especially in boys with Apert and Muenke
10. syndrome.

11. The main findings of this thesis and comments on these findings are discussed in **chap-**
12. **ter 10**, including future perspectives on research. Future studies are needed to improve
13. the recognition of the clinical symptoms of mild, moderate and severe OSA and the
14. consequences of the severity of OSA on growth and development, intracranial pressure,
15. behavior and quality of life. Concerning ambulatory polysomnography the use of X flow
16. should be validated in comparison with full polysomnography in the hospital.

17. A multidisciplinary team should take care of all the different clinical features known in
18. these craniosynostosis patients and centralization of care is highly recommended.

19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.



Chapter 12

Nederlandse samenvatting

Abbreviations

Dankwoord

Curriculum vitae

List of publications

PhD portfolio

1. NEDERLANDSE SAMENVATTING

2.

3. Het doel van dit proefschrift betreft het in kaart brengen van het belang en de impact
4. van het obstructief slaap apneu syndroom bij kinderen met een syndromale of complexe
5. vorm van craniosynostose. Aandachtsgebieden zijn prevalentie, diagnostiek en behande-
6. lingsuitkomst van het obstructief slaap apneu syndroom (OSAS) en de invloed van OSAS
7. op de prevalentie van papiloedeem, de gezondheidsgerelateerde kwaliteit van leven en het
8. gedrag.

9.

10. Achtergrondinformatie over syndromale craniosynostose wordt gegeven in **hoofdstuk 1**.

11. Craniosynostose wordt gekenmerkt door vroegtijdige sluiting of agenesie van de sche-
12. delnaden en is in 40% van de gevallen (1:6.250) onderdeel van een syndroom, zoals het
13. syndroom van Apert, Crouzon, Pfeiffer, Muenke of Saethre-Chotzen. Complexe cranio-
14. synostose wordt gedefinieerd als sluiting van twee of meer schedelnaden zonder bekende
15. mutatie in de fibroblast groeifactor receptor (FGFR) of in het TWIST gen.

16. Patiënten met een syndromale en complexe craniosynostose hebben een verhoogd risico
17. op de ontwikkeling van verhoogde intracranieële (hersen)druk (ICP) en van het obstruc-
18. tief slaap apneu syndroom. Mogelijke factoren die bijdragen aan de verhoogde ICP bij
19. craniosynostose zijn craniocerebrale disproportie, ventriculomegalie of hydrocephalus,
20. veneuze hypertensie en OSAS. De eerste behandeling of preventie van verhoogde ICP bij
21. deze kinderen betreft een operatie in het eerste levensjaar waarbij de schedel groter wordt
22. gemaakt.

23. Het obstructief slaap apneu syndroom is een klinisch syndroom waarbij een gedeelte-
24. lijke of complete obstructie van de bovenste luchtweg optreedt, die wordt gekenmerkt
25. door moeilijkheden met ademhalen, snurken en apneus (stoppen met ademhalen) tijdens
26. de slaap en die leidt tot slaapfragmentatie, hypoxie (zuurstoftekort) en hypercapnie (teveel
27. koolstofdioxide). Een vragenlijst over de aanwezigheid van symptomen kan handig zijn
28. in de screening naar OSAS, maar de gouden standaard om de aanwezigheid en de ernst
29. van OSAS vast te stellen is polysomnografie (PSG). De obstructieve apneu hypopneu
30. index (OAHl) wordt gebruikt om te differentiëren in ernst. De behandeling van OSAS is
31. afhankelijk van de ernst, de oorzaak en het niveau van obstructie.

32. **Hoofdstuk 2** beschrijft de vraag of ouders de aanwezigheid van OSAS bij hun kinderen
33. met een syndromale of complexe craniosynostose kunnen voorspellen. De OSAS score,
34. bekend als Brouillette score, kan gebruikt worden bij de screening op de aanwezigheid van
35. OSAS en bestaat uit drie items, namelijk ademhalingsmoeilijkheden, apneus en snurken.
36. In de craniosynostose populatie heeft de vraag naar moeilijkheden met ademhalen tijdens
37. de slaap een sensitiviteit van 64% en een hoge negatief voorspellende waarde van 91% in
38. vergelijking met polysomnografie. Kortom, als het kind geen moeilijkheden met adema-
39. len tijdens de slaap heeft kan de aanwezigheid van matige en ernstige OSAS zo goed als

1. zeker uitgesloten worden en is een polysomnografie onnodig. De vraag over snurken heeft
2. geen toegevoegde waarde, daar vastgesteld is dat 77% van de kinderen snurkt. Dit komt
3. voornamelijk door een nauwe neusholte.

4. Het gebruik van een cardiorespiratoire thuismonitor (polysomnograaf) voor het stellen
5. van de diagnose OSAS bij deze kinderen wordt besproken in **hoofdstuk 3**. Totaal is 40.5%
6. van de registraties te gebruiken om een OAH te berekenen aan de hand van alle signalen.
7. De belangrijkste beperking is de afwezigheid van de neusflow, geregistreerd door de neus-
8. bril. Bij kinderen met een syndromale of complexe craniosynostose lijkt de belangrijkste
9. reden voor het ontbreken van het neusflowsignaal de afwezigheid van neuspassage te zijn.
10. Dit laatste komt door de anatomische afwijkingen van de neusholte, die leiden tot een
11. bijna complete obstructie van de bovenste luchtweg met als gevolg mondademhaling.
12. Een andere belangrijke reden voor de afwezigheid van de neusflow is het feit dat niet alle
13. kinderen de neusbril accepteren. De som van de amplitudes van de borst- en buikademha-
14. lingsbewegingen (X flow) lijkt een waardevol alternatief, wanneer complete registratie van
15. de neusflow niet gelukt is. Het gebruik van de X flow als screeningsmethode zorgt voor een
16. stijging van het succespercentage van 40.5% naar 75%.

17. De respiratoire uitkomst van een aangezichtscorrectie op de lange termijn bij patiënten
18. met het syndroom van Apert, Crouzon of Pfeiffer met matige of ernstige OSAS, waarvoor
19. ze zuurstof, neuskapbeademing (CPAP) of een tracheacanule nodig hebben, wordt bespro-
20. ken in **hoofdstuk 4**. Ondanks de aangezichtscorrectie bleef respiratoire ondersteuning
21. (afhankelijkheid van CPAP of een tracheacanule) op de lange termijn gehandhaafd bij
22. vijf van de elf onderzochte patiënten. Bij alle patiënten zonder respiratoire verbetering of
23. met een recidief na chirurgie toonde de endoscopie een obstructie op het niveau van de
24. rhino- of hypopharynx (neus-keelholte of het onderste deel van de keelholte). Een dyna-
25. mische collaps van de pharynx kan de respiratoire uitkomst van de aangezichtscorrectie
26. beïnvloeden. Daarom wordt voor deze operatie een endoscopie van de bovenste luchtweg
27. geadviseerd om elk niveau van luchtwegobstructie vast te stellen, dat invloed kan hebben
28. op de respiratoire verbetering na de correctie.

29. De prevalentie van functionele problemen voorkomend bij kinderen met een syndro-
30. male craniosynostose komt aan de orde in **hoofdstuk 5 en 6**. De prevalentie van papiloe-
31. deem bij patiënten met het syndroom van Apert, Crouzon of Pfeiffer is hoog (51%), niet
32. alleen voor de chirurgische decompressie (38%), maar ook na de operatie (43%). Klinische
33. symptomen, zoals hoofdpijn en braken, zijn slechte voorspellers voor de aanwezigheid van
34. papiloedeem. Complexe craniosynostose, exorbitisme en ventrikeldilatatie zijn factoren
35. die geassocieerd zijn met papiloedeem. Jaarlijkse funduscopie is sterk aan te raden gezien
36. de hoge prevalentie van papiloedeem (hoofdstuk 5). Andere functionele problemen, zoals
37. refractiefwijkingen en gehoorverlies komen veel voor (52-56%) bij alle typen syndromale
38. en complexe craniosynostose. Genetische analyse is noodzakelijk voor counseling en scree-
39. ning op syndroom-specifieke afwijkingen en functionele stoornissen. Follow-up door een

1. multidisciplinair team is nodig tot de leeftijd van 18 jaar om de best mogelijke uitkomst
2. te bieden. Een voorstel voor een diagnose-specifieke screening en een behandelprotocol
3. wordt gedaan (hoofdstuk 6).

4. **Hoofdstuk 7** beschrijft de gezondheidsgerelateerde kwaliteit van leven van kinderen
5. en adolescenten met syndromale of complexe craniosynostose. De door ouders gerapporte-
6. eerde scores voor deze patiënten waren significant lager dan die voor de normpopulatie;
7. syndromale craniosynostose heeft een grote impact op de gezondheidsgerelateerde kwali-
8. teit van leven, zowel fysiek als psychosociaal. Het syndroom van Apert heeft de grootste
9. impact op verscheidene domeinen.

10. Om de ziekte-specifieke impact van het obstructief slaap apneu syndroom in de gewone
11. populatie en bij kinderen met een syndromale of complexe craniosynostose te evalueren,
12. is een ziekte-specifieke kwaliteit van leven vragenlijst, de OSA-18, getoetst. De interne
13. consistentie, de test-herstest betrouwbaarheid en de discriminatieve validiteit van de OSA-
14. 18 in de craniosynostose populatie zijn onderzocht in **hoofdstuk 8**. De OSA-18 vragenlijst
15. is als een betrouwbaar en valide instrument getest en kan in toekomstige studies gebruikt
16. worden.

17. **Hoofdstuk 9** rapporteert de impact van OSAS op de kwaliteit van leven bij syndromale
18. en complexe craniosynostose en de prevalentie van gedragsproblemen. De correlatie tussen
19. de OAH1 en de totale OSA-18 en CBCL scores is significant. De domeinen 'slaapproble-
20. men' en 'lichamelijke verschijnselen' scores significant hoger bij patiënten met matige
21. OSAS en kunnen gebruikt worden om de impact van OSAS op hun kwaliteit van leven
22. te bepalen. Binnen de craniosynostose groep wordt bij kinderen met het syndroom van
23. Apert de hoogste totale OSA-18 score gemeten. De prevalentie van gedragsproblemen is
24. hoog, voornamelijk bij jongens met het syndroom van Apert en Muenke.

25. De belangrijkste bevindingen van dit proefschrift en opmerkingen naar aanleiding van
26. deze bevindingen worden bediscussieerd in **hoofdstuk 10**, dat ook de toekomstplannen
27. op onderzoeksgebied bespreekt. Toekomstige studies zijn nodig om de herkenning van
28. klinische symptomen van milde, matige en ernstige OSAS en de consequenties van de
29. mate van ernst op groei en ontwikkeling, hersendruk, gedrag en kwaliteit van leven te
30. verbeteren. Wat de ambulante polysomnografie betreft, het gebruik van de X flow behoeft
31. validatie in vergelijking met volledige polysomnografie uitgevoerd in het ziekenhuis.

32. Een multidisciplinair team dient zorg te dragen voor alle verschillende klinische aspek-
33. ten voorkomend bij deze craniosynostose patiënten en centralisatie van de zorg wordt
34. sterk aangeraden.

35.
36.
37.
38.
39.

I. **ABBREVIATIONS**

- 2.
- 3. ATE adenotonsillectomy
- 4. BiPAP bi-level positive airway pressure
- 5. Br score Brouillette score
- 6. CBCL child behavior checklist
- 7. CHQ-PF child health questionnaire parent form
- 8. CHQ-CF child health questionnaire child form
- 9. CI confidence interval
- 10. CPAP continuous positive airway pressure
- 11. CT scan computed tomography scan
- 12. FGFR fibroblast growth factor receptor
- 13. ICP intracranial pressure
- 14. ITQoL infant toddler quality of life questionnaire
- 15. MRA mandibular repositioning appliance
- 16. NPT nasopharyngeal tube
- 17. NPV negative predictive value
- 18. OAHl obstructive apnea hypopnea index
- 19. ODI oxygenation desaturation index
- 20. OSA obstructive sleep apnea
- 21. PSG polysomnography
- 22. SARME surgically assisted rapid maxillary expansion
- 23. Sens sensitivity
- 24. sd standard deviation
- 25. VP ventriculoperitoneal
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.

1. DANKWOORD

2.

3. Nu mijn proefschrift bijna voltooid is, is het tijd om stil te staan bij de afgelopen vier
4. jaar. Allereerst wil ik mijn co-promotoren, dr. Irene M.J. Mathijssen en dr. Koen F.M.
5. Joosten enorm bedanken, want zonder hen was dit onderzoek niet tot stand gekomen.
6. Het moment dat ik in het trappenhuis van Koen hoorde dat ik was aangenomen voor dit
7. promotieonderzoek kan ik me nog goed herinneren, de weg naar de kindergeneeskunde
8. lag gelukkig nog steeds voor me open. Irene, wat een gedrevenheid en passie heb jij voor
9. je werk. Je werk is je leven en wat heb ik veel van je geleerd, niet alleen het schrijven van
10. de METC aanvraag en de diverse artikelen, het nadenken over verschillende problemen,
11. maar ook het stukje meer assertiviteit dat je me hebt bijgebracht. Koen, wat is het prettig
12. samenwerken met jou. Je bent altijd vriendelijk, geduldig, hebt een groot hart voor je vak,
13. maar ook aandacht voor de dingen eromheen. Jullie zijn een perfect stel begeleiders dat
14. elkaar goed aanvult en me altijd weer vol enthousiasme op de juiste weg kon brengen.

15. Zonder wie ik dit onderzoek ook niet had kunnen doen zijn de 164 zeer gemotiveerde
16. kinderen en hun ouders die hebben willen meewerken aan mijn onderzoek. Bedankt! Wat
17. ongelooflijk om te zien hoe bereid ieder was om vragenlijsten in te vullen, een slaapmeting
18. en echo te ondergaan en elke keer te meten en te wegen. Daarnaast heb ik de interesse in
19. mij als persoon zeer gewaardeerd. Het waren vier mooie jaren. Ik wens jullie het allerbeste
20. toe en wie weet tot ziens.

21. Prof. dr. S.E.R. Hovius wil ik bedanken dat hij mijn promotor wilde zijn en me heeft
22. gesteund op de weg die ik heb bewandeld. Ook de andere leden van de kleine commissie,
23. prof. dr. D. Tibboel, prof. dr. F.C. Verhulst en prof. dr. H.A.M. Marres wil ik natuurlijk
24. bedanken voor hun tijd en moeite die het beoordelen van mijn proefschrift heeft gekost.
25. Prof. dr. K.G.H. van der Wal, prof. dr. J.C. de Jongste, prof. dr. P.J. van der Spek, dr.
26. H. Raat en drs. J.M. Vaandrager wil ik bedanken voor het plaatsnemen in mijn grote
27. commissie. Wat een eer om straks tegenover deze geleerde mensen te mogen staan.

28. Mijn paranimfen wil ik bedanken dat ze straks op 1 september naast mij willen staan en
29. me willen helpen met de voorbereiding. Ten eerste Germaine Liebrechts-Akkerman, mijn
30. vriendin vanuit de collegebank en practica en degene die me voorging op vele vlakken,
31. beginnen als AIOS, trouwen en moeder worden en daarnaast Marianne Maliepaard, in
32. het begin mijn steun als researchverpleegkundige en later mijn directe collega binnen het
33. craniofaciaal team als psycholoog-onderzoeker. Germaine, bedankt voor je gezelligheid
34. tijdens de lunch en binnenkort moeten we weer eens gaan wandelen, met z'n zevenen. En
35. daarna is het jouw beurt om te promoveren. Marianne, wat fijn dat je me wilde helpen
36. met het invoeren van de kwaliteit van leven vragenlijsten, het vergaren van de OSA-18
37. bij de gezonde kinderen en de analyses van de laatste drie stukken. Veel succes met je
38. promotietraject.

39.

1. De collega's van het craniofaciaal team, Hansje Bredero-Boelhauer, Léon van Adrichem,
2. Jacques van der Meulen, Marie-Lise van Veelen, Eppo Wolvius, Hans Hoeve, Edwin Ong-
3. kosuwito, Inge Balk-Leurs, Jeannette Hoogeboom, Jolanda Okkerse en Francien Meertens
4. wil ik bedanken voor hun hulp bij het uitvoeren van mijn onderzoek. Hansje, ik wil jou
5. ook even apart noemen, bedankt voor onze goede samenwerking, het gezellige lunchen en
6. je luisterend oor. En natuurlijk onze reizen naar Montréal, Luxemburg, Antwerpen, Lille
7. en Seoul niet te vergeten, wat hebben we veel geleerd en gezien samen!
8. Anderen die betrokken waren bij mijn onderzoek en die ik wil danken voor hun inzet
9. en ideeën zijn Hein Raat, Maarten Lequin, Yolanda de Rijke, Erik Nout, Sandra van
10. den Berg, Marjolijn Bartels en Marcel van Rijn. Tim de Jong mag ook niet onvermeld
11. blijven, hij is als gemotiveerde geneeskunde student bij mij terechtgekomen en heeft een
12. groot deel van de statussen doorgenomen en het retrospectieve deel van mijn onderzoek
13. compleet gemaakt.

14. Bij klinisch onderzoek is ook de samenwerking met de poliassistenten, de radiologie
15. medewerkers, de anesthesie en de afdeling van groot belang. Marloes, Conny, Annemarie,
16. Irma, Dorien, Margreet, Roland, Edith en de verpleegkundigen van 1 Noord jullie inzet
17. was fantastisch, wat een mooie werkomgeving.

18. Voor mijn vragen kon ik altijd terecht op het secretariaat, Maaïke, Perlita, Joan en in de
19. eerste jaren Karin hartelijk bedankt voor jullie hulp.

20. Ik was in de luxe positie dat ik collega's had bij de plastische chirurgie en bij de kin-
21. dergeneeskunde. Mijn collega-onderzoekers hebben bijgedragen aan een onvergetelijke
22. tijd, van terechtkunnen met allerlei vragen en samen op congres gaan tot het organiseren
23. van het onderzoekersweekend, het bijwonen van de borrels en het jaarlijkse diner. Joyce,
24. Marijke, Sarah, Dirk-Jan, Caroline, Raúl, Mirjam, Femke, Idse, Denise, Petra, Sandra,
25. Marjolein en Nanda bedankt voor de gezelligheid. Joyce, succes met je artikelen, straks
26. mag jij. Caroline, goed dat je het stokje van me hebt overgenomen. Marijke, de kaft en
27. titelpagina's zijn super geworden! Mirjam, wat leuk dat we elkaar weer treffen tijdens de
28. opleiding en samen in het Maasstad zitten.

29. In mijn onderzoekstijd heb ik gelukkig ook tijd gehad voor kletsen, uiteten gaan,
30. wandelen en volleyballen. Sylvia, Christine, Iris, Anouk, Lisette, Daniëlle, Mirjam, Lotte,
31. Merel en Judith bedankt voor jullie betrokkenheid en hopelijk zien we elkaar straks ook
32. nog regelmatig!

33. Tot slot zijn er mensen die al jaren zo niet mijn gehele leven achter me staan, mijn
34. (schoon)familie. Het is bijzonder om te merken dat sommigen zo met mij mee leven,
35. wat ben ik dankbaar voor jullie interesse en steun! Een paar van jullie wil ik nog extra
36. in het zonnetje zetten. Bas en Barbara wat fijn dat jullie zo vaak voor me klaar staan. Ik
37. zal niet vergeten dat jullie me hoogzwanger naar het Sophia hebben gebracht zodat ik
38. kon solliciteren en wat een dag later bleek ook aangenomen werd. Sanne, mijn lieve zus,
39. bedankt voor de kleine dingen die zoveel voor me betekenen! Lieve mamma, wat kan ik

1. me nog meer wensen, je weet hoe belangrijk je voor me bent. Bedankt dat je altijd naar me
2. wilt luisteren, ook als het even niet loopt zoals ik wil.
3. Lieverd, mijn Arno, jij bent altijd zo rustig en voelt gewoon dat alles goed komt. Nu je
4. hebt gelijk gekregen. Wat hadden we een topweek, op dinsdag werd ik aangenomen voor
5. de opleiding kindergeneeskunde en op zaterdag werd Nouschka geboren! En dan nu nog
6. mijn promotie. Bedankt voor je steun en liefde de afgelopen elf jaar! Nouschka, je hebt
7. mijn leven nog mooier gemaakt.

8.

9. *Natalja*

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. **CURRICULUM VITAE**

2.

3. Natalja Bannink was born on 1st January 1980 in The Hague. She finished high school at
4. the Gymnasium Haganum in The Hague in 1998. From her youngest years she knew she
5. wanted to become a pediatrician. She obtained her medical degree at the Erasmus Uni-
6. versity in Rotterdam in 2004 (cum laude). At the outpatient clinic of the Erasmus MC-
7. Sophia Children's Hospital in Rotterdam she finished her research project about learning
8. problems in children with Neurofibromatosis type 1 in 2002. She worked as a pediatric
9. resident (ANIOS) at the department of pediatrics in the Albert Schweitzer Hospital in
10. Dordrecht during six months. In March 2005 she worked for a year in the Erasmus MC-
11. Sophia Children's Hospital at the medium care unit and the neonatal intensive care unit.

12. Between March 2006 and April 2010 she performed her PhD on 'Obstructive sleep
13. apnea in children with syndromic craniosynostosis' at the Dutch Craniofacial Center
14. in the Erasmus MC-Sophia Children's Hospital under the supervision of dr. Irene M.J.
15. Mathijssen and dr. Koen F.M. Joosten (promoter prof. dr. S.E.R. Hovius).

16. In April 2010 she started as a pediatric resident (AIOS) at the Maasstad Hospital in
17. Rotterdam (dr. C.R. Lincke) and at the Erasmus MC-Sophia Children's Hospital in Rot-
18. terdam (dr. M. de Hoog and prof. dr. A.J. van der Heijden).

19. Natalja lives with her husband Arno and daughter Nouschka in Rijswijk.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

I. LIST OF PUBLICATIONS

2.

3. - Bannink N, Joosten KFM, van Veelen MLC, Bartels MC, Tasker RC, van Adrichem
4. LNA, van der Meulen JJNM, Vaandrager JM, de Jong THR, Mathijssen IMJ. Papill-
5. edema in patients with Apert, Crouzon and Pfeiffer syndrome; prevalence, efficacy of
6. treatment and risk factors. *J Craniofac Surgery* 19: 121-127, 2008

7. - De Jong T, Bannink N, Bredero-Boelhouwer HH, van Veelen ML, Bartels MC, Hoeve
8. LJ, Hoogeboom AJ, Wolvius EB, Lequin MH, van der Meulen JJ, van Adrichem LN,
9. Vaandrager JM, Ongkosuwito EM, Joosten KFM, Mathijssen IMJ. Long-term func-
10. tional outcome in 167 patients with syndromic craniosynostosis; defining a syndrome-
11. specific risk profile. *J Plast Reconstr Aesthet Surg* Epub ahead of print, 2009

12. - Florisson JMG, van Veelen MLC, Bannink N, van Adrichem LNA, van der Meulen
13. JJNM, Bartels MC, Mathijssen IMJ. Papilledema in isolated single-suture craniosyn-
14. tosis: prevalence and predictive factors. *J Craniofac Surgery* 21(1): 20-24, 2010

15. - Bannink N, Nout E, Wolvius EB, Hoeve LJ, Joosten KFM, Mathijssen IMJ. Obstructive
16. sleep apnea in children with syndromic craniosynostosis: long-term respiratory outcome
17. of midface advancement. *Int J Oral Maxillofac Surgery* 39(2): 115-121, 2010

18. - Bannink N, Mathijssen IMJ, Joosten KFM. Can parents predict obstructive sleep apnea
19. in children with syndromic or complex craniosynostosis? *Int J Oral Maxillofac Surgery*
20. 39(5): 421-423, 2010

21. - Bannink N, Mathijssen IMJ, Joosten KFM. Use of ambulatory polysomnography in
22. children with syndromic craniosynostosis. *J Craniofacial Surgery* In press, 2010

23. - Bannink N, Maliepaard M, Raat H, Joosten KFM, Mathijssen IMJ. Health-related
24. quality of life in children and adolescents with syndromic craniosynostosis. *J Plast*
25. *Reconstr Aesthet Surg* Epub ahead of print, 2010

26.

27. - De Carolien Bijl Stichting financiert onderzoek bij craniofaciale patiënten. *Face Nieuws-*
28. *brief van Lapos*, nr 2, 2009

29. - Speciale groep kinderen heeft een vergrote kans op OSAS. *Apneu magazine*, nr 2, juni
30. 2009

31.

32.

33.

34.

35.

36.

37.

38.

39.

1. **PHD PORTFOLIO SUMMARY**

2.

3. **Summary of PhD training and teaching activities**

4. Erasmus MC Department: Pediatrics/ Plastic Surgery

PhD period: 01-03-2006 – 01-04-2010

5. Promoter: Prof. dr. S.E.R. Hovius

6. Supervisor: Dr. I.M.J Mathijssen/ Dr K.F.M. Joosten

7. **1. PhD training**

8.

| | Date | Workload
(ECTS) |
|--|------|--------------------|
|--|------|--------------------|

9. **General academic skills**

10. - Introduction for beginning PhD candidates 08-06-06 0.1

11. - How to write and read a medical paper? 12-08-06, 19-08-06 0.7

12. - Biomedical English Writing and Communication 04-09-07 – 18-12-07, 15-01-08 4.0

13. **Research skills**

14. - Statistics

15. Introduction to data-analysis 07-08-06 – 11-08-06 0.9

16. Regression analysis 14-08-06 – 18-08-06 1.3

17. - Methodology

18. Minicursus Methodologie van patiëntgebonden onderzoek 16-03-06 0.3

19. Rotterdam

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

| Oral presentations | | |
|-----------------------------|--|--------------|
| I. | - Obstructive sleep apnea and intracranial pressure in children with syndromic craniosynostosis. Meeting Tyco Healthcare Rotterdam | 19-04-07 1.4 |
| 2. | - Obstructief slaap apneu syndroom en intracranieële drukverhoging bij kinderen met een syndromale craniosynostosis. Onderzoeksdag Sophia Kinderziekenhuis Rotterdam | 18-10-07 1.4 |
| 3. | - De effecten van chirurgische behandeling van het obstructief slaap apneu syndroom bij kinderen met een syndromale craniosynostosis. Vergadering Nederlandse Vereniging van Schisis en Craniofaciale Afwijkingen Zwolle | 17-11-07 1.4 |
| 4. | - Obstructive sleep apnea and intracranial pressure in children with syndromic craniosynostosis. Craniofacial Meeting Rotterdam | 18-01-08 1.4 |
| 5. | - Obstructief slaap apneu syndroom en verhoogde intracranieële druk bij kinderen met syndromale craniosynostosis. Refereerbijeenkomst Plastische Chirurgie Rotterdam | 02-04-08 1.4 |
| 6. | - Lange termijn resultaat van midface advancement voor obstructief slaap apneu syndroom bij kinderen met syndromale craniosynostosis. Vergadering Nederlandse Vereniging van Plastische Chirurgie Zeist | 24-04-08 1.4 |
| 7. | - Obstructive sleep apnea in children with syndromic craniosynostosis: unsatisfactory long-term respiratory outcome of midface advancement. European Society of Craniofacial Surgery Lille, France | 20-09-08 1.4 |
| 8. | - Kunnen ouders van kinderen met syndromale craniosynostosis de aanwezigheid van obstructief slaap apneu syndroom voorspellen? Vergadering Nederlandse Vereniging van Schisis en Craniofaciale Afwijkingen Nijmegen | 15-11-08 1.4 |
| 9. | - Obstructive sleep apnea in children with syndromic craniosynostosis: respiratory outcome of midface advancement. 9 th World Congress on Sleep Apnea Seoul | 26-03-09 1.4 |
| 10. | - Health-related quality of life in children with syndromic or complex craniosynostosis and obstructive sleep apnea. 9 th World Congress on Sleep Apnea Seoul | 28-03-09 1.4 |
| 11. | - Gezondheids gerelateerde kwaliteit van leven van kinderen met een syndromale of complexe craniosynostosis. Vergadering Nederlandse Vereniging van Plastische Chirurgie Utrecht | 03-04-09 1.4 |
| Poster presentations | | |
| 12. | - Elevated ICP in patients with Apert, Crouzon and Pfeiffer syndrome. Wetenschapsdag Erasmus MC Rotterdam | 01-02-07 1.0 |
| 13. | - Kunnen ouders van kinderen met syndromale craniosynostosis de aanwezigheid van obstructief slaap apneu syndroom voorspellen? Dag voor de jonge onderzoeker Nederlandse Vereniging Kindergeneeskunde Veldhoven | 04-11-08 1.0 |
| 14. | - Kunnen ouders de aanwezigheid van obstructief slaap apneu syndroom voorspellen? Posterprijs 30 ^e congres Nederlandse Vereniging voor Kindergeneeskunde Veldhoven | 07-11-08 1.0 |
| 15. | - Can parents predict the presence of obstructive sleep apnea in children with syndromic or complex craniosynostosis? 9 th World Congress on Sleep Apnea Seoul | 26-03-09 1.0 |
| 16. | | |
| 17. | | |
| 18. | | |
| 19. | | |
| 20. | | |
| 21. | | |
| 22. | | |
| 23. | | |
| 24. | | |
| 25. | | |
| 26. | | |
| 27. | | |
| 28. | | |
| 29. | | |
| 30. | | |
| 31. | | |
| 32. | | |
| 33. | | |
| 34. | | |
| 35. | | |
| 36. | | |
| 37. | | |
| 38. | | |
| 39. | | |

| International conferences | | |
|----------------------------------|---|-------------------------|
| 1. | - Sleep and the cardiovascular system Marburg, Germany | 07-04-06 0.3 |
| 2. | - 8 th International Neurotrauma Symposium Rotterdam | 23-05-06 0.2 |
| 3. | - 8 th World Congress on Sleep Apnea Montréal, Canada | 28-09-06 – 30-09-06 0.7 |
| 3. | - Benelux Sleep Congress Mondorf-les-Bains, Luxembourg | 11-05-07 0.2 |
| 4. | - European Society of Craniofacial Surgery Lille, France | 19-09-08 – 20-09-08 0.4 |
| 5. | - Benelux meeting Nederlandse Vereniging van Plastische Chirurgie/
Royal Belgian Society for Plastic Surgery Den Bosch | 04-10-08 0.3 |
| 6. | - Symposium on sleep-disordered breathing in children Antwerpen,
Belgium | 21-11-08 – 22-11-08 0.4 |
| 7. | | |
| 8. | - 9 th World Congress on Sleep Apnea Seoul, Korea | 25-03-09 – 28-03-09 1.0 |
| Seminars and workshops | | |
| 9. | - INVOS Paediatric Master Class Paris, France | 10-04-06 – 11-04-06 0.3 |
| 10. | - Wetenschapsdag Erasmus MC Rotterdam | 01-02-07 0.2 |
| 10. | - Embletta trainingsdag Embla/ Medcare Amsterdam | 14-02-07 0.2 |
| 11. | - Brain RT klinische polysomnografie trainingsdag Universitair
Ziekenhuis Antwerpen, Belgium | 02-07-07 0.1 |
| 12. | | |
| 13. | - Onderzoeksdag Kindergeneeskunde Sophia Kinderziekenhuis
Rotterdam | 18-10-07 0.2 |
| 14. | - Najaarsvergadering Nederlandse Vereniging van Schisis en
Craniofaciale Afwijkingen Zwolle | 17-11-07 0.3 |
| 15. | - Craniofacial Meeting Rotterdam | 18-01-08 0.3 |
| 16. | - Wetenschapsdag Erasmus MC Rotterdam | 07-02-08 0.2 |
| 17. | - Refereerbijeenkomst Plastische Chirurgie Rotterdam | 02-04-08 0.1 |
| 18. | - Voorjaarsvergadering Nederlandse Vereniging van Plastische
Chirurgie Zeist | 24-04-08 0.3 |
| 19. | - The Generation R Symposium Imaging and early brain development
Rotterdam | 19-06-08 0.1 |
| 20. | - Najaarsvergadering Nederlandse Vereniging van Schisis en
Craniofaciale Afwijkingen Nijmegen | 15-11-08 0.3 |
| 21. | | |
| 22. | - Refereerbijeenkomst Plastische Chirurgie Rotterdam | 17-09-08 0.1 |
| 22. | - Dag voor jonge onderzoekers Nederlandse Vereniging voor
Kindergeneeskunde Veldhoven | 04-11-08 0.3 |
| 23. | | |
| 24. | - 30 ^e congres Nederlandse Vereniging voor Kindergeneeskunde
Veldhoven | 07-11-08 0.3 |
| 25. | - Symposium Cognitive deficits in children with Neurofibromatosis
type 1: from recognition to treatment Rotterdam | 26-11-08 0.1 |
| 26. | | |
| 27. | - Symposium Quality of life and quality of care Rotterdam | 02-12-08 0.1 |
| 27. | - Onderzoeksdag Kindergeneeskunde Sophia Kinderziekenhuis
Rotterdam | 18-12-08 0.1 |
| 28. | | |
| 29. | - Refereerbijeenkomst Plastische Chirurgie Rotterdam | 21-01-09 0.1 |
| 29. | - Workshop grant writing Nijmegen | 29-01-09 0.1 |
| 30. | - Workshop TULIPS subsidieaanvraag schrijven Rotterdam | 02-03-09 0.1 |
| 31. | - Voorjaarsvergadering Nederlandse Vereniging van Plastische
Chirurgie Utrecht | 03-04-09 0.3 |
| 32. | - Seminar Epidemiology Success in research: learn from the experts
Rotterdam | 15-04-09 0.1 |
| 33. | | |
| 34. | - Symposium Infant feeding, early growth patterns, and long-term risk
for metabolic and cardiovascular disease Rotterdam | 06-05-09 0.2 |
| 35. | | |
| 36. | | |
| 37. | | |
| 38. | | |
| 39. | | |

2. Teaching activities

| | | | |
|----|--|---------------------|-----|
| 1. | Lecturing | | |
| 2. | - Wetenschappelijk onderzoek OSAS en ICP bij syndromale | 29-01-07 | 1.4 |
| 3. | cranosynostosis. Kinderartsenweek Sophia Kinderziekenhuis | | |
| 4. | Rotterdam | | |
| 5. | - Het obstructief slaap apneu syndroom bij kinderen. Keuzeonderwijs | 12-02-07, 30-01-08, | 2.8 |
| 6. | plastische chirurgie studenten geneeskunde Rotterdam | 26-01-09, 28-01-10 | |
| 7. | Supervising Master's theses | | |
| 8. | - Supervising Tim de Jong, medical student, retrospective research and | 2008 | 3.6 |
| 9. | article writing | | |

- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.

